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vAbstract
This thesis details the synthesis, characterisation and evaluation of novel β-bis-
ketoiminate ruthenium(II) and β-bis-ketoiminate copper(II) complexes for their
biological and chemical applications. The anti-cancer, anti-bacterial and anti-
fungal and catalytic activity of these complexes was investigated, with lead
complexes undergoing further mechanistic investigations.
Chapter 1 contains the background introduction to the project, through literature
research of similar work as well as the aims of this project.
Chapter 2 presents the synthesis and characterisation of novel β-bis-ketoiminate
ruthenium(II) dicarbonyl complexes. 1H NMR, 13C {1H} NMR and detailed X-ray
crystallographic data are given for this series of complexes.
Chapter 3 introduces novel β-bis-ketoiminate copper(II) complexes, their
synthesis and characterisation, with X-ray crystallographic data discussed.
Chapter 4 introduces the MTT technique for assessing cytotoxicity, and discusses
the anti-cancer activities of the series of complexes synthesised in Chapters 2 and
3. In addition, the chapter gives a brief literature review to anti-bacterial and anti-
microbial studies, and the results of anti-bacterial and anti-fungal investigations on
the β-bis-ketoiminate ruthenium(II) and copper(II) complexes.
Chapter 5 presents the results of chemical investigations, hydrolysis and
biomembrane, conducted on the two libraries of complexes.
Chapter 6 contains a brief literature review on catalysis, and the results for
transfer hydrogenation and Ullmann catalytic reactions on β-bis-ketoiminate
ruthenium(II) complexes and β-bis-ketoiminate copper(II) complexes respectively.
Chapter 7 contains experimental details and characterisation data for all the
complexes synthesised within this thesis, and protocols for all the biological and
chemical studies.
Appendix presents a summary of X-ray crystallographic structure analysis for all
the crystal structures reported within this thesis.
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Cancer
Cancer remains one of the main causes of morbidity and mortality worldwide; an
estimated 8.8 million people died from cancer worldwide in 2015. The incidence and
mortality rates of cancer continue to increase globally, more so in developing
countries.1 In the UK, statistics for 2015 indicate that every two minutes someone
was diagnosed with cancer, accounting for 359 960 new cases in that year.2 Cancer
risk is factual and an estimated 1 in 2 people born in the UK after 1960 will be
diagnosed with some form of cancer during their lifetime.
There are over 100 different types of known cancers, however, nearly half (46%) of
the new cases reported in 2014, in the UK, were accounted for by lung, breast,
prostate and colorectal cancers.3 Cancer also has significant economic impacts, with
the NHS spending over £5 billion annually on cancer care,4 a figure that is set to
increase with growth and aging of the population.
Cancer is an umbrella term given to a heterogenic group of complex diseases
characterised by cellular malfunctions. Healthy or normal cells are programmed to
know “what to do” and “when to do it”. Cancerous cells do not have this
programming and therefore grow and replicate out of control, eventually invading
and spreading from the site of origin (primary site) to other parts in the body.5, 6
Mitosis is the process through which cells divide and is controlled by two cancer
genes known as oncogenes and tumour gene suppressors. If one or usually more of
the genes have a mutation the cell can uncontrollably divide causing a lump of
abnormal tissue known as a tumour to develop.
Activated oncogenes can cause the abnormal cell to avert programmed cell death
(apoptosis), survive and cell proliferate.7 This can result in one of the two types of
tumours, benign or malignant. A benign tumour cannot metastasize, is rarely life
threatening and can be treated. However, a malignant tumour can invade surrounding
tissues, spread throughout the body, is usually life threatening and difficult to treat.8
Tumours are not simply isolated masses, but are complex tissues with distinct
originality, cell type and molecular mechanisms, participating in heterotypic
interactions with each other.6 Despite the complexity and diversity, Hanahan and
Weinberg have proposed six essential alterations in normal cell physiology that
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facilitate the evolution of normal cells to a neoplastic state, allowing them to survive,
proliferate and disseminate. The six hallmarks, common for nearly all cancer types
(>100) are; autonomous growth signals, evasion of growth inhibitory signals,
evasion of apoptosis, infinite replicative potential, sustained formation of new blood
vessels (angiogenesis) and tissue invasion and metastasis.6, 9 The hallmarks above
are made possible by two enabling characteristics: genomic instability and tumour
promoting instability, the former being the most prominent.10
The number of cancer survivors has increased over the years due to positive
advances in preventive measures (changes associated with diet and lifestyle), early
detection and prognosis, better treatment and (or) patient care as well as universal
access to health care.11, 12 Treatment options for cancer include but are not limited to,
surgery, chemo-, radiation-, immune- and targeted therapy. In many cases a
combination of therapies are used for enhanced effects.11
Metal based drugs
The pharmaceutical industry is largely made up of organic, biological and (or)
natural based drugs.13 However, metal based medicines and remedies have been
known and used since the ancient days of civilisation of Egypt, India, Mesopotamia
and China. The ancient Egyptians used copper in the sterilisation of water and the
Chinese used gold for medical applications.13-15 Perhaps the birth of modern
chemotherapy was through one of the first known metal based drugs salvarsan
(Figure 1.2.1), an arsenic-based antimicrobial agent used for the effective treatment
of syphilis, until it was replaced by penicillin after World War II.13, 16
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Figure 1.2.1: Cyclic pentamers and trimers of Salvarsan
Natural evolution has also incorporated a number of metal ions in vital and essential
roles in living systems, for example iron in oxygen transportation, calcium and zinc
for structural framework, zinc in insulin for regulation of sugar metabolism as well
as copper and zinc as metallo-enzymes for biological catalytic reactions.14, 17 Such
diverse applications are possible due to the interaction between the positively
charged, electron deficient metal ions and the electron rich biological molecules such
as proteins and DNA.14
Interest in the application, importance and reputation of metal based drugs,
particularly organometallic compounds has gradually increased in the last two
decades. Organometallic compounds have unique and remarkable physiochemical
properties, an added advantage over purely organic based compounds. These
properties include diverse structure and stereochemistry, variable accessible
oxidation states, possibility of ligand exchange as well as redox and catalytic
activities. 16, 18
In greater detail, compared to carbon based chemistry, organometallic compounds
are able to form linear to octahedral. Metal ions are known to readily coordinate to a
diverse range of ligands. This allows for chemical modifications and the tailoring of
the resultant organometallic compound to recognise and specifically interact with
biological targets. The variable accessible oxidation states facilitate the participation
of the compound in biological redox reactions. Additionally, ligand exchange
reactions give the possibility of interaction and coordination of organometallic
compounds with cellular components such as enzymes, proteins and DNA. Most of
Introduction Chapter 1
5
these compounds are kinetically stable, lipophilic and neutral, with the metal atom in
a low oxidation state making them susceptible to chemical reactions.16, 18 Perhaps of
all these advantages the most significant is the control that the medicinal chemist has
over all these properties through rational ligand design and synthesis.
To date, a number of metals including antimony, bismuth, copper, cobalt, gallium,
gold, iridium, iron, osmium, palladium, rhodium, ruthenium, silver, tin, titanium,
vanadium and zirconium have been investigated for therapeutic applications.19-27
Arguably the landmark discovery of the therapeutic activity and subsequent clinical
success of cisplatin (Figure 1.2.2) by Rosenberg et al. was the turning point for
medicinal inorganic chemistry, particularly anti-cancer research.28
1.2.1 Cisplatin
Platinum based drugs form a distinct class of highly regarded and successful
chemotherapeutic compounds with anti-tumour and anti-viral clinical applications.29
Known as Peyrone’s chloride, cisplatin was first synthesised by Peyrone in 1844 and
its structure documented by Alfred Werner in 1893.30 However, the compound did
not gain any scientific significance until the serendipitous discovery of its
therapeutic properties by Rosenberg et al. in 1965. In his experiment Rosenberg
observed cell division inhibition in Escherichia coli when using platinum mesh
electrodes. Further investigations identified cis-diamminedichloroplatinun(II) as the
species responsible for this activity, thus initiating exploration of possible medical
applications.31
Figure 1.2.2: Cisplatin
Cisplatin (Figure 1.2.2) entered clinical phase trials in 1971 and was approved by
the United States Food and Drug Administration (FDA) for pharmaceutical use in
1978.32, 33 Since then cisplatin has become the world's leading anti-cancer drug and is
highly successful in the treatment of different types of neoplasms such as lung,
ovarian, bladder, testicular, head and neck, esophageal, colon, gastric, breast,
melanoma and prostate cancer. More than half a century after its clinical approval,
cisplatin, used as a first-line treatment or in combination with other drugs remains
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the “gold standard” against which potential platinum and non-platinum metal based
anti-cancer drugs are compared.34
The inherent anti-cancer properties of cisplatin are as a result of its interaction with
DNA leading to induction of apoptosis. Once administered, through injection or
infusion, the neutral cisplatin enters the bloodstream where the high chloride
concentration (~100 mM) prevents exchange of labile cis-chloro ligands with water
molecules.35 Cisplatin becomes activated once it enters the cytoplasm through a
combination of passive diffusion and facilitated active transport mechanisms.
Passive diffusion is highly dependent on the concentration of the drug inside and
outside the cell and the overall charge on the platinum species. Transporter proteins
responsible for copper cell regulation, copper influx protein CTR1 and two copper
efflux proteins, ATP7A and APT7B have been implicated in the facilitated and
active uptake of cisplatin.36-38 Inside the cytoplasm, the chloride ion concentration is
low (~10mM) allowing the labile cis-chloro ligands of cisplatin to dissociate and be
replaced by water molecules (Scheme 1.2.1).35, 39
Scheme 1.2.1: Hydrolysis of cisplatin
The mono- or di- aquated hydrolysis products are potent electrophiles that
potentially react with any nucleophile, including the sulfhydryl groups on proteins
and nitrogen donor atoms on nucleic acids. The cytotoxicity of cisplatin is due to its
preferential interaction with the N-7 reactive centre of guanine and adenine in DNA
forming DNA adducts (Figure 1.2.3). The DNA adducts can be DNA-protein, DNA-
DNA interstrand and intrastrand crosslinks (Figure 1.2.3), with DNA-DNA
intrastrand adducts being the most favoured.30, 40 Such cisplatin−DNA adducts, 
together with cellular pathways (including those involving p53, p73, ATR and
MAPK) activated in response to cisplatin lead to cell division blockage, transcription
inhibition, cell-cycle arrests, oxidative stress, failure to repair Pt-DNA adducts and
ultimately apoptosis.13, 30, 41 Transplatin, the trans stereoisomer of cisplatin is known
to be less cytotoxic than cisplatin and inactive against tumours. This is primarily
because of its inability to form intrastrand DNA adducts and the ease with which
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trans adducts are easily repaired compared to their cis analogues. The toxicity of the
diaquo intermediate in the cis configuration is 30 times more than that of the trans
diaquo intermediate.42
Figure 1.2.3: Cisplatin intra- and interstrand DNA cross linking 43
Despite the impressive success of cisplatin in clinical use, a number of drawbacks
and side-effects associated with its narrow therapeutic window limit its application.
Cisplatin is intravenously administered, cytotoxic to a limited spectrum of cancers
and like many antineoplastic agents is not selective between healthy and cancerous
cells. Of major concern is systemic toxicity as a result of cisplatin binding to other
biomolecules other than the primary target DNA.44 A known fact is that only 1% of
the intravenously administered drug reaches DNA, this is because platinum has high
affinity for thiol- and selenium-containing proteins in the cytoplasm. Thiol- and
selenium-containing proteins are abundant both extra- and intracellularly, platinum
subsequently interacts with them leading to disruption of various protein and enzyme
functions. This limits the bioavailability and efficacy of the drug leading to drug
inactivation45 and adverse drug reactions (ADRs). ADRs related to clinical use of
cisplatin are not limited to but include, nephro-,46 neuro-, cardio- oto-, gastro- and
hepatotoxicity,47 hair loss, anaemia, and bone marrow suppression.44, 46, 48, 49
Nephrotoxicity is among the most severe ADRs and occurs in approximately a third
of patients. The kidneys absorb cisplatin more than other body organs and are the
main route for its excretion.30 The exact mechanism of cisplatin-induced
nephrotoxicity has not yet been fully clarified. However, cisplatin is known to induce
degenerative renal lesions characterised by hydropic degeneration, necrosis and
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tubular atrophy which in some cases can lead to severe kidney failure.48 Although to
a lesser extent, cisplatin is also known to induce immunological side effects such as
anaphylactic shock and asthma. Some of the allergic reactions can include abdominal
discomfort (diarrhoea and cramps), rashes (swelling, pruritus and urticaria) and
respiratory dysfunction (for example wheezing).48
Another drawback associated with the clinical use of cisplatin is the development of
resistance, defined as the failure to undergo programmed cell death at clinically
relevant drug concentrations. Resistance can be natural (intrinsic resistance) as seen
in colon cancer or through prolonged drug exposure (acquired resistance) as seen in
non-small cell lung cancer.29 Resistance mechanisms although still under debate are
a combination of insufficient formation of cisplatin-DNA adducts due to changes in
the uptake and efflux of the drug, cellular survival of cisplatin-DNA adducts through
DNA repair or removal or by tolerance mechanisms and increased inactivation of the
drug through interaction with thiol containing molecules such as gluthathione
(GSH).33, 44, 50 Figure 1.2.4 shows the different mechanisms involved in inhibiting
the apoptotic signal in cisplatin resistant tumour cells.40 Better understanding of
mechanisms of action and tumour resistance have led to four strategies being
proposed to bypass cisplatin resistance:
1. Improved delivery of platinum to tumours; targeted delivery using delivery
vehicles
2. Co-administration of cisplatin with pharmacological modulators of resistance
mechanisms
3. Combination of cisplatin with molecularly targeted drugs
4. New, improved platinum drugs.33
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Figure 1.2.4: Mechanisms involved in apoptotic signal inhibition in cisplatin resistant
tumours
1.2.2 Other platinum based anti-cancer drugs
The limitations and drawbacks associated with the clinical use of cisplatin,
particularly toxicity and drug resistance have prompted research into alternative
platinum anti-cancer agents. Various cisplatin analogues have been synthesised and
evaluated over the years with 13 of these going into clinical trials.30 However only
two other platinum anti-cancer drugs have so far gained FDA approval; carboplatin
in 1989 and oxaliplatin in 2002 (European approval in 1999).13 Figure 1.2.5 shows
the platinum based drugs currently in clinical use trials.
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Figure 1.2.5: Platinum drugs in clinical use and trials13
Cisplatin, carboplatin and oxaliplatin (Figure 1.2.5) are structurally similar with a
square planar geometry around the central platinum(II) ion. The amine ligands are
strongly bound to the platinum ion, and as such the carboxylate ligand acts as a
leaving group, allowing the platinum to interact with DNA bases.51
Carboplatin, [cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II)], is an
intravenously administered chemotherapeutic drug for the treatment of ovarian, lung,
head and neck cancer. The chelate effect of the carboxylate ligand makes it less
labile than the chloride leaving groups in cisplatin as such carboplatin is less reactive
than cisplatin, showing slower DNA binding kinetics.29 The inherent stability of
carboplatin leads to less carboplatin-protein adducts being formed and excreted. The
lower excretion rate increases the retention half life of carboplatin, a significant
advantage over cisplatin.30 Similar to cisplatin, the mechanism of action of
carboplatin is through binding to DNA and proteins although carboplatin may be
susceptible to alternative mechanisms. The greatest advantage of carboplatin over
cisplatin is the reduced side effects such as nephro-, oto- and neurotoxicity.13, 33 A
major drawback associated with carboplatin is myelo suppression which leads to
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blood white cell reduction evidently exposing the patient to infection by various
organisms.34
Colorectal cancer was previously known to be insensitive to platinum based
neoplastic agents.33 Oxaliplatin, [(1R,2R)-diaminocyclohexane oxalatoplatinum(II)],
is currently the only platinum based drug to show any activity against colorectal
cancer, especially when used in combination with 5-fluorouracil and leucovorin.52
Oxaliplatin shows activity against cisplatin-resistant tumours, and is less myelo
suppresive than carboplatin. A limitation of oxaliplatin is that the drug induces
peripheral neuropathy (nerve damage).53, 54 Interestingly the intracellular
accumulation of oxaliplatin is less dependent on the copper transporter CTR1, a
feature quite different from cisplatin and carboplatin.33
Heptaplatin, lobaplatin and nedaplatin (Figure 1.2.5) are other cisplatin analogues
that have gained regional clinical use approval but are still under clinical trials in the
United States.13 Hepta-, loba- and nedaplatin are licensed in Korea, China and Japan
respectively.34 A number of platinum based drugs are also under investigation in
either pre-clinical or clinical trials, all in attempt to improve or eliminate the adverse
side effects of the present drugs while maintaining or improving the efficacy of the
drug.
1.2.3 Ruthenium anti-cancer drugs
The last four decades have witnessed a surge in the search for bioorganometallic
anti-cancer drugs based on metals other than platinum. Among these, ruthenium
(RuII and RuIII), gold (AuI and AuIII)55-57 and titanium (TiIV)58, 59 complexes are
among the most studied.60 The following sections discuss some key complexes
currently being investigated for application in the anti-cancer field, with particular
focus on ruthenium (1.2.3) and copper (1.2.4) complexes.
Ruthenium based complexes have emerged as promising anti-tumour and anti-
metastatic agents with potential anti-cancer applications against platinum-resistant
tumours.61 Ruthenium complexes theoretically possess a number of unique
properties that can justify their potential use as alternative therapeutic agents to
platinum based drugs:
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i. The rich synthetic chemistry of ruthenium is well investigated and known,
with most complexes being stable both in solid and solution state.62
Ruthenium is known to form strong chemical bonds and can bind to a variety
of biomolecules with differing electronic properties and hardness.63 The
octahedral geometry around the ruthenium centre offers more diversity in
terms of ligand coordination, substitution and in turn ligand exchange
kinetics, implying a reactivity and mode of action different from cisplatin.61
ii. The ruthenium centre can easily access oxidation states II, III and IV under
physiological conditions. The energy barrier for interconversion between
these oxidation states is relatively small allowing Ru(III) and Ru(IV)
complexes to act as inert prodrugs, being reduced under hypoxic conditions
inside the tumour to the active Ru(II) species. This activation by reduction
phenomenon results in ruthenium complexes being more selective towards
cancerous cells and more importantly hypoxic tumours, known to be resistant
to chemotherapy and radiation.61, 64-66
iii. Ruthenium can mimic iron in binding to serum transferrin and albumin for
transportation into cells.67 In addition to higher membrane permeability,
rapidly dividing cancer cells have a presumed higher need for iron leading to
an over-expression of transferrin receptors on the cancerous cell surface. As
such ruthenium based drugs are able to preferentially accumulate in
neoplastic cells compared to normal cells, a feature which reduces their
systemic toxicity and side effects.61, 64, 68, 69
The discovery in the 1970s of “ruthenium red”, a cytological dye which exhibits
anti-cancer properties through inhibiting mitochondrial calcium transport marked the
first systematic investigation of ruthenium complexes for therapeutic
appliacations.70-72 This preceded the discovery by Clarke et al. that chloro-ammine-
Ru(III) compounds that could be regarded as Ru analogues of chloro-ammine-Pt
compounds showed promising therapeutic properties.62, 73 Poor solubility was the
major obstacle with these complexes leading to termination of further
investigations.74, 75 However, further synthetic investigations into more soluble
complexes led to the discovery of NAMI-A and KP1019, the first ruthenium based
anti-cancer drugs to progress to clinical trials.
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1.2.3.1 NAMI-A
NAMI-A, imidazolium-[trans-imidazole-DMSO-tetrachlororuthenate(III)] (Figure
1.2.6(a)), a Ru(III) coordination compound discovered by Sava et al. is perhaps the
most investigated in the ruthenium family and the first to enter phase I clinical
trials.76 NAMI-A was originally synthesised as NAMI (Figure 1.2.6(b)) in which the
imidazolium counter-ion is replaced by sodium. Due to reproducibility issues in the
synthetic procedure and poor stability and solubility, NAMI was replaced by NAMI-
A in pre-clinical experiments.73, 76
Ru
Cl
Cl Cl
Cl
N
S
NH
O
HN
H
N
(a) (b)
Figure 1.2.6: (a) NAMI-A, (b) NAMI
Similar to cisplatin, hydrolytic decomposition of NAMI-A is highly dependent on
pH. NAMI-A undergoes both chloride and DMSO hydrolysis to form a mixture of
poly-oxo Ru species, that to date have not been fully characterised. According to
Alessio,77 NAMI-A can be considered as the “ultimate prodrug” that gradually loses
all its original (supporting and leaving) ligands, with only the Ru metal ion
eventually reaching the target site. In this scenario once administered there is no
control over the rate and location of ligand release.77
Interestingly NAMI-A has negligible cytotoxicity towards the primary tumour, rather
exhibits anti-metastatic and growth inhibition properties independent of the type of
primary tumour and stage of growth against lung metastases for various solid
tumours.64 The substantial lack of cisplatin-like cytotoxicity against solid tumour cell
lines is related to the rather low cellular internalisation of NAMI-A and its
metabolites. This is as a result of the rapid extracellular transformations that NAMI-
A undergoes and the ability of its metabolites to primarily interact with cell walls
rather than DNA as in cisplatin.78, 79
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Although still under extensive investigation, NAMI-A is thought to inhibit
metastasis through non-traditional cell cytotoxicity mechanisms via multiple
interactions outside and inside the cells. NAMI-A has been shown to temporarily
block cell cycle progression80 leading to DNA and RNA binding81, 82 and the
inhibition of matrix metalloproteinase (MMP-2 and MMP-9) release.83 However,
these intracellular effects are related to cellular uptake and are only feasible at
physiologically non-relevant concentrations (>100 μM) of NAMI-A and thus cannot 
explain the anti-metastatic activity of NAMI-A.77 Other properties that occur at
lower, physiologically relevant drug concentrations such as the inhibition of key
steps in angiogenesis (for example cell proliferation) are more likely involved in the
mechanism of action.84 In addition factors unrelated to the penetration of the
compound inside cells such as increased cell adhesion, reduced cell mobility, and
decreased ability of cells to penetrate into collagen gels better explain the anti-
metastatic property of NAMI-A.85
Phase I dose escalation and pharmacokinetics studies for NAMI-A on several solid
tumours gave promising results with fairly moderate toxicity prompting phase II
clinical trials.86 In support of the proposed mechanisms of action described above, no
ruthenium-DNA adducts were detected in DNA extracted from white blood cells
even at high drug concentrations. However, to a larger extent NAMI-A was found
bound to plasma proteins.77 Based on phase 1 results NAMI-A was given in
combination with gemcitabine to patients with non-small cell lung cancer (NSCLC)
in phase II clinical trials. However, NAMI-A did not progress beyond phase II
clinical trials as the overall efficacy was lower compared to gemcitabine alone.77, 87
1.2.3.2 KP1019 and NKP1339
KP418, imidazolium trans-[tetrachloro-bis(1H-imidazole)-ruthenate(III) (Figure
1.2.7(a)) discovered by Keppler et al. display tumour reduction activity against B16
melanoma cell lines88 and rat colorectal carcinoma models.89 Further investigations
on this class of complexes led to the discovery of KP1019, indazolium [trans-
tetrachloro-bis(indazole)-ruthenate(III)] (Figure 1.2.7(b)), the indazole analogue of
KP418.90 Pre-clinical studies with KP1019 showed higher activity against rat colon
cancer models. Interestingly KP1019 also showed higher activity than 5-fluorouracil,
the standard licensed agent against colorectal cancer.91
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NKP1339 (Figure 1.2.7(c)), the sodium salt analogue of KP1019 was prepared as a
precursor in the synthesis of KP1019.92 However, due to its high water solubility has
become the representative of this class of compounds and lead candidate for further
clinical development.93
(a) (b) (c)
Figure 1.2.7: Structures of (a) KP418 (b) KP1019 (c) NKP1339
Despite being structurally similar to NAMI-A, KP1019 shows no anti-metastatic
effects, rather showing classical characteristics of conventional cytotoxicity against
primary cisplatin-resistant colorectal tumours with negligible occurrence of acquired
resistance.62, 94 Both KP1019 and NKP1339 are intravenously administered and
undergo rapid cellular uptake through interactions with plasma proteins, in particular
albumin and transferrin.95, 96 These proteins transport and deliver the Ru compounds
inside the cell, with KP1019 preferentially binding to albumin. The preferential
tumour accumulation of KP1019 can be explained by the “enhanced permeability
and retention effect” (EPR) in which albumin accumulates in malignant tissues due
to adverse structural changes such as porous capillary tubes.97
NK1019 and NKP1339 are hypothesised to undergo activation by reduction in which
Ru(III) compounds serve as prodrugs, being reduced under hypoxic conditions to the
active Ru(II) species which are in turn more reactive towards biomolecules. Notably
activation by reduction takes place after intracellular release of the compound from
the plasma proteins.75, 93, 98 Thus the mechanism of action of KP1019 and NKP1339
is highly dependent on their redox chemistry and through induction of G2M cell
cycle arrest, blockage of DNA synthesis and initiation of apoptosis via the
mitochondrial pathway.62 Additionally, NKP1339 serves as a direct nitric oxide
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scavenger, possibly inducing effects in cell migration and angiogenesis.84 Taken in
combination, KP1019 and NKP1339 are potential potent drug candidates with
limited side effects as observed so far in clinical phase I trials.93
1.2.4 Copper anti-cancer drugs
In the ongoing search for non-platinum based anti-cancer agents, copper complexes
have received considerable attention.99 Copper is an essential element involved in
many biological pathways such as the function of several enzymes and proteins
involved in energy metabolism, respiration, and DNA synthesis.100, 101 The
concentration of copper in the body is tightly regulated; although rare disruptions in
copper homeostatic balance can result in disorders such as Menkes’ disease102
(copper deficiency) or Wilson’s disease103 (copper overload).104
Facilitated by the hypothesis that copper being an endogenous trace element found in
virtually all living things will be less toxic to healthy cells than non-essential ones,
investigating therapeutic applications for copper based complexes is a logical
advancement.105 The use of multiple copper transporters in the uptake, intracellular
transport and efflux of platinum drugs such as cisplatin offers the possibility of
overcoming cisplatin resistance and improving selectivity towards neoplastic
tumours.106 Ex vivo experiments have shown that in comparison to healthy tissues
cancerous tissues (breast, prostate, brain and lung) have increased copper
concentrations.107 A seemingly appropriate explanation for this is the participation of
copper as a crucial cofactor in angiogenesis,108 a critical factor in tumour growth,
invasion and metastasis.109 Thus, copper based anti-cancer drugs have the ability to
selectively induce cytotoxicity in tumours. In addition, intensive research has gone
into the chemistry and biochemistry of copper,110, 111 its mechanisms of
absorption,112-114 distribution,115-117 metabolism and excretion107, 118 as well as its role
in development of cancer and other diseases.100, 104, 119, 120
Copper can easily access oxidation states I and II under physiological conditions. As
such most common coordination and organometallic complexes of copper in the
literature have the central ion in the +1 and +2 oxidation states, and only a few
examples with +3.121, 122 These copper (I\II) complexes are labile and can
preferentially adopt distorted coordination geometries.100 These factors are highly
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dependent on the donor atoms (N, O, S and halides) bound to the metal ion and the
choice and nature of the ligand(s) (chelation, electronic and steric properties).123
1.2.4.1 Copper complexes with thiosemicarbazone ligands
Thiosemicarbazones (TSCs) (Figure 1.2.8) are a class of diverse ligands that have
found applications as pharmacophores due to their ability to form stable complexes
with transition metal ions.124 Interest in their potential medical application as anti-
viral, anti-fungal, anti-bacterial and anti-cancer agents has been intensively
explored.125
Figure 1.2.8: Thiosemicarbazone frameworks
The anti-neoplastic effects of copper-thiosemicarbazone complexes have been
explored as far back as the 1960s 126, 127 and are still ongoing, with promising
results.128-130 The major obstacle observed with the various analogues of copper-
thiosemicarbazone complexes synthesised over the years is poor water solubility and
high in vivo toxicity.131, 132 As with other transition metals current research is
primarily focused on improving the solubility and toxicity of these complexes
through modification of the TSC ligand framework.133-135
Despite the evident therapeutic efficacy of TSC ligands, chelation to metal
complexes such as copper has been shown to greatly enhance the efficacy and
solubility of the resultant complex.128, 136 Currently many mono and dimeric
copper(II) thiosemicarbazone complexes have been synthesised and investigated as
anti-tumour agents in various in vivo and in vitro experiments.124, 137, 138 A significant
number of these complexes have displayed activity in the nano-molar range against a
broad spectrum of cancers.100, 133, 139 Interest in copper complexes has been fuelled
by the hypothesis that, in addition to lower toxicity copper complexes are able to
overcome cisplatin resistance in tumours. The possibility of different mechanism(s)
of action to that of covalent DNA binding observed in cisplatin and analogues is
possible and supports this hypothesis.100 The mechanisms of action of copper
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thiosemicarbazone complexes, although still under investigation, involve cell
proliferation inhibition, cell cycle arrest and initiation of apoptosis.105
To date, the most successful therapeutic agents in the thiosemicarbazone family are
triapine, (3-aminopyridine-2-carboxaldehyde TSC) (Figure 1.2.9(a)) and di-2-
pyridylketone-4,4-dimethyl-3-TSC (Dp44mT) (Figure 1.2.9(c)), with triapine (3-
AP) having reached phase II clinical trials against several cancer types.100, 140, 141
Triapine R = H; HApT
R = Me; HAp44mT
R = H; HDpT
R = Me; HDp44mT
(a) (b) (c)
Figure 1.2.9: Structures of copper TSCs
Copper(II)-3-AP complexes of the type shown in Figure 1.2.10 have been
synthesised for studies aimed at comparing their inhibitory activity relative to that of
metal free 3-AP. The efficacy of copper(II)-3-AP complexes were in contrast to the
popular hypothesis that coordination to metal ions leads to higher cytotoxic activity.
The complexes displayed similar or decreased biological activity to the free ligand.
Their anti-proliferative activities were likely due to the complexes acting as
intracellular transporters of the ligand that in turn dissociate initiating biological
activity. In addition, the decrease in biological activity may be due to the high
stability of the Cu(II) complexes.142-145
Figure 1.2.10: Copper(II)-3-AP complexes
In further attempts to improve the activity of 3-AP and Dp44mT, copper complexes
with their analogues, ApT (Figure 1.2.9(b)) and DpT (Figure 1.2.9(c)), have been
synthesised and their anti-cancer activities evaluated. Santini100 and other research
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groups146-148 have shown that the monovalent species [Cu(TSC)]+ are the active
potent species in vivo and in vitro and resulted in significant increases in anti-tumour
activity. They have hypothesised that instead of the dissociated ligands, the copper
complexes were responsible for the biological activity. In addition, copper(DpT)
complexes showed higher anti-proliferative effects compared to the copper(ApT)
complexes.146
1.2.4.2 Copper complexes with mixed chelate ligands
Ruiz-Azuara et al. have developed a series of copper based drugs registered under
the trade name Casiopeinas® (Cas) (Figure 1.2.11).149 These mixed-chelate cationic
copper(II) complexes have the general formula (Cu(N-N)(X-X))NO3 where N-N
represents diamine donor type ligands (phen, bipy and analogues) and X-X
represents (N,O) or (O,O) donor ligands (acetylacetone (acac) or salicyaldehydate
(alal)).150-152 In successive investigations the nature of the X-X ligand was found to
have negligible influence on the biological activity of the complexes. However, the
presence of the fused aromatic ring in the phen-containing complexes was necessary
for biological activity, as such phen-containing complexes had higher activity than
their bipy-analogues.100, 153 In vivo and in vitro assays on HeLa, MCF-7 and HCT-15
cells showed cytotoxic,149, 154 genotoxic149 and anti-tumour activity.152, 155
Cas-II-gly Cas-III-ia
Figure 1.2.11: Structures of representative Casiopeinas family of complexes
Figure 1.2.11 shows the two most investigated within this broad and diverse family
of complexes. Cas-II-gly is the most successful having reached clinical trials in
Mexico.105 The mechanism of action of the casiopeinas family of complexes is still
under intense investigations although preliminary results suggest a number of
biological targets leading to a complex mechanism of action. Cytotoxic activity is as
a result of activation of pro-apoptotic pathways (through generation of reactive
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oxygen species (ROS), mitochondrial toxicity or dysfunction and cell cycle arrest),
DNA intercalation (and fragmentation), cell migration and cell proliferation
inhibition.100, 156-158
The chemistry of copper based anti-cancer drugs is broad and diverse; further
compounds with promising therapeutic applications that have not been covered by
the author in this review are summarised in Table 1.2.1100
Table 1.2.1: Summary of other copper based compound with therapeutic applications
Compound Tumour type Ref
Leukemia P380 159
HL60 human
xenografts
160
MNU induced
rat mammary
carcinoma
161
Erlich ascites
carcinoma
162
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Compound Tumour type Ref
MNU induced
rat breast
cancer
163, 164
Erlich ascites
carcinoma
165
Erlich ascites
carcinoma
166O
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Carbon Monoxide Releasing Molecules
Carbon monoxide (CO) was first discovered in 1849 as a naturally occurring
metabolite in the exhaled air of healthy human beings.167 Despite its natural
occurrence and role as an endogenous small signalling molecule in the human body,
carbon monoxide is also known to be relatively toxic and dangerous to mammals at
high concentrations. Commonly referred to as the “silent killer” due to its ability to
rise, undetected, to toxic concentration; the toxicity of this gas partially arises from
increased concentration in the tissues as a result of inhalation, which in turn
interferes with normal mitochondrial function. CO bound to iron centres in
haemoglobin [carboxyhaemoglobin (HbCO)] is also known to reduce the oxygen
carrying capacity of blood, resulting in inhibition of oxygen delivery and release to
tissues eventually leading to hypoxia.168-172
However, endogenous carbon monoxide produced in mammals by the catabolism of
heme by heme oxygenase enzymes (inducible (HO-1) and constitutive (HO-2))
(Scheme 1.3.1) has been shown to have therapeutic and immunomodulatory
applications. Lack of, or excess production of, carbon monoxide has been linked to
the development of conditions such as tissue cellular apoptosis173, diabetes173, 174,
inflammation175-177, cystic fibrosis178, 179, bronchiectasis180, rhinitis181 and
asthma.182, 183 On the other hand, medical evidence170 has shown that CO can assuage
or prevent some conditions such as cell proliferation173, hepatic ischemia184,
cardiovascular inflammation173, 185, 186, anti-atherogenesis187 and cyto-protective
effects.173, 188
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Scheme 1.3.1: Production of CO through catabolism of heme
The therapeutic properties and applications of CO present an interesting and
intriguing area of research in drug discovery. The challenge however has been the
strictly-controlled delivery, localisation and selectivity of carbon monoxide
administered in its gaseous form, in order to avoid toxic side effects and tissue
hypoxia. Carbon monoxide releasing molecules, also known as CORMS, have
emerged as a possible and alternative delivery system. These organometallic
compounds, containing at least one carbonyl ligand bound to a transition metal can
act as a prodrug and upon triggering or activation release the bound CO, which then
acts as endogenously generated CO.168-170, 172, 189 Thus, in principle CORMs act as
prodrugs allow for the controlled, targeted and specific delivery of carbon monoxide
to cellular and tissue targets. To date, different stimuli have been explored in
promoting CO release including photochemical,190, 191 thermodynamic192, 193 and
enzymatic triggers.170, 194, 195
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Over the years a number of metal carbonyl complexes have been prepared and their
medicinal properties investigated, examples include cobalt196, ruthenium197, iron198,
chromium199, 200 and managanese.192 Of particular interest to the author are
ruthenium carbon monoxide releasing molecules, thus a brief over view of these is
provided herein.
1.3.1 Ruthenium CORMs
The commercially available [RuCl2(CO)3]2, tri-carbonyldichlororuthenium(II) dimer
(Figure 1.3.1(a)) also known as CORM-2 is one of the first reported CORMs, and
has attracted considerable attention as a control substance. Extensive research has
gone into the investigation of therapeutic and biological application of CORM-2, as
shown by the large number of publications available.201
(a) (b)
Figure 1.3.1: (a) CORM-2 and (b) CORM-3
Tricarbonylchloro(glycinato)ruthenium(II) (CORM-3) [Figure 1.3.1(b)] is possibly
the most commonly used CORM to date due to its solubility in water. With more
than 100 publications this compound has become the standard CORM for the
investigation of different therapeutic applications of carbon monoxide releasing
molecules on a wide range of biological systems. 169 Interestingly CORM-3 has low
toxicity, can act as a vasodilator and greatly increases the survival rate of mice after
heart transplants.202
To date in vivo and in vitro tests on ruthenium CORMs has shown a variety of good
therapeutic properties. Examples include protection against cisplatin-induced
nephrotoxicity,203 suppression of the inflammatory response204, 205 and prevention of
cardiac graft rejection and positive inotropic effects of the heart.202, 206
Despite their therapeutic advantages, factors controlling the release of CO from these
complexes are not yet fully understood. However, it is thought that factors such as
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solubility in water, electron density, type of ligand and oxidation state of the metal
centre play an important role.207
1.3.2 CORMs in cancer
The immense interest in biological applications of CO and CORMs in inflammatory
and vascular diseases, microbial infections, and organ transplants has led to a large
number of scientific publications on the subject.208-212 In contrast, little interest has
been shown in pursuit of the potential application of CO and CORMs as anti-cancer
agents. The effects of carbon monoxide releasing molecules on specific cancer
processes involved in cancer initiation and progression, such as angiogenesis and
apoptosis, have been studied. Results obtained are as variable as they are cell-type
specific, highlighting a major obstacle in the potential application of CO and
CORMs in cancer therapy. Controversy on the molecular targets and specific
signalling pathways affected by CO remain unclear, often leading to contradicting
reports; affecting research interest in their application as anti-cancer agents.167, 213, 214
The effects of CORM-2 (Figure 1.3.1 (a)) on human pancreatic cancer cell lines
have been investigated by Vítek et al.215 CORM-2 in clinically relevant and
applicable doses was a potent inhibitor of pancreatic carcinogenesis. Prevention of
Akt protein phosphorylation, a key process in pancreatic cancer initiation,216 led to
cell proliferation inhibition and apoptosis. In addition, in vivo treatment of pancreatic
cancer models with CORM-2 led to significant decrease in tumour volume and
increase in survival rate. Further investigations with CO gas confirmed that the anti-
cancer properties were as a result of carbon monoxide release from CORM-2.215
Carrington et al.217 have synthesised azopyridine derived Mn(I) carbonyl complexes
(Figure 1.3.2) and investigated their activity as anti-cancer agents against malignant
cell lines, HeLa (cervical cancer) and MDA-MB-231 (breast cancer). In addition to
favourable visible light dependant CO release, MnBr(azpy)CO3 [Figure 1.3.2(a)]
showed dose-dependent eradication of the cancer cells. On exposure to CO,
morphological changes such as cell shrinkage and bulging, co-factors in apoptosis
were observed. Control reactions in the absence of light showed no cell viability
supporting the potential application of these complexes as photo-activated anti-
cancer drugs.213, 217
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Mn
N CO
CO
CO
Br
N
N
(a) (b)
Figure 1.3.2: Azopyridine derived Mn(I) carbonyl complexes
In a later study, aimed at tracking the photoCORMs in biological targets, the same
group synthesised a fluorescent manganese carbonyl complex that acts as a
“turn-on” photoCORM. This complex, fac-[MnBr(CO)3(pbt)] (Figure 1.3.3), is
visible light sensitive coupled with heightened fluorescence upon CO release to
cellular targets. MTT assays showed trackable CO delivery within cells and dose-
dependent inhibition of breast cancer cells through rapid CO-induced apoptosis.218
Figure 1.3.3: PhotoCORM MnBr(CO)3(pbt)
A series of N-substituted heterocyclic carbonyl complexes with manganese,
molybdenum or tungsten metal centres have been synthesised by Hu and co-workers.
The various growth inhibitory effects observed on HeLa cells were a result of the in
solution slow release of CO and the heterocyclic ligands from the complexes.219
Similarly, proliferation inhibition effects on HeLa cells were observed by Gong et
al.220 with slow CO releasing hexacarbonylcobalt complex esters (Figure 1.3.4). The
mechanism of action is a combination of cell cycle arrest, generation and increase of
ROS, cell division and proliferation inhibition leading to apoptosis.213
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Figure 1.3.4: Hexacarbonylcobalt complex esters by Gong et al.
Metal ketoiminate complexes
β-Ketoiminate (acnac) ligands are analogues of β-diketonate (acac) ligands in which 
one keto group is replaced by an imine group (Figure 1.4.1). β-ketoiminate ligands 
have been widely investigated and applied as chelating systems in main group and
transition metal chemistry. This is mainly due to their ease of preparation and
modification of both steric and/or electronic properties.221 Transition metal
complexes such as copper, cobalt, nickel, palladium, ruthenium, titanium, platinum,
iridium, zinc and zirconium, stabilised by various forms of β-ketoiminate ligands 
have been synthesised and reported with the main applications being in catalysis.222-
234
β-diketone           β-ketoimine
R1 R2
O O
R1 R2
O OH
R1 R2
O NHR
R1 R2
O NR
Figure 1.4.1: Diketonate and Ketoiminate ligands
The McGowan research group has extensively researched β-ketoiminate complexes 
of ruthenium, iridium and titanium.235 A series of ruthenium-arene and iridium-Cp*
complexes with acnac ligands (Figure 1.4.2) have been investigated for their anti-
cancer activity. The complexes have shown high activity against MCF-7, HT-29,
A2780, and A2780cis cell lines, with some complexes being significantly more
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active than cisplatin against the A2780cis cell line. In addition, the complexes were
hypoxia-sensitive, showing enhanced activity under hypoxic conditions. The
proposed mechanism of action is thought to include inhibition of the enzyme
thioredoxin reductase and apoptosis.235, 236
M
N
arene
OCl R
M = Ir; arene = Cp*
M = Ru; arene = p-cym
Figure 1.4.2: Ru-arene and Ir-Cp* acnac complexes studied within the McGowan research
group
Research project objectives
The objective of this research project was to synthesise, characterise and explore the
biological and catalytic activities of a range of ruthenium and copper complexes with
β-ketoiminate (acnac) ligands (Figure 1.5.1). Electronic and steric properties of the
complexes will be varied through functionalisation of the acnac ligands with various
substituents in order to gain structural activity relationships (SARs) and their effect
on potential biological and chemical applications. Results from previous studies of
metal complexes with β-ketoiminate ligands and those of their precursors, namely β-
diketonate (acac) ligands, have shown that complexes with acnac ligands have higher
anti-cancer activity compared to their acac ligand analogues.237 In line with these
findings only the anti-cancer activity of acnac metal complexes will be evaluated.
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Ru-acnac Cu-acnac
Figure 1.5.1: Target complexes within this thesis
The metal ketoiminate complexes synthesised (Figure 1.5.1) will contain several
fragments which have been shown to be important for anti-cancer activity. The
planar aryl rings of the ketoiminate ligand provide a potential site for π-π stacking 
interactions with nucleobases within the DNA chain. Varying the substituents (R1
and R2) on the ketoiminate aryl rings can alter the solubility and hydrophobicity of
the complex, influencing cellular uptake and in turn the corresponding anti-cancer
activity of the complexes. In the case of ruthenium(acnac)2 complexes, the presence
of a labile group X [Figure 1.5.1 (a)] (halide or pseudohalide ligand) allows the
possibility of activation through hydrolysis and ligand exchange forming more
reactive species which may then interact with target biomolecules.
In addition to investigations on potential therapeutic applications, the catalytic
activities of the metal complexes will be evaluated. The proposed catalytic reactions
are transfer hydrogenation and Ullmann reactions for ruthenium- and copper
ketoiminate complexes respectively.
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2.1 Synthesis of Biaryl-β-Ketoiminate Ligands 
This section expands on the library of phenyl-3(phenylamino)-2-buten-1-one (β-
ketoiminate) ligands, previously synthesised and reported within our research group.1,
2 A range of 1,3-β-diketonate ligands were synthesised via a Claisen condensation by
reaction of a substituted acetophenone with ethyl acetate in the presence of sodium
ethoxide.3 The functionalised 1,3-β-ketoiminate ligands (Figure 2.1.1) were
subsequently synthesised according to an adaptation of a method by Tang et al., in
which the β-diketonate ligand is reacted with aniline in the presence of toluene and 
HCl to give the resulting 1,3-ketoiminate ligand (Scheme 2.1.1).4
Ra = H, Rp = H L1 Rp = H, Ra = 4’Cl L21
4’F L2 4’F L22
4’Cl L3 4’Me L23
4’Br L4 3’Br L24
3’F L5 3’Me L25
3’Br L6 2’F L26
4’I L7 2’,4’ diCl L27
4’Me L8 2’,4’ diF L28
2’CI L9 2’,3’ diMe L29
2’Br L10 2’Br L30
4’OMe L11 3’Cl L31
4’CF3 L12 2’,5’ diF L32
4’OEt L13
2’OMe L14
3’,4’ diCl L15
2’,4’,6’ triMe L16
3’,4’ methylene L17
3’Br, 4’F L18
Figure 2.1.1: β-Bis-ketoiminate ligands reported within this thesis
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Scheme 2.1.1: General synthetic route for -β-bis-ketoiminate ligands
The β-bis-ketoiminate ligands show similar 1H NMR spectra, with characteristic
peaks corresponding to NH proton appearing between 12.5-13.5 ppm, as well as the
methine hydrogen peak (H7 in Figure 2.1.2).appearing as a singlet between 5.5-6.1
ppm.
Figure 2.1.2: 1H NMR spectrum example for ligand L3
2.2 Synthesis of Ruthenium(II) Dicarbonyl complexes
The β-bis-ketoiminate Ru(II) dicarbonyl complexes synthesised within this thesis are
shown in Figure 2.2.1. All complexes (C1–C16) were synthesised according to
Scheme 2.2.1 by reacting two equivalents of a functionalised β-bis-ketoiminate
ligand and two equivalents of the base, triethylamine, with one equivalent of
ruthenium(III) salt in 2-ethoxyethanol under reflux for 6 hours.
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Ra= H, Rp = H C1 Rp = H, Ra = 3’Me C9
4’Br C2 4’F C10
4’Cl C3 4’Cl C11
4’F C4 2’F C12
3’F C5 3’Br C13
3’Br C6 2’,4’ diCl C14
3’,4’ diCl C7 2’,4’ diF C15
4’Me C8 2’,3’ diMe C16
Figure 2.2.1: Ru(II) dicarbonyl complexes synthesised in this thesis
Scheme 2.2.1: Synthetic route for Ru(II) dicarbonyl complexes
This synthesis is characterised by the reduction of ruthenium in the metal precursor
from Ru(III) to Ru(II). The carbonyl ligands, though initially unexpected, are thought
to be a result of the decarbonylation of the primary alcohol 2-ethoxyethanol acting as
the solvent. Although unusual, the possibility of the formation of hydride, carbonyl or
hydridocarbonyl metal complexes when a transition metal complex is in contact with
an alcoholic medium is well documented. Known alcohols such as allyl alcohol,
ethanol, methanol and 2-methoxyethanol are readily decarbonylated by metal salts
resulting in the formation of CO-containing complexes and a degraded fragment of
the alcohol. These products are likely to be formed under vigorous and basic
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conditions, although in some cases the decarbonylation of primary alcohols has been
shown to occur under neutral conditions.5-7
This synthesis of complexes was characterised by yields within the range 30-43%.
While choice of base did not result in any improvement in the yield of the final
product or elimination of side products, reactions without base did not yield any
isolable complexes. Investigative reactions with bases such as triethylamine,
potassium hydroxide and potassium carbonate gave the carbonyl product in relatively
similar yields. Triethylamine was therefore used as the base of choice for all
reactions.
Chatt et al.8 have shown that ruthenium phosphine complexes can form ruthenium
carbonyl complexes in alcoholic solutions of methanol and ethanol, however, in this
synthesis substitution of 2-ethoxyethanol with either solvent did not result in the
formation of β-bis-ketoiminate Ru(II) dicarbonyl complexes. Subsequent
investigative reactions with other solvents such as dichloromethane, tetrahydrofuran,
acetonitrile and toluene have led to the conclusion that, the solvent 2-ethoxyethanol
facilitates the formation of the carbonyl species. In addition, reactions where the
ketoiminate ligand was removed or replaced with other ligands such as picolinamides
did not result in the formation of the carbonyl complex.
Scheme 2.2.2: Proposed mechanism for the formation of Ru(II) dicarbonyl complexes
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Although the mechanism of the reaction has not been investigated to sufficient detail,
a reaction scheme similar to that of Chatt et al. is proposed (Scheme 2.2.2) for the
formation of these complexes. The mechanism is thought to go via the formation of a
ruthenium-alkoxide complex (1 in Scheme 2.2.2). Transition metal alkoxide
complexes have been implicated as intermediates in alcohol dehydrogenation
reactions.9,10 However due to the instability of the alkoxide complexes in protic
solvents they decompose via β–hydride elimination to form ruthenium hydride 
species (2 in Scheme 2.2.2). The hydride ligand is labile to acids, therefore is
abstracted by the protonated form of triethylamine, allowing for the formation of the
carbonyl complex (4 in Scheme 2.2.2).
As observed by Hin Ling Lee et al.,7 incorporation of the alkyl group of the alcohol
into the final complex is unusual and was not observed in this synthesis. Instead,
methoxyethane was produced as a side product. Other work has highlighted the
formation and isolation of either the hydride or hydridocarbonyl complexes,8 but in
this synthesis only the dicarbonyl complexes were isolated. This could be because the
β-ketoiminate Ru(II) dihydride complexes and the β-ketoiminate Ru(II) 
hydridocarbonyl complex are highly unstable compared to the final dicarbonyl
complex.
The isolation of the Ru(II) carbonyl complexes was made difficult by the presence of
an uncharged starting material and several bands in thin layer chromatography that
could not be identified. In an effort to eliminate side products, reactions under inert
atmosphere with dry solvents were carried out. However, this neither improved the
yield of the reaction nor eliminated side reactions. Subsequently column
chromatography using dicholoromethane and hexane as the eluant was used to
achieve pure solids of the β-bis-ketoiminate Ru(II) dicarbonyl complexes. Yields
were improved when the base was used in excess. Use of excess ligand resulted in the
isolation of the excess ligand via column chromatography as part of the side products.
These β-bis-ketoiminate Ru(II) dicarbonyl complexes are air and thermal stable
crystalline complexes with yellow to green colours. They are soluble in most organic
solvents such as acetonitrile, dichloromethane and ethanol.
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Using trimethylamine promoted alcohol decarbonylation, only the cis-β-ketoiminate 
Ru(II) dicarbonyl complexes and not the trans-β-ketoiminate Ru(II) dicarbonyl 
complexes were isolated. Carbon monoxide being a strong π-backbonding ligand 
prefers not to be in a trans position to another carbon monoxide. The ketoiminate
ligand being a better σ–donor than it is a π–acceptor when compared to carbon 
monoxide assumes a position trans to the carbon monoxide.
2.3 Characterisation of Ruthenium(II) Dicarbonyl Complexes
Complexes C1-C16 (Figure 2.2.1) were synthesised, purified and characterised by
infrared spectroscopy, 1H NMR, 1H-1H COSY, 13C{1H} NMR, 1H-13C{1H} HMQC
spectroscopy, mass spectrometry, elemental analysis and single crystal X-ray
crystallography.
2.4 Infrared Spectroscopy of Ruthenium(II) Dicarbonyl
Complexes
The IR spectra of complexes C1 to C16 are very similar, with several bands of
different intensities due to C=C bonds observed in the 400-1600 cm-1 region. A
comparison of the spectra of the uncoordinated ligand and the corresponding
complex, (Figure 2.4.1)Error! Reference source not found., shows a strong stretch
due to the terminal CO ligands bonded to the metal centre. These stretches are
observed in the region 1900-2100 cm-1 and are consistent for all the Ru(II) dicarbonyl
complexes (Table 2.4.1).
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Figure 2.4.1: Example of infrared spectra of free ligand and complex
Table 2.4.1: Infrared spectroscopy data for complexes C1-C16
Complex Substituent ῡ(C≡O) Complex Substituent ῡ(C≡O)
C1 H(p) 2039, 1964 C9 3’Me(a) 2037, 1964
C2 4’Br(p) 2037, 1963 C10 4’F(a) 2036, 1963
C3 4’Cl(p) 2039, 1969 C11 4’Cl(a) 2041, 1971
C4 4’F(p) 2033, 1963 C12 2’F(a) 2047, 1972
C5 3’F(p) 2039, 1963 C13 3’Br(a) 2045, 1973
C6 3’Br(p) 2039, 1962 C14 2’,4’diCl(a) 2045, 1978
C7 3’,4’ diCl(p) 2043, 1975 C15 2’,4’ diF(a) 2047, 1971
C8 4’Me(p) 2033, 1964 C16 2’,3’ diMe(a) 2036, 1961
(p) = substituent on phenolate ring; (a) = substituent on aniline ring
The results shown in Table 2.4.1 indicate that the electronic nature of the substituent
and the position of the substituent on either of the phenyl rings (phenolate or aniline)
have little or no significant effect on the resulting wavenumbers of the carbonyl
ligands. This can be seen by a lack of trend when moving from the least to the most
electronegative complexes, for example, C2, C3 and C4.
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2.5 NMR Data of Ruthenium(II) Dicarbonyl Complexes
A comparison of the 1H NMR of the uncoordinated ligand and the complex shows the
disappearance of the broad singlet due to the NH peak at around 13ppm indicating the
deprotonation and coordination of N-. A slight upfield chemical shift upon
complexation is observed for all the protons, with the exception of the aniline ring
protons 2 and 6 [Figure 2.5.1 (b)]. In the uncoordinated ligand, aniline ring protons 2
and 6 are seen as a doublet (for example at δ~7.09 ppm for ligand L3 (Figure 2.1.2),
but upon complexation split into two doublets with significantly different chemical
shifts (for example two doublets at δ~7.25 and δ~6.85 (Figure 2.5.1(b)). This is
attributed to the geometry of the ligands around the metal centre, and the steric clash
with the carbonyl ligand which blocks the free rotation of the aniline ring. The CO
ligands are cis to each other thereby causing a slight difference in the chemical
environments experienced by protons 2 and 6.
The 13C{1H} NMR spectra for the β-ketoiminate Ru(II) dicarbonyl complexes, given 
in Figure 2.5.1(c), shows a characteristic peak in the region 196-198 ppm due to the
terminal carbon monoxide ligands, 17. Quaternary carbons, 1, 8, 10, 11 and 14 have
higher chemical shifts in the range 130-170 ppm. The aromatic carbon peaks for the
ketominate ligand are in the range 120-130 ppm, while the methine carbon (9) is
observed at lower chemical shifts 94-96 ppm. The methyl carbon (7) is in the range
23-25 ppm. Similar 13C{1H} NMR spectra trends are observed for all the β-
ketoiminate Ru(II) dicarbonyl complexes.
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Figure 2.5.1: Example of a typical (b) 1H NMR (c) 13C {1H} NMR for Ru(II) dicarbonyl
complexes (part of the spectra omitted for clarity)
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2.6 X-Ray Crystallography of Ruthenium(II) Dicarbonyl
complexes
After column chromatography, single crystals suitable for X-ray crystallography were
obtained either by slow vapour diffusion of pentane or hexane into a saturated
dichloromethane solution of the complex, or by slow cooling of a saturated solution
of the complex in acetonitrile.
A consistent pseudo octahedral geometry around the Ru(II) centre is observed for this
series of complexes. In the molecular structures of these complexes four coordination
sites are occupied by the bidentate ketoiminate ligands, in a trans configuration to
each other, and the two remaining sites are occupied by the carbonyl ligands, in a cis
configuration to each other (Figure 2.6.1).
Figure 2.6.1: General structure of β-bis-ruthenium(II) dicarbonyl complexes
As expected for pseudo octahedral structures, the molecular structures are
characterised by unequal bond lengths and angles around the Ru(II) centre. The
angles between the metal centre and the ligands are in the ranges, 83–96o and 170-
185o, deviating from the expected 90o and 180o respectively. The Ru-N and Ru-O
bond lengths, are within the ranges 2.08-2.10 Å and 2.04-2.10 Å respectively. These
are consistent with ketoiminate Ru(II) complexes reported in the literature.1 The Ru-
carbonyl (Ru-C≡O) bond lengths, in the range 1.86-1.88 Å, are considerably shorter 
than typical Ru-C bonds (ca. 2.1 Å)12, and shorter than most Ru-carbonyl bonds
(1.92-1.93 Å) reported within the literature.13 Characteristic short bond lengths, in the
range 1.13-1.14 Å are observed for C≡O in all complexes and are within reported 
literature values.14-16
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2.6.1 X-Ray characterisation for C1
Complex C1 crystallised as yellow plates from slow vapour diffusion of hexane into a
concentrated solution of the complex in dichloromethane. The complex crystallised in
a monoclinic cell with a single molecule per asymmetric unit cell. Structural solution
was performed in the C2/c space group. The molecular structure of C1 is shown in
Figure 2.6.2, and selected bond lengths and angles are given in Table 2.6.1.
Figure 2.6.2: Molecular structure of C1, displacement ellipsoids are at the 50% probability
level and hydrogen atoms are omitted for clarity
Table 2.6.1: Selected bond lengths and angles for C1
Bond Distance / Å Bond Angle/ o
Ru(1)–O(1) 2.0605(16) O(1)-Ru(1)-N(1) 89.39(7)
Ru(1)–O(2) 2.0555(16) O(2)-Ru(1)-N(2) 91.26(7)
Ru(1)–N(1) 2.0824(19) O(1)-Ru(1)-O(2) 83.98(7)
Ru(1)–N(2) 2.0863(19) N(1)-Ru(1)-N(2) 172.93(8)
Ru(1)-C(33) 1.869(3) N(1)-Ru(1)-C(33) 91.22(9)
Ru(1)-C(34) 1.876(3) N(2)-Ru(1)-C(34) 90.80(9)
C(33)≡O 1.141(3) C(33)-Ru(1)-C(34) 89.76(11)
C(34)≡O 1.137(3)   
The molecules pack through intermolecular hydrogen bonding in a head to tail
arrangement as seen in Figure 2.6.3, with no evidence of π-π interactions. There is 
evidence of weak intramolecular hydrogen bonds between the oxygen atom of C≡O 
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and the phenolate phenyl ring hydrogen atoms (Figure 2.6.4(a)). Several
intermolecular hydrogen bonds contributing to the packing of the molecule are
observed and shown in Figure 2.6.4(b). Table 2.6.1 gives the bond length of the
respective hydrogen bonds.
Figure 2.6.3: Molecular packing seen in complex C1
(a) (b)
Figure 2.6.4: (a) Intramolecular hydrogen bonds and (b) intermolecular hydrogen bonds in
complex, C1
Table 2.6.2: Bond lengths for intra- and intermolecular hydrogen bonds in complex C1
Interaction Atoms (A….D) Bond length / Å
Intramolecular C(22)-H……O(4) 3.773(3)
Intermolecular C(5)-H……..O(1) 3.526(3)
C(6)-H……..O(3) 3.468(3)
C(7)-H……..O(4) 3.498(4)
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C(22)-H……O(4) 3.773(3)
2.6.2 X-Ray characterisation for C2
Complex C2 crystallised as pale green plates, from vapour diffusion of hexane into a
dichloromethane solution of the complex.. The complex crystallised in a triclinic cell
and was solved in the PĪ space group, with one complex molecule and a disordered
molecule of dichloromethane in the asymmetric unit. The molecular structure of C2 is
given in Figure 2.6.5 and selected bond lengths and angles are given in Table 2.6.3.
Figure 2.6.5: Molecular structure of C2, displacement ellipsoids are at the 50% probability
level and hydrogen atoms and disordered solvent are omitted for clarity
Table 2.6.3: Selected bond lengths and angles for C2
Bond Distance Bond Angle / Å
Ru(1)–O(1) 2.063(3) O(1)-Ru(1)-N(1) 90.62(14)
Ru(1)–O(2) 2.061(3) O(2)-Ru(1)-N(2) 90.56(15)
Ru(1)–N(1) 2.093(4) O(1)-Ru(1)-O(2) 85.44(14)
Ru(1)–N(2) 2.079(4) N(1)-Ru(1)-N(2) 172.85(16)
Ru(1)-C(33) 1.881(5) N(1)-Ru(1)-C(33) 94.61(19)
Ru(1)-C(34) 1.872(6) N(2)-Ru(1)-C(34) 93.71(19)
C(33)≡O 1.132(6) C(33)-Ru(1)-C(34) 89.7(2)
C(34)≡O 1.141(6)   
C-Br 1.889(5)
The molecules pack in sheets with π-π interactions evident between the phenolate and
aniline phenyl rings as shown in Figure 2.6.6.
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Figure 2.6.6: Molecular packing of C2 with evident π-π interactions (solvent molecules
omitted for clarity)
Figure 2.6.7 shows additional interactions such as intra- and intermolecular hydrogen
bonds, participating in the packing of the molecules. Selected bond lengths of these
interactions are given in Table 2.6.4.
(a) (b)
Figure 2.6.7: Selected (a) Intramolecular hydrogen bonds and (b) intermolecular hydrogen
bonds in complex, C2
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Table 2.6.4: Bond lengths for intra- and intermolecular hydrogen bonds in complex C2
Interaction Atoms(A…….D) Bond length / Å
Intramolecular C(6)-H………..O(4) 3.763(6)
Intermolecular C(4)-H………..O(3) 3.838(6)
C(21)-H………O(4) 3.882(8)
C(28)-H………Br(1) 3.839(3)
C(29)-H…........Br(1) 3.865(3)
π-π interactions (phenolate phenyl rings) 3.819
π-π interactions (aniline phenyl rings) 3.793
2.6.3 X-Ray characterisation for C3
Recrystallisation of complex C3 from slow vapour diffusion of hexane into a solution
of the complex in dichloromethane afforded yellow plates suitable for X-ray
crystallography. The molecular structure is shown in Figure 2.6.8, with selected bond
angles given in Table 2.6.5. The compound crystallised in a triclinic cell and was
solved in the PĪ space group, with two complex molecules, and disordered solvent in 
the asymmetric unit.
Figure 2.6.8: Molecular structure of C3, displacement ellipsoids are at the 50% probability
level and hydrogen atoms and disordered solvents are omitted for clarity
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Table 2.6.5: Selected bond lengths and angles for C3
Bond Distance Bond Angle / Å
Ru(1)–O(1) 2.059(2) O(1)-Ru(1)-N(1) 90.40(10)
Ru(1)–O(2) 2.063(2) O(2)-Ru(1)-N(2) 91.24(9)
Ru(1)–N(1) 2.084(3) O(1)-Ru(1)-O(2) 85.33(9)
Ru(1)–N(2) 2.087(3) N(1)-Ru(1)-N(2) 174.03(11)
Ru(1)-C(33) 1.872(4) N(1)-Ru(1)-C(33) 88.38(13)
Ru(1)-C(34) 1.872(3) N(2)-Ru(1)-C(34) 91.50(12)
C(33)≡O 1.134(4) C(33)-Ru(1)-C(34) 92.39(14)
C(34)≡O 1.138(4)   
C-Cl 1.731(4)
A packing diagram of complex C3 viewed along the b axis is given in Figure 2.6.9
and shows no evidence of π-π interactions as seen with some of the complexes in this 
family. Instead, the molecules are held together by intra- and intermolecular hydrogen
bonding. These bonds are shown in Figure 2.6.10 and the respective bond lengths are
given in Table 2.6.6.
Figure 2.6.9: Packing in complex C3, viewed along the b axis (solvent omitted for clarity)
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(a) (b)
Figure 2.6.10: Selected (a) Intramolecular hydrogen bonds and (b) intermolecular hydrogen
bonds in complex, C3
Table 2.6.6: Bond lengths for intra- and intermolecular hydrogen bonds in complex C3
Interaction Atoms(A…….D) Bond length / Å
Intramolecular C(2’)-H……....O(3’) 3.843(8)
Intermolecular C(9)-H………..O(2’) 3.864(7)
C(7)-H………..O(2’) 3.537(8)
C(6)-H………..O(4’) 3.406(7)
2.6.4 X-Ray characterisation for C4
Single crystals suitable for X-ray crystallography for complex C4, were obtained
from slow vapour diffusion of hexane into a solution of the complex in
dichloromethane. The complex crystallised as yellow needles, in a triclinic cell and
the structural solution performed in PĪ space group with two molecules of C4 and a
molecule of water per asymmetric unit
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Figure 2.6.11: Molecular structure of C4, displacement ellipsoids are at the 50% probability
level. Hydrogen atoms, disordered solvent and 2nd molecule are omitted for clarity
Table 2.6.7: Selected bond lengths and angles for C4
Bond Distance Bond Angle / Å
Ru(1)–O(1) 2.080(4) O(1)-Ru(1)-N(1) 90.50(18)
Ru(1)–O(2) 2.072(4) O(2)-Ru(1)-N(2) 85.80(17)
Ru(1)–N(1) 2.087(5) O(1)-Ru(1)-O(2) 86.27(16)
Ru(1)–N(2) 2.092(5) N(1)-Ru(1)-N(2) 175.09(18)
Ru(1)-C(33) 1.871(6) N(1)-Ru(1)-C(33) 88.8(2)
Ru(1)-C(34) 1.870(6) N(2)-Ru(1)-C(34) 89.7(2)
C(33)≡O 1.134(7) C(33)-Ru(1)-C(34) 91.7(3)
C(34)≡O 1.144(7)   
C-F 1.361(7)
(a) (b)
Figure 2.6.12: Selected (a) Intramolecular hydrogen bonds and (b) intermolecular hydrogen
bonds in complex, C4
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Table 2.6.8: Bond lengths for molecular interactions in complex C4
Interaction Atoms(A………D) Bond length / Å
Intramolecular C(6)-H……….O(2) 3.3936(8)
Intermolecular C(23)-H……...O(1’) 3.4797(6)
C(22)-H……...O(3’) 3.354(5)
The molecules pack together in layers of two molecules bound by intermolecular
hydrogen bonds, with no evidence on π-π interactions between the phenyl rings. A 
selected view of the packing, along the c axis is shown in Figure 2.6.13.
Figure 2.6.13: Molecular close packing seen in complex C4
2.6.5 X-Ray characterisation for C5
Single crystals suitable for X-ray crystallography were obtained through vapour
diffusion of hexane into a saturated solution of the complex in dichloromethane.
Complex C5 crystallised in a triclinic cell, the structural solution was performed in PĪ 
space group with one molecule per asymmetric unit. The molecular structure of C5 is
shown in Figure 2.6.14, with selected bond lengths and angles given in Table 2.6.9.
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Figure 2.6.14: Molecular structure of C5, displacement ellipsoids are at the 50% probability
level and hydrogen atoms are omitted for clarity
Table 2.6.9: Selected bond lengths and angles for C5
Bond Distance Bond Angle / Å
Ru(1)–O(1) 2.048(2) O(1)-Ru(1)-N(1) 90.43(9)
Ru(1)–O(2) 2.047(2) O(2)-Ru(1)-N(2) 82.95(9)
Ru(1)–N(1) 2.076(2) O(1)-Ru(1)-O(2) 86.60(9)
Ru(1)–N(2) 2.087(2) N(1)-Ru(1)-N(2) 171.10(10)
Ru(1)-C(33) 1.870(3) N(1)-Ru(1)-C(33) 90.35(12)
Ru(1)-C(34) 1.874(3) N(2)-Ru(1)-C(34) 91.05(11)
C(33)≡O 1.146(4) C(33)-Ru(1)-C(34) 91.73(13)
C(34)≡O 1.139(4)   
C-F 1.363(4)
The molecules pack in rows with π-π interactions between the phenolate phenyl rings
as shown in Figure 2.6.15.
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Figure 2.6.15: π-π interactions in complex C5
Figure 2.6.16 shows additional interactions such as intra- and intermolecular
hydrogen bonds contributing to the packing of the molecules. The respective bond
lengths of these interactions are given in Table 2.6.10.
(a) (b)
Figure 2.6.16: (a) Intramolecular hydrogen bonds and (b) intermolecular hydrogen bonds in
complex, C5
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Table 2.6.10: Bond lengths for molecular interactions in complex C5
Interaction Atoms(A………D) Bond length / Å
Intramolecular C(18)-H………..O(1) 3.603(4)
C(2)-H…………O(3) 3.855(4)
Intermolecular C(5)-H……........F(1) 3.391(5)
C(9)-H…………F(2) 3.811(4)
C(12)-H………..F(2) 3.457(4)
π-π interactions (phenolate phenyl rings) 3.633
π-π interactions (phenolate phenyl rings) 3.735
2.6.6 X-Ray characterisation for C6
Yellow blocks of C6 suitable for X-ray crystallography were obtained from vapour
diffusion of pentane into a solution of the complex in dichloromethane. The
molecular structure of C6 is shown in Figure 2.6.17, with selected bond lengths and
angles given in Table 2.6.11. This complex crystallised in a triclinic cell and
structural solution was performed in the PĪ space group with one molecule per 
asymmetric unit.
Figure 2.6.17: Molecular structure of C6, displacement ellipsoids are at the 50% probability
level and hydrogen atoms are omitted for clarity
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Table 2.6.11: Selected bond lengths and angles for C6
Bond Distance Bond Angle / Å
Ru(1)–O(1) 2.042(3) O(1)-Ru(1)-N(1) 90.59(12)
Ru(1)–O(2) 2.055(3) O(2)-Ru(1)-N(2) 82.56(12)
Ru(1)–N(1) 2.085(3) O(1)-Ru(1)-O(2) 85.90(12)
Ru(1)–N(2) 2.084(3) N(1)-Ru(1)-N(2) 170.35(13)
Ru(1)-C(33) 1.874(4) N(1)-Ru(1)-C(33) 95.59(15)
Ru(1)-C(34) 1.876(4) N(2)-Ru(1)-C(34) 96.21(16)
C(33)≡O 1.137(5) C(33)-Ru(1)-C(34) 90.98(18)
C(34)≡O 1.144(5)   
C-Br 1.875(5)
The molecules pack in alternating rows with π-π interactions between the phenolate
phenyl rings as shown in Figure 2.6.18.
Figure 2.6.18: π-π interactions in complex C6
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Addition interactions in the form of intra- and intermolecular hydrogen bonds
contribute to the packing of the molecules. Selected examples of these are shown in
Figure 2.6.19, and the bond lengths given in Table 2.6.12.
(a) (b)
Figure 2.6.19: (a) Intramolecular hydrogen bonds and (b) intermolecular hydrogen bonds in
complex, C6
Table 2.6.12: Bond lengths for molecular interactions in complex C6
Interaction Atoms(A……….D) Bond length / Å
Intramolecular C(22)-H………..O(1) 3.659(5)
C(6)-H…………O(4) 3.714(6)
Intermolecular C(3)-H……........Br(1) 3.705(6)
C(30)-H……......O(3) 3.326(5)
C(7)-H……........O(4) 3.485(6)
π-π interactions (phenolate phenyl rings) 3.637
π-π interactions (phenolate phenyl rings) 3.766
2.6.7 X-Ray characterisation for C8
Complex C8 crystallised as yellow blocks from slow vapour diffusion of hexane into
a concentrated solution of the complex in dichloromethane. The complex crystallised
in a monoclinic cell with a half molecule per asymmetric unit cell. Structural solution
was performed in the I2/c space group. The molecular structure of C8 is shown in
Figure 2.6.20 and selected bond lengths and angles are given in Table 2.6.13.
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Figure 2.6.20: Molecular structure of C8, displacement ellipsoids are at the 50% probability
level and hydrogen atoms are omitted for clarity. Only one part of the disordered
aniline phenyl ring is shown
Table 2.6.13: Selected bond lengths and angles for C8
Bond Distance Bond Angle / Å
Ru(1)–O(1) 2.0449(15) O(1)-Ru(1)-N(1) 91.20(6)
Ru(1)–O(2) 2.0449(15) O(2)-Ru(1)-N(2) 82.64(6)
Ru(1)–N(1) 2.0449(15) O(1)-Ru(1)-O(2) 85.90(9)
Ru(1)–N(2) 2.0449(15) N(1)-Ru(1)-N(2) 171.61(10)
Ru(1)-C(33) 1.863(3) N(1)-Ru(1)-C(18) 90.65(9)
Ru(1)-C(34) 1.863(3) N(2)-Ru(1)-C(18’) 90.65(9)
C(18)≡O 1.138(3) C(18)-Ru(1)-C(18’) 89.74(18)
Complex C8 only displays intramolecular hydrogen (Figure 2.6.21) bonding within
its molecules, with no presence of intermolecular hydrogen bonding or π-π 
interactions. The intramolecular hydrogen bond is 3.341(10) Å and is comparable to
similar bonds within this series of complexes.
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Figure 2.6.21: Intramolecular hydrogen bonding in C8
Figure 2.6.22 shows the herringbone type of crystal close packing seen in complex
C8.
(a) (b)
Figure 2.6.22: Herringbone arrangement in C8 viewed along the (a) the a-axis and (b) the b-
axis
2.6.8 X-Ray characterisation for C9
Recrystallisation of complex C9, from vapour diffusion of hexane into a concentrated
solution of the complex in dichloromethane afforded yellow blocks suitable for
crystallography. Complex C9 crystallized in an orthorhombic cell and the structural
solution performed in Pbcn space group with one molecule per asymmetric unit. The
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molecular structure is given in Figure 2.6.23 and selected bond lengths and bond
angles are given in Table 2.6.14. The molecule shows disorder of the aniline phenyl
ring across two positions in a 55:45 ratio.
Figure 2.6.23: Molecular structure of C9, displacement ellipsoids are at the 50% probability
level and hydrogen atoms are omitted for clarity. Only one part of disordered aniline
phenyl ring is shown
Table 2.6.14: Selected bond lengths and angles for C9
Bond Distance Bond Angle / Å
Ru(1)–O(1) 2.0582(19) O(1)-Ru(1)-N(1) 89.90(8)
Ru(1)–O(2) 2.0582(19)) O(2)-Ru(1)-N(2) 91.74(8)
Ru(1)–N(1) 2.094(2) O(1)-Ru(1)-O(2) 84.80(7)
Ru(1)–N(2) 2.083(2) N(1)-Ru(1)-N(2) 172.37(9)
Ru(1)-C(33) 1.862(3) N(1)-Ru(1)-C(33) 91.17(10)
Ru(1)-C(34) 1.876(3) N(2)-Ru(1)-C(34) 90.33(11)
C(33)≡O 1.138(3) C(33)-Ru(1)-C(34) 89.75(12
C(34)≡O 1.136(3)   
The complex packs in a herringbone arrangement as shown in Figure 2.6.24, with no
evidence of π-π interactions between the phenyl rings. Intra- and intermolecular 
hydrogen bonds participate in the packing of the complex and are shown in Figure
2.6.25, with selected bond lengths given in Table 2.6.15.
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Figure 2.6.24: Herringbone close packing C9, viewed along a-axis
(a) (b)
Figure 2.6.25: (a) Intramolecular hydrogen bonds and (b) intermolecular hydrogen bonds in
complex, C9
Table 2.6.15: Selected bond lengths for intra- and inter-molecular interactions in complex C9
Interaction Atoms(A……D) Bond length / Å
Intramolecular C(2)-H………O(2) 3.73002(8)
Intermolecular C(3)-H………O(3) 3.37081(7)
C(4)-H………O(3) 3.42860(9)
C(7)-H……....O(4) 3.79207(8)
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2.6.9 X-Ray characterisation for C11
Complex C11 crystallised as yellow plates from slow vapour diffusion of hexane into
a concentrated solution of the complex in dichloromethane. The complex crystallised
in a monoclinic cell with a single molecule and a distorted solvent molecule per
asymmetric unit cell. Structural solution was performed in the P21/c space group. The
molecular structure of C11 is shown in Figure 2.6.26, and selected bond lengths and
angles are given in Table 2.6.16.
Figure 2.6.26: Molecular structure of C11, displacement ellipsoids are at the 50% probability
level and hydrogen atoms and so disordered solvent are omitted for clarity
Table 2.6.16: Selected bond lengths and angles for C11
Bond Distance Bond Angle / Å
Ru(1)–O(1) 2.0471(19) O(1)-Ru(1)-N(1) 82.73(8)
Ru(1)–O(2) 2.0627(19) O(2)-Ru(1)-N(2) 83.09(8)
Ru(1)–N(1) 2.079(2) O(1)-Ru(1)-O(2) 83.17(8)
Ru(1)–N(2) 2.085(2) N(1)-Ru(1)-N(2) 172.37(9)
Ru(1)-C(33) 1.873(3) N(1)-Ru(1)-C(33) 95.13(10)
Ru(1)-C(34) 1.876(3) N(2)-Ru(1)-C(34) 96.07(10)
C(33)≡O 1.137(3) C(33)-Ru(1)-C(34) 91.52(12)
C(34)≡O 1.140(3)   
C-Cl 1.741(3)
A packing diagram of complex C11 viewed along the b axis is shown in Figure
2.6.27 and shows no evidence of π-π interactions as seen with some of the complexes 
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in this series. Instead, the molecules pack in layers, held together by intra- and
intermolecular hydrogen bonding. The intra- and intermolecular hydrogen bonds are
shown in Figure 2.6.28 and the respective bond lengths are given in Table 2.6.16.
Figure 2.6.27: Packing in complex C11, viewed along the b axis (solvent omitted for clarity)
(a) (b)
Figure 2.6.28: (a) Intramolecular hydrogen bonds and (b) intermolecular hydrogen bonds in
complex, C11
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Table 2.6.17: Selected bond lengths for intra- and intermolecular interactions in complex
C11
Interaction Atoms(A………D) Bond length / Å
Intramolecular C(2)H………….O(1) 3.63817(7)
C(18)-H………..O(3) 3.76571(7)
Intermolecular C(2)-H……........Cl(2) 3.83597(13)
C(3)-H…………Cl(2) 3.79035(9)
C(28)-H………..O(2)
C(29)-H………..O(4)
3.47027(10)
3.51927(14)
2.6.10 X-Ray characterisation for C12
Complex C12 crystallised as yellow blocks from slow vapour diffusion of hexane
into a concentrated solution of the complex in dichloromethane. The complex
crystallised in a monoclinic cell with one molecule per asymmetric unit cell, showing
distortion in the ortho position of the aniline ring. Structural solution was performed
in the P21/c space group. The molecular structure of C12 is shown in Figure 2.6.29,
and selected bond lengths and angles are given in Table 2.6.18.
Figure 2.6.29: Molecular structure of C12, displacement ellipsoids are at the 50% probability
level and hydrogen atoms and so disordered parts are omitted for clarity
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Table 2.6.18: Selected bond lengths and angles for C12
Bond Distance Bond Angle / Å
Ru(1)–O(1) 2.046(2) O(1)-Ru(1)-N(1) 85.14(9)
Ru(1)–O(2) 2.0643(19) O(2)-Ru(1)-N(2) 90.76(9)
Ru(1)–N(1) 2.084(2) O(1)-Ru(1)-O(2) 86.78(8)
Ru(1)–N(2) 2.082(2) N(1)-Ru(1)-N(2) 173.77(9)
Ru(1)-C(33) 1.870(3) N(1)-Ru(1)-C(33) 94.62(11)
Ru(1)-C(34) 1.861(3) N(2)-Ru(1)-C(34) 95.59(11)
C(33)≡O 1.140(3) C(33)-Ru(1)-C(34) 90.00(13)
C(34)≡O 1.146(4)   
C-F 1.331(9)
Complex C12 packs in alternating layers as shown in Figure 2.6.30. There is no
evidence of π-π interactions, instead, the molecules are held together by intra- and 
intermolecular hydrogen bonding. These intra- and intermolecular hydrogen bonds
are shown in Figure 2.6.31, and the respective bond lengths are given in Table
2.6.19.
Figure 2.6.30: Packing in complex C12, viewed along the c axis (solvent and disordered
parts omitted for clarity)
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(a) (b)
Figure 2.6.31: (a) Intramolecular hydrogen bonds and (b) intermolecular hydrogen bonds in
complex, C12
Table 2.6.19: Selected bond lengths for intra- and intermolecular interactions in complex
C12
Interaction Atoms(A………D) Bond length / Å
Intramolecular C(7)H……….....F(1’) 3.4536(3)
Intermolecular C(23)-H………..O(1)
C(23)-H………..O(2)
3.8991(4)
3.7390(3)
2.6.11 X-Ray characterisation for C14
Single crystals suitable for X-ray crystallography were obtained through vapour
diffusion of hexane into a saturated solution of complex C14 in dichloromethane.
Complex C14 crystallised in a monoclinic cell, the structural solution was performed
in P21/n space group with one molecule per asymmetric unit. The molecular structure
of C14 is shown in Figure 2.6.32, with selected bond lengths and angles given in
Table 2.6.20.
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Figure 2.6.32: Molecular structure of C14, displacement ellipsoids are at the 50% probability
level and hydrogen atoms and disordered parts are omitted for clarity.
Table 2.6.20: Selected bond lengths and angles for C14
Bond Distance Bond Angle / Å
Ru(1)–O(1) 2.056(3) O(1)-Ru(1)-N(1) 90.91(10)
Ru(1)–O(2) 2.055(2) O(2)-Ru(1)-N(2) 91.60(10)
Ru(1)–N(1) 2.090(3) O(1)-Ru(1)-O(2) 84.82(10)
Ru(1)–N(2) 2.084(3) N(1)-Ru(1)-N(2) 173.35(12)
Ru(1)-C(33) 1.864(4) N(1)-Ru(1)-C(33) 94.42(13)
Ru(1)-C(34) 1.883(4) N(2)-Ru(1)-C(34) 93.68(13)
C(33)≡O 1.147(4) C(33)-Ru(1)-C(34) 90.14(16)
C(34)≡O 1.127(4)   
The molecules pack through intra- and intermolecular hydrogen bonds as shown in
Figure 2.6.33. Respective bond lengths for these interactions are given in Table
2.6.21.
Ruthenium(II) dicarbonyl complexes Chapter 2
83
(a) (b)
Figure 2.6.33: (a) Intramolecular hydrogen bonds and (b) intermolecular hydrogen bonds in
complex, C14
Table 2.6.21: Selected bond lengths for intra- and intermolecular bonding in C14
Interaction Atoms(A……..D) Bond length /Å
Intramolecular C(6)-H……….O(4) 3.833(8)
C(22)-H……...Cl(1) 3.780(8)
C(2)-H……….Cl(3) 3.434(8)
Intermolecular C(31)-H……...O(1) 3.502(8)
C(22)-H……...Cl(1) 3.781(8)
π-π interactions (phenolate phenyl rings) 3.730
Additional intermolecular interactions in the form of π-π interactions between the 
phenolate phenyl rings, shown in Figure 2.6.34, are observed and participate in the
close packing of the molecules.
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Figure 2.6.34: π-π interactions present in C14
2.6.12 X-Ray characterisation for C15
Complex C15 crystallised as green plates from slow vapour diffusion of hexane into a
concentrated solution of the complex in dichloromethane. The complex crystallised in
a monoclinic cell with a single molecule per asymmetric unit cell. Structural solution
was performed in the I2/a space group. The molecular structure of C15 is shown in
Figure 2.6.35, and selected bond lengths and angles are given in Table 2.6.22.
Figure 2.6.35: Molecular structure of C15, displacement ellipsoids are at the 50% probability
level and hydrogen atoms and disordered parts are omitted for clarity
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Table 2.6.22: Selected bond lengths and angles for C15
Bond Distance Bond Angle / Å
Ru(1)–O(1) 2.0475(12) O(1)-Ru(1)-N(1) 90.67(5)
Ru(1)–O(2) 2.0578(12) O(2)-Ru(1)-N(2) 90.78(5)
Ru(1)–N(1) 2.0827(14) O(1)-Ru(1)-O(2) 85.29(5)
Ru(1)–N(2) 2.0935(15) N(1)-Ru(1)-N(2) 171.07(6)
Ru(1)-C(33) 1.8667(18) N(1)-Ru(1)-C(33) 90.52(7)
Ru(1)-C(34) 1.8795(18) N(2)-Ru(1)-C(34) 92.71(7)
C(33)≡O 1.141(2) C(33)-Ru(1)-C(34) 88.65(7)
C(34)≡O 1.134(2)   
Figure 2.6.36 shows intra- and intermolecular hydrogen bonds participating in the
close packing of the molecules. Selected bond lengths given in Table 2.6.23. There is
no evidence of π-π interactions between the phenyl rings of the molecules. 
(a) (b)
Figure 2.6.36: (a) Intramolecular hydrogen bonds and (b) intermolecular hydrogen bonds in
complex, C15
Table 2.6.23: Selected bond lengths for intra- and intermolecular bonding in C15
Interaction Atoms(A……..D) Bond length / Å
Intramolecular C(7)-H………..F(2) 3.56119(7)
Intermolecular C(13)-H……....O(1) 3.72628(6)
C(13)-H………O(3) 3.47940(6)
C(14)-H………O(3) 3.52838(6)
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2.7 Conclusion
A range of novel functionalised β-bis-ketoiminate ruthenium(II) dicarbonyl
complexes, showing pseudo octahedral geometry around the Ru(II) centre have been
synthesised and characterised, with X-ray crystallographic analysis obtained for most
complexes. The synthesis is characterised by the unexpected reduction of ruthenium
from Ru(III) to Ru(II) and coordination of carbon monoxide as labile ligands. The
carbonyl ligands are proposed to be a result of the base promoted decarbonylation of
the solvent, 2-ethoxyethanol. Investigative reactions have shown that the combination
of a base (trimethylamine), high reflux temperatures, 2-thoxyethanol (as the solvent)
and the ketoiminate ligand are necessary for the formation of the ruthenium(II)
dicarbonyl complexes. The complexes all show similar 1H and 13C{1H} NMR spectra,
with a distinctive splitting of protons in the ortho position of the aniline ring (H2 and
H6 for all complexes) to two different chemical environments. This is supported by
space filling models of the crystal structures which show breaking of the symmetry
around the aniline phenyl ring as a result of steric clash between the aniline phenyl
ring and the carbonyl ligands. Intra- and intermolecular hydrogen bonding is
observed for this series of complexes, with addition π-π stacking seen in some of the 
complexes. The β-ketoiminate ligands were functionalised to include electron 
withdrawing groups, electron donating groups and increased steric bulk. These were
to allow structure activity relationships to be determined when testing for anti-cancer
activity (see Chapter 4).
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Chapter 3
Synthesis and Characterisation of Functionalised
β-bis-Ketoiminate Copper(II) Complexes
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3.1 Introduction to β-bis-Ketoiminate Copper(II) Complexes
Ketoiminate ligands (discussed briefly in Chapter 2) are analogues of β-diketonates 
in which one of the oxygen atoms has been replaced by an amine group.1 Despite
being known in the literature for a number of years,2 β-ketoiminate ligands have 
only received attention over the last few years. This interest is due to their
simplicity, ease of preparation and ease of modification of both steric and electronic
properties.3-5 Examples of ketoiminate ligands with nickel, titanium, iridium,
ruthenium and cobalt have been studied and reported,6-10 however little has been
reported on their complexes with copper.11, 12 Copper complexes with bidentate,
tridentate or tetradentate (N,O) ligands have found wide application in many fields,
particularly in catalysis and polymerisation.1, 11, 13-17
Most of the bis-ketoiminate copper complexes reported in the literature are in the +2
oxidation state and exhibit a square planar geometry. These complexes were
prepared through the reaction of a copper source, for example, Cu(NO3)2.3H2O with
a Schiff base ligand in a protic solvent under reflux or at room temperature.17
Alternatively, Stabnikov et al. have synthesised copper bis-ketoiminate complexes
in moderate yields by reacting copper acetate with the ketoiminate ligands in
aqueous alcohol in the presence of excess ammonia (Scheme 3.1.1).18 This
procedure has since become the most popular synthetic procedure for metal
ketoiminate complexes.
Scheme 3.1.1: General literature procedure for the synthesis of β-bis-ketoiminate Cu(II)
complexes
Archer et al have shown that the use of a base in the synthesis of these complexes is
important, as reactions without base did not yield the desired product.19
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3.2 Synthesis of β-bis-Ketoiminate Copper(II) Complexes
With slight modifications to the synthetic route discussed above (Scheme 3.1.1),
novel β-bis-ketoiminate copper(II) complexes have been synthesised according to
Scheme 3.2.1. These complexes, shown in Figure 3.2.1, were synthesised from the
reaction of one equivalent of copper(II) chloride with two equivalents of the
ketoiminate ligand and two equivalents of sodium methoxide as the base.
Scheme 3.2.1: Synthetic route for β-bis-ketoiminate copper(II) complexes in this
chapter
Reactions under aerobic and anaerobic conditions both gave the desired product
although reactions under anaerobic conditions gave a purer product, without need
for intensive isolation and purification steps. As a result all reactions were carried
out under an atmosphere of nitrogen. Reactions in the absence of a base did not
result in any isolable product
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Ra = H, Rp = H C17 Ra = H, Rp = 3’,4’ methylene C31
2’Br C18 3’Br, 4’F C32
2’Cl C19 2’OMe C33
4’Br C20 3’F C34
4’Cl C21 2’OEt, 4’F C35
4’F C22 Rp = H, Ra = 2’Br C36
4’I C23 2’F C37
4’Me C24 3’Br C38
4’OMe C25 3’Cl C39
4’OEt C26 4’Cl C40
4’CF3 C27 2’,4’ diF C41
2’,3’diMe C28 2’,5’ diF C42
2’,4’,6’ triMe C29
3’,4’ diCl C30
Figure 3.2.1: β-Ketoiminate copper(II) complexes synthesised by the author 
Complexes C17-C42 were obtained as brown or black solids in moderate to high
yields. The complexes are air stable, soluble in chlorinated solvents and sparingly
soluble in ethanol, acetonitrile and diethyl ether. They are however insoluble in
water, hexane and pentane. The resulting solids were further purified by slow vapour
diffusion of hexane or pentane into a solution of the complex in dichloromethane.
3.3 Characterisation of β-bis-Ketoiminate Copper(II) Complexes 
With a +2 oxidation state, the copper complexes have a d9 configuration and are
paramagnetic. After purification the complexes were analysed by mass
spectrometry, elemental analysis and X-ray crystallography. Paramagnetic NMR
was also done, although no conclusive data was obtained.
3.3.1 X-Ray crystallography β-bis-ketoiminate Copper(II) complexes
Single crystals suitable for X-ray crystallography for all complexes were obtained
by slow vapour diffusion of hexane or pentane into a concentrated solution of the
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complex in dichloromethane, at room temperature. Typical shapes for these
complexes were either brown/black plates/blocks, although in some cases irregular
shaped crystals were obtained. The crystal structures of all the complexes show a 2:1
ligand to metal ratio.
The crystallographic data for copper complexes C17-C42 are shown in Figure
3.3.1. Complexes crystallised in either monoclinic, triclinic or orthorhombic cell
systems, with half, one or two molecules in the asymmetric unit. A summary of the
respective structural solutions and space groups is given in Table 3.3.1. Selected
bond lengths and angles are stated in Table 3.3.2 and Table 3.3.3 respectively.
Table 3.3.1: X-ray crystallography data for Cu(II)(acnac)2 complexes
Complex Z Cell type Space group
C17 4 orthorhombic P212121
C18 2 triclinic P-1
C19 4 monoclinic I2/a
C20 4 orthorhombic P212121
C21 4 monoclinic I2/a
C22 2 monoclinic P21/n
C23 4 orthorhombic P212121
C24 4 monoclinic I2/a
C25 4 orthorhombic Pbca
C26 2 triclinic P-1
C27 2 monoclinic P21/c
C28 8 orthorhombic Pbca
C29 4 monoclinic P21/n
C30 4 monoclinic C2/c
C31 2 monoclinic P21/n
C32 4 monoclinic C2/c
C36 4 monoclinic I2/a
C37 4 monoclinic I2/a
C40 2 monoclinic P21/n
C41 2 monoclinic P21/n
C42 4 monoclinic P21/n
Four coordinate Cu(II) complexes are usually characterised by either square planar
or distorted (flattened) tetrahedron geometry.11, 20 In addition, steric and electronic
effects due to the substituents on the ligand may influence the planarity observed in
the molecular structure. The molecular structures for this series of complexes, given
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in Figure 3.3.1, shows that the metal centre is four-coordinated by two phenolate
oxygen atoms and two imine nitrogen atoms from the ketoiminate ligands. These
ketoiminate ligands coordinate to the copper(II) centre in the sterically favoured O-
Cu-O and N-Cu-N trans geometries. A distorted square planar geometry is thus
observed for all complexes as shown by the unequal metal-ligand bond distances
and angles (Table 3.3.2 and Table 3.3.3). The distortion can be attributed to the
restrictions imposed by the chelating effects of the bidentate ketoiminate ligands.
C18, X = Br; C19, X = Cl;
C33, X = 2’OMe
C18, X = Br
C20, X = Br; C21, X = Cl;
C22, X = F; C23, X = I;
C24, X = Me; C25, X = OMe;
C26, X = OEt; C27, X = CF3
C22, X = F
Copper(II)acnac complexes Chapter 3
95
C28
C29
C30
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C31
C32
C36, X = Br; C37, X = F
C36, X = Br
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C40
C41
C42
Figure 3.3.1: Molecular structures of complexes C17-C32 and C36-C42. Displacement
ellipsoids are at the 50 % probability level. Hydrogen atoms and co-crystallising
solvent molecules are omitted for clarity. For C19, C26 and C27 only one part of
major disordered components is shown
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The copper-phenolate oxygen and copper-imine nitrogen bonds lengths are in the
ranges 1.89 – 1.91 Å and 1.96 – 2.03 Å respectively (Table 3.3.2). This is consistent
with related copper(II) ketoiminate complexes found in the literature.17 Relative
bond angles are in the range 88.8 – 94.5o, deviating from the expected 90o, in
agreement with the distorted square planar geometry prediction.
Table 3.3.2: Selected bond lengths Cu(II)(acnac)2 complexes
Bond Length / Å
Cu(1)-N(1) Cu(1)-N(2) Cu(1)-O(1) Cu(1)-O(2) C-Halogen
C17 1.991(4) 1.987(4) 1.909(4) 1.913(3) -
C18a 1.989(3) 1.989(3) 1.899(2) 1.899(2) 1.898(4)
C19a 1.969(4) 1.969(4) 1.910(3) 1.910(3) 1.737(6)
C20 1.997(4) 1.989(4) 1.904(3) 1.902(3) 1.900(5)
C21a 1.9773(15) 1.9773(15) 1.8983(13) 1.8983(13) 1.7459(19)
C22a 2.0042(14) 2.0042(14) 1.8935(12) 1.8935(12) 1.354(2)
C23 1.994(5) 2.002(4) 1.908(4) 1.902(4) 2.108(5)
C24a 1.9751(18) 1.9751(18) 1.9009(14) 1.9009(14) -
C25a 1.998(2) 1.998(2) 1.9054(19) 1.9054(19) 1.294(3)
C26 1.976(2) 1.9745(19) 1.8984(16) 1.8922(17) 1.370(3)
C27a 2.004(4) 2.004(4) 1.910(3) 1.910(3) 1.368(10)
C28 1.9558(19) 1.9652(18) 1.9021(16) 1.9169(16) -
C29 1.973(4) 1.974(4) 1.907(4) 1.892(3) -
C30a 1.986(2) 1.986(2) 1.8966(19) 1.8965(19) 1.735(3)
C31a 2.014(2) 2.014(2) 1.9172(17) 1.9172(17) 1.383(3)
C32a 1.977(2) 1.977(2) 1.9053(17) 1.9053(17) 1.886(3)
C36a 1.979(3) 1.979(3) 1.906(3) 1.906(3) 1.896(5)
C37a 1.966(2) 1.966(2) 1.9071(19) 1.9071(19) 1.345(4)
C40a 1.9945(19) 1.9945(19) 1.8978(17) 1.8978(17) 1.750(2)
C41a 1.998(2) 1.998(2) 1.8965(19) 1.8965(19) 1.340(4)
C42 1.968(2) 1.966(2) 1.9080(18) 1.9148(18) 1.360(3)
a = half molecule in asymmetric unit
Copper(II)acnac complexes Chapter 3
99
Table 3.3.3: Selected bond angles Cu(II)(acnac)2 complexes
Angles / o
O(1)-Cu(1)-N(1) O(1)-Cu(1)-N(2) O(1)-Cu(1)-O(2) N(1)-Cu(1)-N(2)
C17 91.78(16) 87.92(16) 172.93(18) 175.6(2)
C18a 91.98(11) 88.02(11) 180.0 180.00(17)
C19a 93.83(15) 89.77(15) 155.7(2) 162.8(2)
C20 92.22(15) 89.23(15) 174.25(17) 175.06(18)
C21a 93.85(6) 92.54(6) 148.92(9) 155.98(9)
C22a 91.51(6) 88.49(6) 180.0 180.0
C23 91.62(17) 87.66(17) 174.53(19) 174.3(2)
C24a 94.20(7) 92.43(7) 148.84(9) 155.15(10)
C25a 90.86(8) 89.14(8) 180.0 180.0
C26 93.65(8) 92.43(7) 148.77(7) 155.05(8)
C27a 90.97(14) 89.03(14) 180.00(18) 180.0
C28 94.07(7) 92.16(7) 149.64(7) 155.87(8)
C29 93.69(17) 92.33(17) 153.50(17) 154.49(19)
C30a 93.83(9) 93.83(9) 152.00(15) 158.11(15)
C31a 90.86(8) 89.14(8) 180.0 180.00(11)
C32a 93.03(8) 91.18(8) 155.46(11) 160.09(12)
C36a 94.59(13) 94.59(13) 146.2(2) 158.2(2)
C37a 93.92(9) 92.05(9) 149.73(13) 156.98(14)
C40a 92.03(7) 87.97(7) 180.0 180.0
C41a 91.46(9) 88.54(9) 180.0 180.0
C42 92.86(8) 92.69(8) 148.90(9) 153.38(10)
a = half molecule in asymmetric unit
For this series of complexes, intramolecular hydrogen bonding is absent in all
complexes with the exception of complex C42. Complex C42, shows intramolecular
hydrogen bonding between the fluorine substituents in the aniline ring and the C-H
in the phenolate ring (Figure 3.3.2).
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Atom (A…D) Bond length / Å
C(23)-H……F(3) 3.757(4)
C(7)-H..…….F(1) 3.366(4)
C(32)-H…....F(2) 3.533(3)
Figure 3.3.2: Intramolecular hydrogen bonding seen in complex C42
Non-classical intermolecular hydrogen bonds between the phenolate oxygen atom
and methyl protons on carbon atom C7 (shown in Figure 3.3.3) are common for all
complexes. Typical bond lengths for such interactions are in the range of 3.40- 3.85
Å. Selected examples, complexes C20 and C25 are shown in Figure 3.3.3.
C20 C25
Figure 3.3.3: Intermolecular hydrogen bonding
Other non-classical hydrogen bonds as a result of the substituents on the phenolate
or aniline phenyl rings are observed. In many cases the molecules are predominantly
linked together through this type of hydrogen bonds. These substituents form
hydrogen bonds with C(H) hydrogen atoms in the phenyl rings (Figure 3.3.4) or
with the C(H) hydrogen atoms of carbon atom C7 (C22 in Figure 3.3.4). Selected
non-classical hydrogen bond lengths are given in Figure 3.3.4. Although other
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authors have reported coupling of similar complexes through weak Cu...H contacts,1
no such interactions were observed for this particular series of complexes.
Atom (A…D) Bond length / Å
C(12)-H…….Cl(2) 3.806(3)
C(2)-H……....N(1) 3.691(3)
C21
Atom (A…D) Bond length / Å
C(6)-H……….F(1) 3.538(2)
C(7B)-H……F(1) 3.605(3)
C22
Atom (A…D) Bond length / Å
C(13)-H……Cl(3) 3.645(3)
C30
Atom (A…D) Bond length / Å
C(13)-H........F(1) 3.344(4)
C(6)-H…......N(1) 3.679(4)
C37
Figure 3.3.4: Intermolecular hydrogen bonding with substituents
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All the complexes show close packing crystal arrangement, with selected examples
shown in Figure 3.3.5. There is no evidence of π-π interactions and some complexes 
showing herringbone arrangement along the c-axis, Figure 3.3.6.
C19 C27
C28 C36
Figure 3.3.5: Selected examples of crystal close packing arrangement
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C22 C23
C25 C27
C29 C41
Figure 3.3.6: Herringbone crystal packing arrangement observed in some complexes
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3.4 Conclusion
This chapter presents the synthesis and characterisation of a range of novel
functionalised β-bis-ketoiminate copper(II) pseudo square planar complexes, with
X-ray crystallographic analysis obtained for all complexes. Synthesis of the
complexes is possible under both aerobic or inert conditions; reactions under inert
atmosphere allowed for reproducible synthesis and was adopted for all complexes.
This range of complexes show bidentate (N,O) coordination around the copper(II)
centre with the ligands trans to each other. Crystallographic data shows that these
complexes have close packing crystal arrangement with some complexes showing
interesting herringbone packing, as well as intermolecular hydrogen bonding
between molecules. The efficacy of these complexes as anti-cancer agents and
catalysts is discussed in Chapter 4 and Chapter 6 respectively.
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Chapter 4
Biological investigations on β-bis-Ketoiminate
analogue Complexes of Ruthenium and Copper
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4.1 Introduction to biological studies
The discovery of new anti-cancer drugs generally follows conventional well known
stages in the drug discovery and development process. The preliminary non-clinical
stages are not limited to, but include, identification and validation of a drug target,
assay development and identification of lead compounds and their optimisation. The
lead compounds, defined as molecules that show efficacy towards the biological target
are identified by screening a large library of compounds against functional assays or
known biological targets. The lead compounds are then modified to produce other
compounds with a better profile of desirable properties compared to unwanted
properties. Such properties include water solubility, potency and stability. Successful
candidates are then taken further into clinical trials, where properties such as
pharmacokinetics, pharmacodynamics and toxicity are evaluated.1-5
4.2 Cytotoxicity
Biological assays such as in vitro cytotoxicity screening are widely used to measure the
effectiveness of drug candidates against a variety of human cancer cell lines and to
identify potential drugs for further analysis. Drug candidates can be classified as
inactive, moderately active or highly active based on their IC50 values. The IC50 value is
defined as the concentration of the drug required to inhibit 50% of cell proliferation.
The cytotoxicity of the drug candidates can be monitored using the MTT 6 or SRB 7
assays.
This chapter briefly describes the theory behind the MTT assay followed by an
evaluation of the potency of novel ruthenium carbonyl and copper ketoiminate
complexes synthesised by the author, under both normoxic and hypoxic conditions.
4.2.1 MTT Assay
The well know, rapid colorimetric tetrazolium salt based MTT assay was developed in
1983 by Mosmann.6 It is used to measure mammalian cytotoxicity, cell survival and
proliferation by the use of a yellow water soluble 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazoliumbromide (MTT) salt which is reduced in living cells to purple or
dark blue formazan crystals that are water insoluble. This reduction involves the
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pyridine nucleotide cofactors, NADP and NADPH, which appears as the basis of
established in vitro cell viability assays (Figure 4.2.1). The formazan crystals formed
are solubilised and the colour quantified using a scanning multiwall spectrophotometer
(TECAN) reader. The amount of formazan formed is directly proportional to the
number of metabolically viable cells present after the MTT exposure.8
Figure 4.2.1: Reduction of yellow MTT salt to purple formazan
Mitochondrial succinate dehydrogenase in living cells have been implicated in the
reduction of MTT, as a result the sites for reduction and formation of the formazan
were thought to be the mitochondria. However recent studies show that the non-
mitochondria, cytosolic enzymes which utilise NADH/NADPH are also responsible for
MTT reduction.9
4.3 Results and Discussion
4.3.1 Cytotoxicity of β-bis-Ketoiminate Ru(II) Dicarbonyl Complexes
The cytotoxicity of β-bis-ketoiminate ruthenium(II) dicarbonyl complexes described in
Chapter 2 with the general structure shown in Figure 4.3.1 were evaluated on two
cancerous cell lines, MIA PaCa-2 (human pancreatic carcinoma) and HCT116++
(human colon carcinoma) and on one non-cancerous cell line, ARPE19 (human retinal
pigment epithelial cell). All thebiological work was done at The University of
Huddersfield by Pablo Carames-Mendez in collaboration with Professor Roger Phillips.
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Figure 4.3.1: β-Bis-ketoiminate Ru(II) dicarbonyl complexes under investigation
A 96 hour MTT assay at 37oC in an atmosphere of 5% CO2 was carried out on the
ruthenium carbonyl complexes at various concentrations, ranging from 100 μM to 
0.046 μM. After incubation and addition of MTT, cell survival was determined by 
measuring the absorbance at 540 nm. All cytotoxicity assays were performed in
triplicate. The IC50 values of the complexes were obtained from plotting graphs of %
cell survival against drug concentration (M).
The results for the cytotoxicity evaluation of β-bis-ketoiminate Ru(II) dicarbonyl
complexes, C1-C16, are summarised in Table 4.3.1 and Figure 4.3.2.The complexes
vary in their cytotoxicity, with active complexes highlighted in red (IC50 = < 25 M)
and moderately active complexes in green (IC50 = 25-60 M) (Table 4.3.1). In all
assays, values are compared to the values of cisplatin and oxaliplatin.
The ruthenium(II) dicarbonyl complexes display a wide range of potency against all
three cell lines. These complexes are generally inactive against the Mia PaCa-2 cell
line, with a decrease in IC50 values observed for HCT116++ cell lines. This is most
evident with complexes C3 and C4 in which the IC50 values are 96.05 μM (for C3) and
> 100 μM (for C4) for Mia PaCa-2 cell line compared to 43.40 μM (for C3) and 21.61
μM (for C4) for HCT116++ cell line. This is true for all for complexes except C7, C14
and C16 which are inactive against both cell lines. The most active complexes, C3, C4,
C8 and C12
(highlighted in Table 4.3.1) show poor selectivity towards ARPE19 cell line and are as
cytotoxic as they are toxic.
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Table 4.3.1: IC50 values of Ru(II) dicarbonyl complexes
Complex Substituent
(Rp/Ra)
IC50/μM 
Mia PaCa-2 HCT116++ ARPE19
C1 H(p) 89.37±9.31 85.96±22.07 92.01±13.84
C2 4’Br(p) 92.89±12.31 68.21±11.04 82.40±21.32
C3 4’Cl(p) 96.05±6.84 43.40±5.67 50.98±2.54
C4 4’F(p) >100 21.61±3.55 37.74±8.59
C5 3’F(p) >100 65.29±19.49 >100
C6 3’Br(p) >100 96.01±6.91 >100
C7 3’,4’ diCl(p) >100 >100 >100
C8 4’Me(p) >100 54.20±14.00 51.62±12.28
C9 3’Me(a) >100 64.80±16.19 >100
C10 4’F(a) 91.80±14.20 66.79±6.84 88.59±19.76
C11 4’Cl(a) >100 71.90±5.62 >100
C12 2’F(a) 61.49±9.64 59.50±6.53 77.50±20.17
C13 3’Br(a) 84.02±19.23 81.61±8.07 90.18±17.01
C14 2’,4’diCl(a) >100 >100 >100
C15 2’,4’diF(a) 80.90±11.82 63.31±7.84 78.61±25.15
C16 2’,3’diMe(a) >100 >100 >100
cisplatin 3.62±0.74 3.26±0.38 6.41±0.95
oxaliplatin 6.44±1.05 0.93±0.12 6.15±2.68
(p) = substituent on phenolate ring; (a) = substituent on aniline ring
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Figure 4.3.2: IC50 values of Ru(II) dicarbonyl complexes (C1-C16)
Previous work within the McGowan research group on β-diketonate complexes of 
titanium have shown the para fluoro substituted diketonate titanium complex as the
lead complex.10,11 Thus, the activities of the para substituted complexes with differing
electronic and steric effects (C2 = 4’Br, C3 = 4’Cl and C8 = 4’Me) was compared for
this class of complexes. The para iodo complex is not included as it was not fully
characterised due to purification difficulties. From the IC50 values shown in Table
4.3.1, the most active complex is the para fluoro substituted complex, C4. These
results are consistent with those previously highlighted within our research group.
Furthermore the para substituted complex C4 (IC50 = 21.61 μM) shows higher efficacy 
when compared to its meta substituted analogue C5 (IC50 = 65.29 μM). 
Although further investigative experiments are needed to ascertain the effect of fluorine
on the cytotoxicity of drug candidates, literature review shows that the introduction of
fluorine into a drug candidate, in drug design and development is of critical
importance.12 The incorporation of fluorine can affect properties such as pKa,
conformation, intrinsic potency, metabolic pathways, membrane permeability,
bioavailability and pharmacokinetics.13 These properties have significant effects in the
overall potency of a drug molecule.
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A rather unusual result is the potency of complex C8 (IC50 = 54.20 μM), the electron 
donating methyl group results in enhanced cytotoxicity when compared to the para
bromo substituted complex, C2 (IC50 = 68.21 μM). This result potentially implies that 
with complexes of the type β-bis-ketoiminate Ru(II) dicarbonyl, electronics (electron
donating or electron withdrawing ability) have a minor effect on the resultant potency
of the complexes.
Incorporation of halide substituents in either of the phenyl rings (aniline (Ra) or
phenolate (Rp)) of the ketoiminate ligands results in significant effects on the potency
of the complexes. The unsubstituted complex C1 has an IC50 value of 85.96 μM and is 
classed as inactive, addition of halide substituents going from the most electronegative
to the least electronegative results in an increase in the potency of the complexes. This
is shown by complexes C4 (4’F, IC50 = 21.60 μM), C3 (4’Cl, IC50 = 43.40 μM) and C2
(4’Br, IC50 = 68.21 μM). Overall we can conclude that the electronegativity of halide 
substituents can influence the anticancer activity of these complexes.
The cytotoxicity of the lead complex C4 is significantly reduced when the phenyl ring
carrying the substituted halide is changed, such as in its analogue C10 (Figure 4.3.3).
A similar result is observed for the para chloro substituted complexes, C3 (4’Cl, IC50 =
43.40 μM) and C11 (4’Cl, IC50 = 71.90 μM). However, in order to justify this as a trend 
the library of β-bis-ketoiminate Ru(II) dicarbonyl complexes must be extended and
fully investigated.
C4 C10
IC50 = 21.61 μM IC50 = 66.79 μM 
Figure 4.3.3: Representation of phenyl ring effect on anti-cancer activity
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4.3.2 Hypoxia
Molecular oxygen, O2, required by many organic and inorganic reactions as an electron
receptor is also required for aerobic metabolism to maintain intracellular
bioenergetics.14 The pioneering work by Peter Vaupel et al. has shown that solid
tumours that have reached 2-3 mm in diameter are usually characterised by areas of
low oxygen levels, characterised by a reducing environment in comparison to
surrounding normal tissues. Such under-perfused regions, referred to as hypoxic
regions, are used to selectively distinguish between healthy and cancerous cells.15
Hypoxia can also be found in a number of conditions such as tissue ischaemia, stroke
and inflammation. Healthy mammalian organs typically exist at 2-9% O2 (40mmHg)
(normoxia), hypoxic regions exist at ≤ 2% O2, while severe hypoxia (anoxia) is defined
as ≤ 0.02%.14 16 It is also important to note that although it a common feature in solid
tumours, the incidence, extent and severity of hypoxia varies between and within
individual tumours.17, 18
Solid tumours are known to have fundamentally different vascular networks in
comparison to normal tissues. In order to metastasize and obtain the necessary nutrients
to facilitate their rapid and uncontrolled growth, cancer cells use host cell vessels to
create new vessels (angiogenesis). The result is the tumour vasculature being
structurally and functionally abnormal. In addition to the solid pressure from
proliferating cancer cells, typical cancer cell blood vessels are dilated, hyper-
permeable, tortuous, saccular with a random pattern of interconnection. All these
factors result in heterogeneous blood flow leading to abnormal microenvironments
within the tumour (Figure 4.3.4). Typically oxygen can diffuse 170 μm through tissue 
cells but cells located at a distance greater than this from a functioning blood vessel
will have impaired blood supply.19-21
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  150 μm   
Figure 4.3.4: Schematic representation of the effect impaired blood supply in tumour cells.21
The abnormal vasculature and microenvironment of solid tumours present difficulties
in chemotherapy and radiation cancer treatments. Although cancer cells are able to
survive in hypoxic environments, drug delivery and efficacy are greatly compromised;
most cytotoxic agents are highly dependent on normal blood circulation and delivery at
correct concentrations.20, 22 The ultimate result is compromised clinical outcomes such
as poor prognosis, treatment failure, recurrence and ultimately patient mortality.21
Hypoxia has been pursued as a therapeutic target through the development of bio-
reductive (hypoxia activated) prodrugs, which are activated when they reach the
hypoxic regions with reducing environments. Nitro groups, quinones, aliphatic and
aromatic N-oxides and transition metals are some of the chemical moieties that can be
enzymatically reduced under hypoxic conditions.16-18 The proposed molecular
pharmacology (Figure 4.3.5) of these hypoxia activated prodrugs is initiated by one-
electron enzymatic reduction to give a radical anion of the prodrug. In normoxia, this
radical anion is quickly taken up by molecular oxygen, resulting in a failed redox
process. However, in hypoxic environments the radical anion spontaneously fragments
or is further reduced to produce a cytotoxic species. The cytotoxic species can then
target biological agents through processes such as oxidation or poisoning of
topoisomerase II, DNA alkylation and kinase inhibition.17, 23
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Figure 4.3.5: Mechanism for activation of bio-reductive prodrugs
Transition metal complexes have been exploited as potential bio-reductive prodrugs
due to their ability to vary their coordination number, geometry and redox states
making them accessible in the reducing biological surroundings. They can possibly be
transported to the targeted environment as inert prodrugs, becoming reduced
metabolically into their active form.24 Transition metals such as platinum(IV),25
ruthenium(III),26, 27 chromium28 and iron(III)29 have been investigated as hypoxia
activated prodrugs; the author will give a brief overview on copper and cobalt.
Cobalt: Polyazamacrocyclic nitrogen mustards are a well-known class of potent but
non-selective cytotoxins. Their selectivity has been shown to improve when they are
deactivated through coordination to an inert metal centre. Denny et al.28, 30, 31 have
synthesised a number of inert cobalt complexes (Figure 4.3.6), that are activated in
hypoxic medium.
Figure 4.3.6: Hypoxia selective Co(III) acetylacetonate complex
The cobalt centre inhibits early hydrolysis of the mustard ligand, allowing the inert
complex to be taken up by the cells. Once taken up the Co(III) complex is then reduced
to the labile Co(II) which subsequently undergoes slow decomposition to free the
active cytotoxin nitrogen mustard ligand. The mustard alkylating agents can then
covalently interact with cellular components such as DNA and enzymes.32-35
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Copper: Copper has two oxidation states, +2 and +1, which are accessible within the
physiological cellular potential range. This ability makes copper an attractive metal for
hypoxic activated prodrugs.36 Parker et al. have synthesised Cu(II) complexes with
polyazamacrocyclic N-mustard ligands and evaluated their potential as hypoxia
activated prodrugs on lung derived human tumour cell line A549.37
The cyclen-based mustard complex shown in
Scheme 4.3.1 was the most selective, with a 24 fold increase in its cytotoxicity under
hypoxia compared to normoxia.
Scheme 4.3.1 shows the proposed bio-reduction mechanism; the Cu(II) complex acts as
a prodrug, becoming reduced to Cu(I) in the hypoxic region, releasing the cytotoxic
cyclen ligand to its target cell.
Scheme 4.3.1: Hypoxia selective Cu(II) cyclen-based mustard complex
4.3.2.1 MTT assay under hypoxic conditions
In order to determine the hypoxia-selective potential activity of the ruthenium
dicarbonyl complexes, the efficacy of the lead complex, C4, with an IC50 value of
21.61 μM under normoxic conditions was further evaluated under hypoxia. The 
HCT116++ colon cancer cell line was selected for this assay as the ruthenium
dicarbonyl complexes were previously found to be more potent and selective towards
this cell line compared to the Mia PaCa-2 pancreatic cancer cell line.
Hypoxia cytotoxicity studies were carried out in a Whitley hypoxia-station with the
oxygen level at 0.1%, a physiologically relevant hypoxic level that has been associated
with drug resistance in chemotherapy and radiotherapy.38 In order to remove oxygen
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from the media, the media used for this study was conditioned for at least 24 hours in
the hypoxic chamber. The MTT assay procedure described in 4.3.1 was followed, with
the cells being exposed to the lead complex after 24 hours of seeding.
The results for hypoxia studies on complex C4 are shown in Table 4.3.2 and Figure
4.3.7. Although the complex retains its potency, the two fold increase in its IC50 value
indicates that the complex is less active under hypoxia compared to normoxia,
however, is still significantly more active than cisplatin.
Table 4.3.2: IC50 values of complex C4 under normoxia and hypoxia
Hypoxia Normoxia
C4 50.5 21.61±3.55
cisplatin 95.49 3.26±0.38
Figure 4.3.7: IC50 values for complex C4 under normoxia and hypoxia
4.3.3 Cytotoxicity of β-bis-Ketoiminate Copper(II) Complexes
The β-bis-ketoiminate copper(II) complexes, C17-C42, discussed in Chapter 3 and
shown in Figure 4.3.8 were evaluated for their cytotoxicity against two cancerous cell
lines, Mia PaCa-2 (human pancreatic carcinoma) and HCT116++ (human colon
carcinoma) and on one non-cancerous cell line, ARPE19 (human retinal pigment
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epithelial cell). Similar to the ruthenium(II) dicarbonyl complexes previously discussed
(4.3.1), all the biological work was done at The University of Huddersfield by Pablo
Carames-Mendez in collaboration with Professor Roger Phillips.
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Figure 4.3.8: β-Bis-ketoiminate copper(II) complexes under investigation
Figure 4.3.9: IC50 values of ketoiminate copper(II) complexes C17-C42
The results for the cytotoxicity evaluation of β-bis-ketoiminate copper(II) complexes,
C17-C42, are summarised in Table 4.3.3 and Figure 4.3.9. The copper(II)acnac
complexes were inactive against the two cancerous cell lines, with only complexes
C33, C34 and C42 displaying moderate activity (highlighted in green in Table 4.3.3).
The moderately active complexes did not show any selectivity between the colon and
pancreatic cancer cell lines. Complex C34 and C42 were as toxic as they were
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cytotoxic, however complex C33 was selective towards the healthy cells. The results
suggest that there is no correlation between the electronic and steric properties of the
complex and the potency of the compound. No further cytotoxicity studies were carried
out on these complexes.
Table 4.3.3: IC50 values of ketoiminate copper(II) complexes C17-C42
Complex Substituent IC50/μM 
(Rp/Ra) MiaPaca HCT116++ ARPE19
C17 H(p) >100 >100 >100
C18 2'Br(p) >100 >100 >100
C19 2'Cl(p) >100 >100 >100
C20 4'Br(p) >100 >100 >100
C21 4'Cl(p) >100 >100 >100
C22 4'F(p) >100 >100 >100
C23 4'I(p) >100 >100 >100
C24 4'Me(p) >100 >100 >100
C25 4'OMe(p) >100 >100 >100
C26 4'OEt(p) >100 >100 >100
C27 4'CF3(p) >100 >100 >100
C28 2',3'diMe(p) >100 >100 >100
C29 2',4',6'triMe(p) >100 >100 >100
C30 3',4'diCl(p) >100 >100 >100
C31 3',4' methylene(p) >100 >100 >100
C32 3'Br,4'F(p) >100 >100 >100
C33 2'OMe(p) 61.36±2.87 66.87±14.55 >100
C34 3'F(p) 78.33±12.48 57.14±11.41 35.73±3.26
C35 2'OEt,4'F(p) >100 >100 >100
C36 2'Br(a) >100 >100 >100
C37 2'F(a) >100 >100 >100
C38 3'Br(a) >100 >100 >100
C39 3'Cl(a) >100 >100 >100
C40 4'Cl(a) >100 >100 >100
C41 2',4' diF(a) >100 >100 >100
C42 2',5' diF(a) 64.02±10.35 42.35±12.88 38.11±8.84
Cisplatin 3.62±0.74 3.26±0.38 6.41±0.95
Oxaliplatin 6.44±1.05 0.93±0.12 6.15±2.68
(p) = substituent on phenolate ring; (a) = substituent on aniline ring
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4.4 Anti-bacterial Studies
One of the major advances in the medical field has been the development and
widespread use of antimicrobials. However, this was followed by the unfortunate rapid
and ever increasing emergence of antimicrobial resistance (AMR) which has become a
global pandemic, placing a significant amount of burden on public health systems and
global economic finance. AMR threatens the effective prevention and treatment of a
range of infections caused by bacteria, fungi, parasites and viruses by reducing clinical
efficacy while increasing diagnostic uncertainties, treatment costs, mortality and
morbidity.39-42
In recent years, a group of the most antimicrobial resistant bacteria referred to as
“ESKAPE pathogens” have been associated with nosocomial infections among
severely ill and immune-compromised individuals. ESKAPE pathogens include both
Gram-(+ve) and Gram-(-ve) bacteria, and is made up of Enterococcus faecium,
Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii,
Pseudomonas aeruginosa and Enterobacter species.41, 43, 44
Antimicrobial resistance can be active or passive. Active resistance results when the
bacteria, over a period of time, adopts a counter-attack mechanism against an
individual antibiotic or a family of antibiotics. An example of passive resistance is
when bacteria, for example Gram-negative bacteria develop resistance due to the non-
specific barrier in their outer membrane.45 Bacteria are able to acquire their resistance
through several categories such as drug inactivation, mutation and modification of drug
binding target/site, reduced intracellular drug accumulation due to changes in cell
permeability and biofilm formation.45-47 It is anticipated that development of bacterial
resistance to a given antibiotic evolves within an average of 50 years from initial use.48
Old targets, new drugs is one of the several strategies that are being exploited in an
attempt to develop improved antimicrobial agents. In this approach the functional
lifetime of existing antimicrobials is extended by generations of synthetic tailoring,
leading to “new”, improved antimicrobials. In addition to a higher affinity for mutated
targets, these modified scaffolds have better solubility, drug uptake and are less prone
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to efflux.42, 46, 49 Although effective, this strategy delays the problem of resistance rather
than offer a solution. New targets, new drugs as the phrase suggests seeks to eliminate
the problem of antimicrobial resistance through the development of novel and effective
antimicrobial agents, with new targets, modes of actions and mechanisms.46
As research into new organic based antimicrobial agents continues, transition metals
have received remarkable interest for the development of metal based antimicrobial
agents.42 The antimicrobial activity of metal complexes has been known since antiquity
when the antimicrobial properties of the organic molecule oxine where proposed to rise
from its chelation with copper and iron ions available in the medium.50, 51 The
antimicrobial efficacy of bioinorganic complexes can be modified by tuning the
coordination sphere around the metal, as well as the metal’s oxidation state. The
possibility of simultaneous multiple mechanisms of action from these complexes makes
the notion of overcoming the drug resistance of micro-organisms using metal based
complexes feasible.52
Over the years there has been a growing interest in ruthenium based compounds as
alternatives to platinum based complexes for biological applications. As such,
considerable focus has been on developing ruthenium(II) complexes as antimicrobial
agents.42 Dwyer et al. have synthesised polypyridylruthenium(II) complexes and
evaluated their efficacy on Gram-positive, Gram-negative and acid fast bacteria. They
proposed that the complexes were well suited for topical application for surface
infection rather than injection routes.53-55
4.4.1 Ruthenium CORMs in anti-bacterial studies
CORMs, are known to have a different mode of action in their biological and
therapeutic applications when compared to other transition metal based molecules. This
has prompted investigations into their potential application for treatment of antibiotic
resistant bacteria.56 Control experiments such as depleting the carbonyl group in
CORMs and cell growth experiments with CORMs in the presence of Hb, a high-
affinity CO scavenger, have led to the conclusion that the bactericidal effect of CORMs
is due to the CO and not the metal ion.56, 57
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The well-known CORMs, the lipid soluble CORM-2 [Figure 4.4.1 (a)] and the water
soluble CORM-3 [Figure 4.4.1 (b)] have been shown to reduce the viability of Gram-
positive and Gram-negative bacterial species such as Staphylococcus aureus,
Pseudomonas aeruginosa and Escherichia coli.57-59 In a recent study on E. coli,
Saraiva et al. have investigated the antimicrobial activity, the amount of ROS species
released into bacterial cells, toxicity to eukaryotic cells as well as the ability of CORMs
to deliver carbon monoxide to bacterial cells and eukaryotic cells. This was done using
a range of CO-releasing molecules with different chemical and biocompatibility
profiles, coordination sphere type and metal centre. Their results show that CORMs
have a viable potential application as antimicrobial drugs as (i) their activity can be
modified through manipulation of their coordination spheres, (ii) their toxicity to
eukaryotic cells is innocuous or relatively low even at their bactericidal concentrations
and (iii) they exhibit opposite toxicity profiles towards bacteria and eukaryotic cells.60,
61
Figure 4.4.1: (a) CORM-2 and (b) CORM-3
The novel β-bis-ketoiminate ruthenium(II) dicarbonyl complexes Figure 4.4.2 were
screened for their anti-bacterial activity by measuring the inhibition growth against
Gram-positive Staphylococcus aureus (S. aureus) and Gram-negative Escherichia coli
(E. coli), Klebsiella pneumoniae (K. pneumoniae), Pseudomonas aeruginosa (P.
aeruginosa) and Acinetobacter baumannii (A. baumannii) by CO-ADD, The
Community for Antimicrobial Drug Discovery at The University of Queensland,
Australia. For all the complexes, assays were carried out in duplicate at a single
concentration of 32 μg/mL by incubating with the bacterial strains at 37 °C for 18 hours 
without shaking. Inhibition of bacterial growth was determined by measuring the
absorbance at 600 nm (OD600), using a Tecan Pro monochromator plate reader.
Complexes with growth inhibition values above 80% are classed as active, while
complexes with growth inhibition values between 50 - 80% are classed as partial active.
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Vancomycin and colistin were used as positive bacterial inhibitor standards for
Gram-(-) and Gram-(+) bacteria, respectively.
The anti-bacterial screening assay results for the ruthenium(II) carbonyl complexes are
summarised in Table 4.4.1. The results show that the complexes are generally inactive,
except for complex C12 which is partially active against Gram-positive S. aureus
species, with a growth inhibition of 58%. Partially active complexes are highlighted in
purple. Negative growth inhibition values indicate that the growth rate for the
complexes in question are higher than the negative control. These complexes could be
causing cell proliferation than growth inhibition.
Complex Substituent (Rp/Ra)
C1 H(p)
C2 4’Br(p)
C3 4’Cl(p)
C4 4’F(p)
C5 3’F(p)
C6 3’Br(p)
C7 3’,4’ diCl(p)
C8 4’Me(p)
C9 3’Me(a)
C10 4’F(a)
C11 4’Cl(a)
C12 2’F(a)
C13 3’Br(a)
C14 2’,4’ diCl(a)
C15 2’,4’ di F(a)
C16 2’,3’ diMe(a)
(p) = substituent on phenolate ring; (a) = substituent on aniline ring
Figure 4.4.2: β-Bis-ketoiminate Ru(II) dicarbonyl complexes under investigation 
Complex, C12 (with an ortho-fluoro substituent on the aniline ring) shows selectivity
against the Gram-positive S. aureus and is inactive against the other four Gram-
negative bacterial species, a trend observed for all the complexes. Bolhuis et al. who
observed similar selectivity with their Ru(II) complexes suggested that this selectivity
against Gram-positive bacteria may be due to the inability of the complexes to cross the
outer membrane characteristic of Gram-negative bacterial species.62 This outer
membrane is known to decrease the permeability of anti-bacterials and is regarded as
one of the major mechanisms of resistance to drugs for many pathogenic Gram-
negative bacteria.42
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Table 4.4.1: Growth inhibition of Ru(II) dicarbonyl complexes against bacterial strains
Complex Inhibition (%)
S. aureus E. coli K. pneumoniae P.aeruginosa A.baumannii
C1 18.24 1.92 6.31 20.87 4.02
C2 7.82 4.03 -2.85 20.71 -2.52
C3 20.52 4.83 5.43 22.73 12.98
C4 -12.85 -25.79 -31.78 13.86 -37.98
C5 21.58 -2.18 6.55 18.83 3.63
C6 21.36 3.09 10.12 20.96 16.45
C7 13.12 -5.76 -8.64 20.38 -2.04
C8 -9.81 -18.19 -22.32 12.31 -18.13
C9 20.17 -9.26 -2.28 5.07 -12.95
C10 6.95 -27.37 -16.83 14.29 -26.80
C11 8.37 -17.07 -23.92 15.15 -16.54
C12 58.29 -35.64 -31.94 12.73 -48.41
C13 12.52 -11.13 -10.57 16.08 -9.17
C14 20.94 -10.25 -3.27 10.01 -8.62
C15 -6.49 -27.95 -37.23 0.48 -42.00
C16 9.93 -15.75 -5.72 -3.00 -7.06
Although further investigative work needs to be done, some structure-activity
relationship can be observed from the results. Moving the fluoro substituent from an
ortho position to a para position results in a tenfold decrease in the activity of the
complex (Table 4.4.1, C10 and C12). Similarly addition of another fluorine moiety on
the same phenyl ring results in inactivity of the complex (Table 4.4.1, C12 and C15).
The addition of electron donating and electron withdrawing groups on either of the
phenyl rings of the ligands has no noticeable effect on the activity or selectivity of the
complexes against S. aureus.
Comparison of the anti-bacterial results of the β-bis-ketoiminate ruthenium(II)
dicarbonyl complexes (Table 4.4.1) shows there is no overall selectivity for neither
Gram-negative nor Gram-positive bacterial species (except for C12). This result is
consistent with the results of Nobre et al. who concluded that CORMs have the
potential to be used as bactericides against a wide range of microorganisms regardless
of the type of bacterial cell wall and the oxygen requirements, aerobic and anaerobic
conditions.60
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4.4.2 Copper complexes in anti-bacterial studies
Although transition metals such as copper, zinc and iron are essential for the growth
and development of organisms from bacteria to mammals, free copper ions are known
to be toxic to numerous bacteria and fungi. To increase its antimicrobial efficacy
several compounds have been synthesised through the coordination of organic moieties
to copper.52, 63 For thousands of years the antimicrobial benefits of copper have been
well known and researched, dating as far back as the ancient Egyptian times when
copper was first reported for its water and wound sterilisation properties.64 With
increasing transmission from pathogens on various surfaces, evolving research and
development has seen the establishment of metallic copper surfaces as antimicrobial
surfaces that rapidly kill bacteria, yeast and viruses. “Contact killing” as it termed is
largely used in hospitals and other health care settings to curb nosocomial infections.65,
66
Several copper complexes with ligands such as Schiff bases, heteroatomic
thiophene/furan carboxamides and perimidine derivatives, with the general
compositions [ML2] have been synthesised and their antimicrobial activities against a
range of Gram-negative and Gram-positive pathogens investigated. A trend common to
these complexes is that the complexes showed enhanced inhibitory activity than the
free parent ligands.67-71 The copper(II) Schiff base complexes were more potent against
Gram-positive bacteria than Gram-negative bacteria. This result, consistent with the
antimicrobial activity results of complexes and compounds of Schiff bases with amino
acids was ascribed to the presence of the outer membrane cell wall present in Gram-
positive bacteria which acts a barrier, interacting with the complexes and reducing their
permeability.67, 68 Copper sulfonamide complexes synthesised by Karacan et al.
however displayed no antimicrobial activity when tested against a range of bacterial
pathogens.69
The β-bis-ketoiminate copper(II) complexes, C17-C42 (Figure 4.4.3), discussed in
Chapter 3 were screened for their anti-bacterial activity by measuring the inhibition
growth against Gram-positive Staphylococcus aureus (S. aureus) and Gram-negative
Escherichia coli (E. coli), Klebsiella pneumoniae (K. pneumoniae), Pseudomonas
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aeruginosa (P. aeruginosa) and Acinetobacter baumannii (A. baumannii) by CO-ADD,
The Community for Antimicrobial Drug Discovery at The University of Queensland,
Australia. The same procedure as that previously outlined (for β-bis-Ketoiminate
ruthenium(II) dicarbonyl complexes was followed.
Figure 4.4.3: Copper(II) acnac complexes under anti-bacterial and anti-fungal studies
Table 4.4.2: Growth inhibition of copper(II)acnac complexes against bacterial strains
Complex Inhibition (%)
S. aureus E. coli K. pneumoniae P.aeruginosa A.baumannii
C17 -14.67 -21.81 -7.38 27.86 25.34
C18 17.37 -10.42 -4.27 24.85 -30.96
C19 24.13 -4.45 -11.59 23.02 -28.87
C20 24.89 -10.39 -13.08 25.28 -29.87
C21 19.90 -11.95 -10.79 17.18 -29.91
C22 21.10 -9.02 -10.73 23.80 -32.74
C23 7.04 -14.83 -24.09 12.55 -35.24
C24 23.14 -3.20 -5.78 18.40 -9.30
C25 11.01 -0.44 -9.15 29.07 -26.58
C26 16.82 -6.49 3.89 17.10 -27.00
C27 23.60 -4-40 -2.08 18.4 -8.60
C28 17.34 -6.62 5.52 15.13 -33.38
C29 16.62 -12.20 -7.07 19.49 -7.09
C30 5.98 -15.15 -4.85 16.49 -42.98
C31 10.72 -13.30 -17.20 15.66 -2.66
C32 -0.26 14.61 -15.97 11.72 -40.89
C33 15.24 -5.43 -19.04 29.45 -24.35
C34 19.63 -4.92 -4.42 22.5 -14.45
C35 23.67 -6.39 -10.62 16.19 -23.85
C36 3.51 -20.57 -5.58 29.38 -3.92
C37 -0.48 -13.32 -29.78 24.65 -41.98
C38 2.63 -15.21 -16.89 16.21 -37.78
C39 2.21 -16.07 -3.12 23.53 -10.67
C40 1.75 -14.12 -9.03 9.76 -18.61
C41 3.76 -15.22 -14.53 17.49 -22.09
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C42 -9.99 -18.64 -14.35 21.79 -43.57
The results for the screening assays are summarised in Table 4.4.2. Complexes, C17-
C42 were generally classed as inactive against all the different strains of Gram-
negative and Gram-positive bacteria. Contrary to the results discussed earlier on other
copper(II) complexes found in the literature, Gram-negative P. aeruginosa bacteria
showed the most positive response towards the copper(II)acnac complexes, as seen
from the positive inhibition values. Although further investigative work needs to be
done, the results indicate that these novel copper(II) are able to a certain extent, interact
with the outer membrane cell wall present in Gram-negative P. aeruginosa bacteria.
The negative inhibitory growth results shown for the other three Gram-negative
bacteria, E. coli, K. pneumoniae and A. baumannii suggest that the complexes initiated
cell proliferation rather than growth inhibition. The positive response, although poor, of
the complexes to Gram-positive bacteria, S. aureus, implies that the complexes have
the potential to be used as bactericidal agents for both Gram-negative and Gram-
positive bacteria.
4.5 Anti-fungal Studies
Fungi are eukaryotic cells that closely resemble mammalian eukaryotic cells. They are
more complex than bacterial pathogens; universally found in the environment they are
more difficult to treat than bacterial infections.72 The past decades have seen an
increase in the rate of fungal infections. A study by the National Institute of Health,
United States, showed that the rate of fungal infections was directly proportional to the
number of immune-compromised individuals, carcinoma, autoimmune disorders and
organ transplants and this has resulted in high mortality and morbidity. Drug resistance,
lack of effective anti-fungal therapy and poor diagnosis are some of the leading
contributors to high morbidity and mortality.73, 74
Although significant, advances in medical and surgical therapy such as the discovery of
chemotherapeutic agents, bone marrow or solid-organ transplants, broad spectrum
antimicrobial agents, use of invasive monitoring devices, assisted ventilation and
parenteral nutrition have resulted in an appreciable increase in the number of immune-
compromised individuals susceptible to mycosis infections.74-76 Immune-compromised
patients suffering from diseases like HIV-AIDS, cancer, diabetes and cystic fibrosis are
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particularly prone to infections from opportunistic mycoses, Candida albicans,
Cryptococcus neoformans, and Aspergillus fumigatus, resulting in life threatening
infections.77-79 Currently they are five main classes of anti-fungals in use, (i) azoles, (ii)
polyenes, (iii) allylmines, (iv) echinocandins and (v) pyrimidine analogues, based on
their site of action.80, 81 The efficacy of these anti-fungals is limited by the development
of anti-fungal resistance, fungi-static activity and host toxicity.45
4.5.1 Ruthenium complexes in anti-fungal studies
Despite the remarkable increase in the application of coordination and organometallic
compounds of ruthenium in medicine and biology, very little has been reported on their
application as anti-fungal agents. Schiff base complexes of bases were the first known
ruthenium anti-fungals.82 Since then the activity against fungi, namely, Aspergillus
flavus and fusarium species, of a number of ruthenium Schiff base complexes has been
evaluated. Under identical experimental conditions and the same microorganisms, the
vast majority of these complexes exhibited higher cytotoxicity when compared to the
free or parent Schiff base ligand(s). This increase in anti-fungal activity is likely due to
the effect of chelation on the normal cell process, as explained by Tweedy’s
theory.83-86 The activity of the complexes was both dependent and independent of the
concentration of the complexes, with some of the complexes showing a direct
proportional between complex concentration and anti-fungal activity.85 The anti-fungal
activity of other ruthenium complexes with perimidine derivates70, β-diketones87 and
catecholamine88 ligands have also been evaluated on a range of fungi, for example,
Candida albicans, Candida glubrata and A. niger. It is interesting to note that free
catecholamine ligands did not show any anti-fungal activity, whilst the catecholamine
complexes showed strong inhibitory activity against pathogenic yeast fungus.88
β-Bis-ketoiminate ruthenium(II) dicarbonyl complexes, C1-C16 (Figure 4.4.2), were
screened for their anti-fungal activity on two fungi, Candida albicans (C. albicans)
and Cryptococcus neoformans var. grubii (C. neoformans), by CO-ADD, The
Community for Antimicrobial Drug Discovery at The University of Queensland,
Australia. Assays were carried out in duplicate at a single concentration of 32 μg/mL 
by incubating with the fungal strains at 35 °C for 24 hours without shaking. Growth
inhibition of C. albicans was determined by measuring absorbance at 530 nm (OD530),
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while growth inhibition of C. neoformans was determined measuring the difference in
absorbance between 600 and 570 nm (OD600-570), using a Biotek Synergy HTX plate
reader. Fluconazole was used as a positive fungal inhibitor standard for C. albicans and
C. neoformans. Complexes with growth inhibition values above 80% are classed as
actives, while complexes with growth inhibition values between 50-80% are classed as
partial actives.
The anti-fungal screening assay results for complexes C1-C16 are summarised in
Table 4.5.1. Although not significantly active, the complexes showed selectivity
towards C. albicans fungal strain as shown by the positive growth inhibition values
when compared to the negative values obtained for C. neoformans.
Table 4.5.1: Growth inhibition of Ru(II) dicarbonyl complexes against fungal strains
Complex Substituent Inhibition (%)
(Rp/Ra) C. albicans C. neoformans
C1 H(p) 14.47 -11.64
C2 4’Br(p) 34.89 -5.14
C3 4’Cl(p)) 26.74 -16.64
C4 4’F(p) 10.02 -9.24
C5 3’F(p) 25.93 -17.85
C6 3’Br(p) 44.1 2.38
C7 3,4’diCl(p) 5.93 9.24
C8 4’Me(p) 7.03 -15.43
C9 3’Me(a) 12.23 -23.9
C10 4’F(a) -0.23 -16.79
C11 4’Cl(a) 8.44 -8.92
C12 2’F(a) -2.67 -18.6
C13 3’Br(a) 6.47 -22.69
C14 2,4’diCl(a) 0.37 -15.27
C15 2,4’diF(a) 5.93 -24.81
C16 2,3’diMe(a) 7.69 -18.3
(p) = substituent on phenolate ring; (a) = substituent on aniline ring
Complex C6 showed the highest activity against C. albicans with a growth inhibition
of 44.1%. Tuning the electronic and steric properties of the complexes via the
substituents, Ra and Rp on the ketoiminate ligands had a negligible effect on the activity
of the complexes. This is highlighted by the broad spectrum activity of complexes C2–
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C16 when compared to that of C1. The position of the substituent R1 and R2 seemingly
have an effect on the activity of the complexes. The anti-fungal activity of the
complexes decreases when similar substituents are on the aniline phenyl ring as
compared to the phenolate phenyl ring, for example, C6 (44.1%) compared to C13
(6.47%); C3 (26.74%) compared to C11 (8.44%) and C4 (10.02%) compared to C10 (-
0.23%). Direct comparison of the anti-fungal activity of these complexes with other
carbon monoxide releasing molecules is not possible as these complexes are novel and
the few CORMs that have been tested have been on different fungi strains and use
different methods to quantify anti-fungal activity.
4.5.2 Copper complexes in anti-fungal studies
Similar to its anti-bacterial activities discussed above, copper, as metallic Cu, Cu salts
and Cu complexes have been investigated as an anti-fungal agent. Schiff base
complexes of copper have been evaluated by several researchers for their anti-fungal
activity on Candida albicans, Aspergillus fumigatus and Aspergillus niger.67-69, 71 These
complexes displayed broad spectrum anti-fungal activity when compared to that of the
free ligand. Sevgi et al.,on studying the Schiff base complexes of copper, iron and
cobalt found that the Cu complexes were less active than the Fe and Co complexes.
Contrary to the trend observed in their anti-bacterial activity, the complexes were less
active that the free ligand.68 Orojloo et al. also observed that Schiff base complexes of
copper showed no anti-bacterial activity but were significantly active against C.
albicans fungi.67
Amphotericin B (AmB) is a polyene anti-fungal antibiotic extracted from Streptomyces
nodosus, used as anti-fungal medication against acute systemic fungal infections for
more than 50 years.89 In an attempt to enhance the activity of AmB at lower dose
concentrations, Chudzik et al. synthesised AmB-Cu2+ complexes and evaluated the
fungicidal activity against C. albicans. As expected the AmB-Cu2+ complex had higher
anti-fungal activity compared to the conventional amphotericin. The unique structure of
this molecule also contributed to the increase in toxicity of the copper complex.90
Recently metal organic frameworks based on copper have been investigated as anti-
fungals. The copper based benzenetricarboxylate MOF (Cu-BTC MOF) was shown to
inhibit the growth rate of C. albicans, while inhibiting the spore growth rate of A. niger,
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A. oryzae and F. oxysporum.91 These results support the potential application of copper
complexes as anti-fungals.
Copper complexes, C17–C42 (Figure 4.4.3) were evaluated as anti-fungal agents
against Candida albicans (C. albicans) and Cryptococcus neoformans var. grubii (C.
neoformans), by CO-ADD, The Community for Antimicrobial Drug Discovery at The
University of Queensland, Australia. A similar procedure as that outlined for the β-bis-
ketoiminate ruthenium(II) dicarbonyl complexes was followed. The results for
complexes C17–C42 are summarised in Table 4.5.2.
Table 4.5.2: Growth inhibition of copper(II)acnac complexes against fungal strains
Complex Substituent Inhibition (%)
(Rp/Ra) C. albicans C. neoformans
C17 H(p) 11.2 -16.64
C18 2'Br(p) 9.11 -22.39
C19 2'Cl(p) 3.73 -14.06
C20 4'Br(p) 7.08 -20.87
C21 4'Cl(p) 7.83 -22.99
C22 4'F(p) 4.1 -21.33
C23 4'I(p) 7.36 -16.79
C24 4'Me(p) 6.96 -21.78
C25 4'OMe(p) 4.6 -13.01
C26 4'OEt(p) 15.01 -20.27
C27 4'CF3(p) 6.88 -21.33
C28 2',3'diMe(p) 8.30 -15.88
C29 2',4',6'triMe(p) -0.23 -19.81
C30 3',4'diCl(p) 2.59 -22.23
C31 3',4' methylene(p) 7.15 -23.75
C32 3'Br,4'F(p) 5.21 -19.66
C33 2'OMe(p) 2.27 -20.12
C34 3'F(p) 9.85 -22.69
C35 2'OEt,4'F(p) 4.27 -19.21
C36 2'Br(a) 5.11 -17.54
C37 2'F(a) 5.52 -13.46
C38 3'Br(a) 5.32 -17.7
C39 3'Cl(a) 7.43 -25.71
C40 4'Cl(a) 8.71 -15.88
C41 2',4' diF(a) 9.93 -12.85
C42 2',5' diF(a) 3.06 -20.57
(p) = substituent on phenolate ring; (a) = substituent on aniline ring
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Complexes C17–C42 had a positive response towards C. albicans compared to C.
neoformans. Focusing on C. albicans, ligand tuning of steric and electronic properties
had no significant effect on the fungicidal efficacy of the copper complexes. No further
work was done on these complexes as they did not show sufficient activity to undergo
hit confirmation to determine their MIC (minimum inhibitory concentration).
4.6 Conclusions
Anti-cancer activity screening using the MTT assay were carried out on novel β-bis-
ketoiminate analogue complexes of ruthenium(II) and copper(II), on three cell lines,
pancreatic carcinoma, colon carcinoma and retinal epithelial cells. Ruthenium(II)
dicarbonyl complexes were the most active showing significant selectivity towards
colon cancer cell line. This work presents the first time that ruthenium(II) dicarbonyl
complexes with ketoiminate (N,O) ligands, potentially acting as carbon monoxide
releasing molecules have shown high potency as anti-cancer agents. The complexes
showed a broad spectrum activity; high, moderate and poor activity. The most active
was complex C4, with the fluoro substituent in the para positon of the ligands’
phenolate phenyl ring. Although expansion of the library of complexes is necessary,
some structure-activity relationships (SARs) were deduced from the lack of or activity
of the complexes. The most intriguing being the pronounced activity as a result of the
presence of either electron donating or electron withdrawing groups. In addition the
complexes were as cytotoxic as they were toxic. Copper(II) ketoiminate complexes
were generally inactive against the cancerous cell lines with IC50 values greater than
100, with the exception of complexes. Complexes C34 and C42 were more potent than
cytotoxic while complex C33 showed high selectivity towards the healthy cell line,
ARPE19. In further investigative assays, the lead complex C4 was found to be less
active in reducing (hypoxic) environments compared to normal oxygen (normoxic)
environments.
Anti-bacterial and anti-fungal activity studies were also carried out on β-bis-
ketoiminate ruthenium(II) dicarbonyl complexes and β-bis-ketoiminate copper(II)
complexes. Both complexes showed poor activity as anti-bacterial or anti-fungal
agents, with only complex C12 showing moderate anti-bacterial activity.
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Chapter 5
Biological Relevance Studies on β-bis-Ketoiminate
Complexes of Ruthenium and Copper
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5.1 Introduction to biological relevance
This chapter discusses further biological assays and experiments conducted on the
β-bis-ketoiminate ruthenium(II) dicarbonyl and β-bis-ketoiminate copper(II)
family of complexes synthesised within this thesis and discussed in Chapter 2 and
3 respectively.
The major drawback for potential organometallic drug candidates is the subsequent
failure of these molecules in early stage clinical trials or late development stages,
mainly due to poor pharmacokinetic properties. In depth analysis of structure-
activity relationships (SARs) that can be related to the molecular structure of the
drug candidate allow for further rationale of synthesis and modification leading to
new drug candidates with better efficacy, bio-chemical reactivity and
physicochemical properties. These SARs assist the medicinal chemist with the
fundamental challenge of turning a structural lead into a “drug like” molecule.1, 2
5.2 Hydrolysis Studies
5.2.1 Introduction to hydrolysis
In the application of metal based drugs such as cisplatin in cancer treatment, it is
assumed that the form of the complex that binds to biomolecules, such as DNA,
inside the cell is quite different from the complex initially introduced into the
organism.3 In many cases the original metal complex is treated as a prodrug that is
inert which later becomes activated through various metabolic pathways.
Activation by hydrolysis is a mechanism known to be important for metal based
complexes such as cisplatin,4-6 and the ruthenium complexes, NAMI-A and
KP1019,7-10 and aquation has been proved to be the crucial step in these
mechanisms.3 The steps leading to complex activation include ligand substitution,
a change in oxidation state, a photochemical process, or in some cases a
combination of these. These reactions can be a result of enzyme catalyzed
chemical transformation or more commonly internal stimulus such as physiological
difference in the environment (pH, salt concentration and redox potential).11 Sadler
et al.11 have proposed that generally, with few exceptions, the rate of hydrolysis is
directly proportional to the cytotoxicity of the complex. This hypothesis has been
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observed with ruthenium(III) bis-picolinamide complexes previously synthesised
within our research group.12
5.2.2 Hydrolysis of β-bis-Ketoiminate Ru(II) Dicarbonyl Complexes
Hydrolysis studies were not investigated for all complexes, a range of complexes
from the least active to the most active were selected, for both classes of
complexes. 1H NMR samples were prepared in 9:1 d3-acetonitrile/D2O to give a
final concentration of 8 mg ml-1, and run every 24 hours over a 4 day period.
UV/vis samples were prepared in 9:1 acetonitrile/water to give a final
concentration of 50 μM. The concentration of the complexes could not be 
increased due to poor solubility in water. The solutions were scanned using UV/vis
spectrophotometry every 24 hours, over a period of 4 days, to correlate with the
MTT assay, and after the final analyses, the UV/vis samples were analysed by ESI-
MS.
For β-bis-ketoiminate Ru(II) dicarbonyl complexes, the most active or partially
active complexes (C3, C4 and C8), and their inactive closest analogies (C10 and
C11) were analysed (Figure 5.2.1). In addition, the unsubstituted complex C1, was
also analysed for comparison purposes. Changes in the UV\vis spectra of the
complexes are displayed in Figure 5.2.2 and the changes in wavelengths of
absorption bands are summarised in Table 5.2.1. The arrows on the graphs in
Figure 5.2.2, in either up or down direction, indicate changes in absorption
intensities upon hydrolysis, from day 0 to day 4. Slow darkening of the initial
colour, from yellow to brown, was observed for all complexes, from day 0 to day
4, with C3 giving the least colour change.
Complex Substituent (Rp/Ra)
C1 H
C3 4’ Cl(p)
C4 4’ F(p)
C8 4’ Me(p)
C10 4’ F(a)
C11 4’ Cl(a)
Figure 5.2.1: Ru(II) dicarbonyl complexes under hydrolysis studies
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Distinctive changes in the UV/vis spectra were observed for the Ru(II) dicarbonyl
complexes under study over the 4 day period. Absorption peaks in the ultraviolet
region (190 – 350 nm) were observed for all the complexes. The most intense and
evident ultraviolet region absorption within the range 198 - 202 nm, are due to
ligand based π – π* transitions. Furthermore, at least one (complexes C1 and C4
have two) relatively weak peak due to ligand based charge-transfer was observed
for all the complexes in the ultraviolet region. The visible light region (350 – 750
nm) of the complexes is characterised by an intense absorption peak at
approximately 368 nm, characteristic of metal to ligand charge transfer (MLCT)
transitions.13, 14
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Figure 5.2.2: UV/vis spectra for the hydrolysis of Ru(II) dicarbonyl complexes
Key: day 0 = Black, day 1 = blue, day 2 = grey, day 3 = red, day 4 = green
Table 5.2.1: UV/vis absorption bands for complexes C1, C3, C4, C8, C10 and C11
Complex Substituent (Rp/Ra) Wavelength / nm
Day 0 Day 4
C1 H 200, 229, 261, 368 202, 224, 267, 368
C3 4’ Cl(p) 198, 237, 368 201, 228, 272, 368
C4 4’ F(p) 200, 227, 261, 368 200, 224, 268, 368
C8 4’ Me(p) 200, 267, 368 201, 266, 368
C10 4’ F(a) 200, 231, 368 200, 270, 368
C11 4’ Cl(a) 202, 239, 368 199, 228, 368
(p) = substituent on phenolate ring; (a) = substituent on aniline ring
As seen from Figure 5.2.2, all the complexes under study, active (C4 (IC50 = 21.61
μM)), moderately active (C3 (IC50 = 43.40 μM), C8 (IC50 = 54.20 μM)) and 
inactive (C1 (IC50 = 85.96 μM), C10 (IC50 = 66.79 μM), C11 (IC50 = 71.90 μM)), 
undergo hydrolysis to a greater or lesser degree. A similar trend is observed for all
complexes from day 0 to day 4, with changes in the absorption bands indicating
that there are ligand substitution reactions occurring when the complexes are in
aqueous solution.15 A decrease in the intensity of the absorption peaks is seen from
day 0 to day 4, with the most significant decrease being observed between day 0
and day 1.
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However, the rate of hydrolysis differs, and the proposed rate of hydrolysis as seen
from the UV/vis absorption spectra is as follows; C4 > C1 > C3 > C10 > C11 >
C8. Complex C4 is completely hydrolysed by day 1, complex C1 is completely
hydrolysed by day 2, complex C3 is completely hydrolysed by day 3 and C10 and
C11 are completely hydrolysed by day 4, while C8 is still undergoing hydrolysis
by day 4. The relatively similar hydrolysis rates of the unsubstituted complex C1
and the electron withdrawing substituted complex C4 suggest that addition of the
electron withdrawing substituents on the ligand has no significant effect on the rate
of hydrolysis. Contrary to this, electron donating substituents such as the para
methyl group significantly lower the rate of hydrolysis as seen when comparing the
spectra of complex C1 and C11.
In addition, the nature of the phenyl ring (phenolate or aniline phenyl ring)
carrying the substituents affects the rate of hydrolysis. This can be seen by
comparing the spectra of complexes C4 and C10. Complex C4, with a para fluoro
substituent on the phenolate phenyl ring is completely hydrolysed by day 1, while
C10, with a para fluoro substituent on the aniline phenyl ring is only completely
hydrolysed by day 4. Analogue complexes, C3 and C11 also show comparable
results. These results suggest that complexes with substituents on the phenolate
phenyl ring undergo hydrolysis faster than their aniline phenyl ring substituted
analogues. These differences in the rate of hydrolysis for complexes C4, C3, C10
and C11 are consistent with their observed anti-cancer activities discussed in
Chapter 4. The anti-cancer activity of complexes C3 and C4 with substituents on
the phenolate phenyl ring is higher than that of their analogue complexes C10 and
C11 where similar substituents are on the aniline phenyl ring, Figure 5.2.3.
Rate of
hydrolysis
Complex IC50 / µM
C4 21.61±3.55
C3 43.40±5.67
C10 66.79±6.84
C11 71.90±5.62
Figure 5.2.3: Rate of hydrolysis and anti-cancer activity of some complexes
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However, the overall proposed rate of hydrolysis; C4 > C1 > C3 > C10 > C11 >
C8, does not correlate with the observed anti-cancer activities of these complexes.
The unsubstituted, inactive complex C1 has a higher hydrolysis rate compared to
other moderately active complexes (C3 and C8). This is in contrast with most
metal based anti-cancer complexes whose mode of activation is based on
“activation by reduction”. For these complexes, inactive complexes are known not
to undergo hydrolysis. The contrasting patterns highlight that for this series of
complexes hydrolysis plays a role in the resultant anti-cancer activities of the
complexes but is not the only influential factor.
Under physiological conditions, β-bis-ketoiminate Ru(II) dicarbonyl complexes are
likely to undergo hydrolysis reactions similar to that of cisplatin, NAMI-A,
KP1019 and Ru(II)-arene complexes. However, the presence of the carbonyl ligand
as the labile group further implicates the use of this class of compounds as
CORMs, allowing for different pathways to the conventional ones. A proposed
hydrolysis pathway for the neutral Ru(II) dicarbonyl complexes is shown in
Scheme 5.2.1.13, 16
In this mechanism, hydrolysis of the complexes begins with dissociation of the
carbonyl labile ligand to create intermediate 1 with a vacant site. The intermediate
can then react with water to form 2, or undergo further dissociation of the second
carbonyl ligand to give intermediate 3. The latter route is highly unlikely due to the
instability of intermediate 3, which if formed is likely to decompose. The most
probable route is that in which intermediate 3 losses the second carbonyl ligand
and is further hydrolysed to 4.
Hydrolysis or ligand exchange mechanisms can thus act as CO release triggers17
and Mortellini et al.16 have proposed the dissociation of CO as the rate determining
step. Even with water adducts likely to form, the intermediates in this mechanism
can be toxic and are likely to be reactive, particularly intermediate 1, with a vacant
site. These reactive intermediates can potentially explain the toxicity observed in
anti-cancer cell line studies of β-bis-ketoiminate Ru(II) dicarbonyl complexes
(Chapter 4). Loss of the labile carbonyl group can lead to a number of possibilities
for the complexes:
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i. Decomposition of the Ru-ligand intermediate after carbonyl ligand loss due
to instability. For this class of complexes this could explain why hydrolysis
is observed even for the inactive complexes.14, 18
ii. The intermediates may be able to react with off-target biomolecules before
reaching the target site, resulting in toxicity to healthy cells and decrease in
cytotoxicity.
iii. The rapid and premature release of CO may increase the toxicity while
decreasing the selectivity of the active complexes.
Scheme 5.2.1: Proposed hydrolysis mechanism for Ru(II) dicarbonyl complexes
Hydrolysis studies done through observing changes in the 1H NMR spectra are
shown in Figure 5.2.4. Only the spectra of complexes C4 and C8 are given.
Complex C4 showed the highest rate of hydrolysis according to UV/vis spectra
while complex C8 had the least rate (Figure 5.2.2). Minor changes in the 1H NMR
spectra are observed from day 0 to day 4. Overall the spectra of the selected
complexes show changes in the intensity of the peaks particularly in the aromatic
region (7-8 ppm) and for the characteristic methine β-ketoiminate proton peak (5.7-
5.9 ppm). In both complexes the peak due to the methine proton disappears by day
4. There is no obvious broadening of peaks suggesting that no paramagnetic or
charged species are being formed in solution.
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Figure 5.2.4: 1H NMR of complexes C4 and C8 over 4 days
The loss of the methine proton peak potentially indicates the dissociation and
degradation of the ketoiminate ligand from the complex. This is supported by mass
spectrometry data obtained for the complexes at the end of day 4, in which no
peaks can be assigned to the free ligand. The mass spectra of the complexes are
characterised by various peaks each with the ruthenium metal isotope pattern. This
suggests that these complexes undergo hydrolysis in which the carbonyl ligand is
substituted or released. However, the by-products of hydrolysis differ for each
individual complex. Major peaks found in both spectra have been assigned to the
complexes shown in Figure 5.2.5.
Biological Relevance Chapter 5
150
ES MS (+) m/z 502.11 [MH+]
ES MS (+) m/z (expected) 502.11
Original complex Hydrolysis product A Hydrolysis product B
Figure 5.2.5: Possible hydrolysis products (from mass spectrometry)
Although a ruthenium aqua species can be identified from mass spectra, the
presence of other various peaks suggests that the complexes also undergo
degradation over time.
5.2.3 Hydrolysis of β-bis-Ketoiminate Cu(II) Complexes
Hydrolysis studies were also carried out on β-bis-ketoiminate copper(II)
complexes, C22 (IC50 > 100 μM) and C42 (IC50 = 42.35 μM) which are inactive 
and moderately active, respectively, against HCT116++ cell line. UV/vis samples
were prepared in 9:1 acetonitrile/water to give a final concentration of 50 μM. The 
concentration of the complexes could not be increased due to poor solubility in
water. The solutions were scanned using UV/vis spectrophotometry every 24
hours, over a period of 4 days, to correlate with the MTT assay.
Changes in the UV/vis spectra of the complexes are displayed in Figure 5.2.6 and
the arrows on the graphs indicate changes in absorption intensities upon hydrolysis,
from day 0 to day 4. Both complexes, C22 and C42 show similar changes in the
UV/vis spectra indicating that the resultant anti-cancer activity of this family of
complexes is independent of hydrolysis. At day 0, the complexes show intense
ligand based absorbance (π-π*) at approximately 200nm and 360 nm with 
additional less intense ligand based charge transfer bands (n-π*) at 245 nm for 
complex C22 and 255 nm and 285 nm for complex C42. By day 4 the distinct
peaks are still present at approximately the same wavelength, with no significant
changes in the intensity. No quantitative information could be inferred from the
mass spectrometry data of these complexes
Biological Relevance Chapter 5
151
Figure 5.2.6: UV/vis spectra for the hydrolysis of copper complexes C22 and C42
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5.3 Biomembrane Studies
5.3.1 Introduction to biomembrane studies
Organisms, including the human body, have a number of biological membranes
whose functions range from protecting cells from foreign molecules, hosting
bioactive molecules to regulating traffic between the inside of the cell and the
extracellular medium. Post administration, a drug molecule encounters one or more
of these biomembranes, from simple ones such as blood vessel endothelium to
circulating macrophages to the more complex ones such as blood-brain or blood-
retinal barriers. Therefore, its interaction with a biomembrane physically or
chemically is unique.19
Biological membranes acting either as a barrier to drug permeation or the site of
action of a drug molecule can act as the final step. However, in many cases drug-
membrane interactions are the start of a series of chemical and physical processes
that affect the rate of penetration and partitioning of the drug molecule into the cell
and ultimately its specific site of action. As such drug distribution, in terms of both
concentration and rate is highly dependent on the interactions of a drug molecule
with various biomembranes.20
The study of drug-membrane interactions during the preclinical phase is a powerful
tool as it can be used to design and optimise the activity and tolerability profiles of
new drug candidates, and also to allow compatible drugs to enter clinical trials.
Simplified artificial models of biological membranes, still under intensive
development, have been used to study and better understand drug-membrane
interactions such as cellular uptake, drug transport, drug activity and toxicity.19-22
Four types of lipid membrane models have been identified and are commonly used:
monolayers (Langmuir monolayers), vesicle forming bilayers (liposomes),
supported bilayers and tethered bilayer lipid membranes.22
Phospholipid monolayers on the surface of a mercury electrode have received
widespread interest and application as biological membrane models.23, 24 Over the
last decade, Nelson et al. have developed a unique membrane based sensing
device. In this model shown in Scheme 5.3.1 a phospholipid monolayer is
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deposited on a mercury electrode strongly bound to a platinum contact. This
sensing electrode is connected to a to a high throughput flow system which uses
rapid cyclic voltammetry (RCV) to monitor changes in capacitance current with
voltage and allows rapid screening of large numbers of compounds. The monolayer
is selectively damaged, through interaction with biomembrane active compounds
in the sample.21, 25-29
Scheme 5.3.1: Schematic representation of model biomembrane system 28
Compared to other supported membrane techniques, the smooth mercury support
surface is complimentary to the fluidity and hydrophobic nature of the
phospholipids forming defect-free, self-renewing phospholipid monolayers.
Monolayers made from phospholipid dioleoyl phosphatidylcholine (DOPC) act as
the model biomembrane.28 The model has been used for analysing ion channel
function and co-enzyme electron transfer.30, 31 However its main application is as a
sensor for biological membrane active compounds. The fluid and highly ordered
phospholipid monolayers allow for easy detection of any alterations arising from
the active compounds.21, 32 The model has been applied on biomembrane studies
with peptides,33-36 nanoparticles37, 38 and organic molecules such as steroids,
flavonoids, polycyclic aromatic hydrocarbons, tricyclic anti-depressants and
tricyclic phenothiazines.28, 39 In line with the widespread interest in the application
of organometallic compounds in the medical and biological fields, this model was
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recently applied and reported for a series of silver(I) non-heterocyclic carbene
(NHC) complexes.40
Monolayers of DOPC are known to undergo various phase transitions in response
to changes in potential. These phase transitions are visualised as sharp peaks in the
capacitance current [Figure 5.3.1 (a)]. The capacitance peaks correspond to the
entrance of electrolytes into the layer leading to a mixed electrolyte phospholipid
and the re-organisation of the layer to form bilayer areas [Figure 5.3.1 (b)]. In an
experimental flow system, such as the one used in this study, a typical RCV plot
with two capacitance peaks such as that shown in Figure 5.3.2 is
observed.25, 26, 41-43 The capacitance peaks have been intensely investigated and
characterised, undisputedly their formation is dependent on the interaction of the
lipid monolayer with biological membrane active species in solution.42, 44
(a) (b)
Figure 5.3.1: (a) Typical RCV plot of DOPC monolayer with (b) associated phase
transitions 43
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Figure 5.3.2: Typical RCV plot of DOPC monolayer in a flow cell 25
As the biomembrane active species in solution interact with the monolayer, any
modifications in its organisation and fluidity results in alterations in the
characteristic peak shapes, heights and/or positions in the RCV plot. Increase in
capacitance current; with subsequent reduction in the peak heights indicate
disruption of the monolayer due to penetration of the DOPC layer. In cases where
the active species adsorb to the monolayer, changes such as reduction in peak
height and broadening of peaks with no changes in capacitance current are seen on
the RCV plot.45
5.3.2 Biomembrane Studies of β-bis-Ketoiminate Ru(II) Dicarbonyl 
Complexes
In collaboration with the Nelson Research Group at The University of Leeds, β-
bis-ketoiminate ruthenium(II) dicarbonyl complexes were tested for their potential
to interact with the artificial biomembrane by Danielle Marriott and Dr. Shahrzad
Mohamadi. Deposition of dioleoyl phosphatidylcholine (DOPC) on the Pt/Hg
electrode is performed before introduction of a complex. A potential excursion
from -0.4 to -3.0 V at 100 V s-1 scan rate is applied, and 100-200 μL of DOPC 
introduced into the flow cell. The potential excursion is then altered to -0.4 to -1.2
V. By repetitive cycling, the characteristic RCV plots of DOPC are obtained. The
complex is introduced into the flow cell and the RCV plot monitored while varying
the electrode potential from -0.4 to -3.0 V. Recovery, or failure to recover, of the
characteristic RCV peaks after complex exposure, indicate that the interaction
leads to a permanent damage of the membrane.
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Biomembrane studies were not conducted on the entire series of β-bis-ketoiminate
Ru(II) dicarbonyl complexes, only complexes C1, C4, C7, C8, C9 and C11 were
analysed. The selected complexes include active C1 (IC50 = 21.61 μM), partially 
active C8 (IC50 = 54.20 μM) and C9 (IC50 = 64.80 μM), as well as inactive 
complexes C1 (IC50 = 85.96 μM) and C11 (IC50 = 71.90 μM), with varying 
electronic and steric properties. The RCV plots of the interaction of the complexes
with the artificial biomembrane are shown in Figure 5.3.3.
The complexes show varying degrees of changes from the typical DOPC RCV
membrane plots, with complex C9 showing the most pronounced distortions. The
RCV plots show changes mainly in peak height and breath, with no changes in
baseline current. This indicates that the complexes are able to adsorb and to some
extent interact with the DOPC monolayer. Thus, the implication is that, unlike
cisplatin, the complexes are able to enter the cell membrane via passive diffusion.
This is in agreement with literature reports in which passive diffusion has been
implicated as the fundamental mode of entry into cell membranes for carbon
monoxide delivery from CORMs.46-48
There is no distinct correlation between biomembrane interaction and neither
electronic nor steric properties of the complexes. Complexes C4, C7 and C11 have
electronegative substituents that can provide an area of negative surface charge.
Thus, compared to complexes C8 and C9 with electropositive substituents, they
can potentially interact to a greater extent with the positively charged DOPC
monolayer head group. However, the RCV plots show no such differences.
Comparing the RCV plot for the unsubstituted complex C1 with all the other
complexes, the author can conclude that addition of either electron donating or
withdrawing groups has negligible effect on the degree of interaction of the
complexes with the monolayer. Although complexes C9 and C11 are structurally
similar, the distinctively different RCV plots show that structural properties such as
steric have no effect on the membrane interactions.
Complex C11 is inactive with an IC50 value of 71.90 µM, however, it shows
changes in the RCV DOPC plot consistent with interactions with the monolayer.
Complex C9 which shows the most pronounced changes in the RCV DOPC plot is
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moderately active, less active than C4 and C8. Complex C4, the most cytotoxic of
this series of complexes shows a similar DOPC RCV plot to all the other
complexes. These comparisons show that there is no direct correlation between
cytotoxicity and membrane interactions. Thus, for this class of complexes the
ability to passively diffuse through the cell membrane has no relation to the
resultant potency of the complex. This conclusion is in-line with the findings by
Stamellou et al.47 who concluded that for enzyme triggered CORMS, it is unclear
how factors such as structural differences influence cellular uptake, which in turn
influences the biological activity.
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Figure 5.3.3: RCV plots for the interaction of complexes with the DOPC artificial biomembrane: Key: Black = DOPC membrane in the absence of complex,
Red = DOPC membrane in the presence of complex
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5.4 Conclusion
Two complexes C22 and C42 taken as representatives from the β-bis-ketoiminate
copper(II) family of complexes showed changes in their respective UV/vis spectra
upon hydrolysis over four days. These results from the moderately active complex
C42 (IC50 = 42.35 μM) and the inactive complex C22 (IC50 > 100 μM) show that 
the cytotoxicity of this family is independent on the ability of these complexes to
hydrolyse. In a similar way, complexes from the β-bis-ketoiminate ruthenium(II)
dicarbonyl family displayed distinct changes in the UV/vis spectra, showing that
these complexes also undergo hydrolysis. The presence of the carbonyl groups, as
labile ligands is thought to promote decomposition of the initial complex into
various products as seen from the mass spectrometry. The rate of hydrolysis was
found to be dependent on the nature of the substituent present on the phenolate or
aniline phenyl rings of the ketoiminate ligands. Complexes with electron
withdrawing groups resulted in faster hydrolysis compared to complexes with
electron donating groups. In addition, the complexes with substituents on the
phenolate phenyl ring had a higher hydrolysis rates than their analogue complexes
with substituents on the aniline phenyl ring. However, for this family of
complexes, the rate of hydrolysis did not correlate to the anti-cancer activity for all
complexes.
Although to varying degrees, selected β-bis-ketoiminate ruthenium(II) dicarbonyl
complexes were able to adsorb and interact with the artificial biomembrane. This
suggests that passive diffusion is a potential mode of entry into the cell for this
family of complexes. Interestingly, the RCV plot of the inactive complex, C9
showed the most pronounced distortions, prompting the conclusion that the anti-
cancer activities of this series of complexes is not dependent on the ability of the
complex to passively diffuse through the cell membrane.
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Chapter 6
Catalytic Investigations on β-bis-Ketoiminate
Complexes of Ruthenium and Copper
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6.1 Transition metals in catalysis
The use of transition metals in catalysis is well studied and established dating back
to the 20th century when Fischer and Tropsch used Fe and Co in the synthesis of
hydrocarbons.1, 2 Their ability to catalyse and accelerate important chemical
transformations without being consumed is due to a number of reasons.3-5
1. Bonding ability: Transition metals are able to coordinate to any functional
groups; once coordinated the reactivity of the functional group can be tuned
to enhance catalytic activity. More importantly, highly reactive species can
coordinate to the metal and be stabilised enough to react in a controlled and
productive way, evading degradation.
2. Ligand effects: Transition metal catalysts are able to accommodate a number
of ligands, participative and non-participative, in their coordination sphere.
These ligands can influence the behaviour of the catalyst through
modification of electronic and steric properties.
3. Variable oxidation states: A common feature of transition metals is the ability
to form stable compounds with variable oxidation states. As such,
organometallic compounds used in catalysis readily interchange between
oxidation states during the course of a catalytic reaction, an inherent property
that purely organic catalysts lack.
4. Variable coordination numbers: Organometallic compounds acting as
catalysts have variable coordination numbers, and are able to accommodate
several different ligands in the coordination sphere. This feature is of
importance as it allows these compounds to catalyse and tolerate reactions
with a broad range of substrates.
Of primary importance in catalysis is selectivity, and organometallic compounds
have been shown to enhance selectivity through modulation and fine tuning of the
ligand, its chirality and metal centre.5-7
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6.2 Catalytic transfer hydrogenation
Introduction to transfer hydrogenation
Hydrogenation, with industrial applications ranging from fine chemicals to
pharmaceutical synthesis, is one of the most important and extensively investigated
reactions in catalysis.8-10 Hydrogenation of organic unsaturated substrates can be
achieved via direct hydrogenation using pressurised H2 gas or transfer
hydrogenation. According to Braude and Linstead, hydrogen transfer reactions can
be sub divided into three classes, (i) hydrogen migration within one molecule, (ii)
hydrogen transfer disproportionation between identical donor and acceptor substrates
and (iii) transfer hydrogenation-dehydrogenation, with different donor and acceptor
units.11, 12
Of the three subdivisions, transfer hydrogenation-dehydrogenation, simply known as
transfer hydrogenation (TH) is the most important and widely applied. In transfer
hydrogenation, hydrogen is abstracted from molecules such as alcohols or amines
acting as hydrogen donors, and unsaturated compounds such as aldehydes or
ketones, imines or alkenes acting as hydrogen acceptors.12
Hydrogenation using molecular hydrogen involves the use of high temperatures and
pressure, therefore transfer hydrogenation is an attractive alternative as it only
requires mild temperature and pressure conditions, suitable for both laboratory and
industrial applications. More importantly, molecules acting as hydrogen donors are
readily available, easy to handle and inexpensive.13-15 In transfer hydrogenation
reactions, several catalysts can be employed; enzyme-, thermal-, transition metal-,
base- and organo catalysts. Of particular importance to the author are transition
metal catalysts, mainly those of ruthenium which will be briefly discussed.12
The use of transition metals in transfer hydrogenation dates as far back as the 1960s
when Henbest and colleagues showed that an iridium hydride complex could
catalyse the reduction of ketones to alcohols with isopropanol.16-18 The most
common and frequently employed catalysts for TH are platinum group metal (Ru, Ir
and Rh) complexes with N, O, P and C element based ligands, such as multidentate
complexes, half sandwich complexes and metal-N-heterocyclic carbenes.12 Within
this group ruthenium based catalysts have proved to be the most widely used.
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Figure 6.2.1 shows the first ruthenium complex used in the transfer hydrogenation
of acetophenone with isopropanol.19-21 Chowdhury et al. later improved on the
efficiency of the reaction using the same ruthenium complex as a catalyst, but with
addition of catalytic amounts of a base.22 Since then remarkable improvements on
ruthenium catalysed TH reactions have been reported. Of particular significance are
expansions on the library of applicable ligands, the application of economical and
“greener” catalytic processes, the practical application of such systems in fine
chemicals and pharmaceuticals and the intensive investigations into the mechanisms
of the catalytic processes.12
Figure 6.2.1: First ruthenium complex used in transfer hydrogenation
Asymmetric transfer hydrogenation (ATH), a sub class of transfer hydrogenation is
an important process in pharmaceutical and fragrance industries.23, 24 Noyori, who
received a Nobel Prize in 2001 for his outstanding contribution in the field of ATH,
has developed a series of highly efficient Ru-arene complexes (1 in Figure 6.2.2) as
catalysts (Noyori catalysts) for the stereo-selective transfer hydrogenation of
ketones25, 26 and imines27 in the presence of a base (Figure 6.2.2).
Figure 6.2.2: Noyori catalysts for stereo-selective ATH
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Scheme 6.2.1 shows one of the best performing catalysts from the 1st generation
Noyori catalysts for the transfer hydrogenation of acetophenone. In this reaction, the
Ru catalyst was prepared in situ from the reaction of [RuCl2(η6-mesitylene)]2 and
(S,S)-N-(p-toluenesulfonyl)-1,2-diphenylethylenediamine ((S,S)-Ts-DPEN), in
isopropanol with KOH as the base, at room temperature. The reaction gave a 95%
conversion of acetophenone to (S)-1-phenylethanol with 97% ee in 15 hours.
Reaction under similar conditions, without Ts-DPEN resulted in < 8% of 1-
phenylethanol.26
Scheme 6.2.1: ATH of acetophenone using [RuCl2(mesitylene)]2 and (S,S)-TsDPEN
Over the years, the Noyori catalysts’ family has been extensively investigated, well
established and widely applied for TH and ATH using either isopropanol or formic
acid as hydrogen sources.28 In an effort to increase the activity and efficiency of this
robust family of catalysts several structural variations have been explored and
reported. Interestingly, the catalytic efficiency and coordination behaviour of the Ru-
arene complexes could be fine tuned through minute modifications in the ligand
system.24, 29-31
Of notable interest in the various alternatives to monotosylated diamines in Noyori
catalysts was the discovery that replacing the (N,N) DPEN ligands with (N,O)
amino-alcohol ligands significantly increased the catalytic activity when an
appropriate arene and chiral amino-alcohol auxiliary are combined.31
Figure 6.2.3 shows the 2nd generation Ru-arene catalyst generated in situ from the
reaction of Ru-arene dimer and N-substituted amino-alcohol in isopropanol with
KOH at room temperature. Substitution of the chiral diamines, whose synthesis is
lengthy and complicated, with chiral β-amino alcohols that are readily available and 
variable has greatly improved the industrial applications of Noyori catalysts.12
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Figure 6.2.3: An example of 2nd generation Noyori half sandwich Ru-η6-arene TH catalysts
with (N,O) ligands
Investigative reactions on the Ru-η6-arene amino-alcohol complexes have shown that
the N-H proximity in the ligand is important for catalytic activity, a trend common to
other Ru-catalysed reactions.26, 32 Catalytic activity was also shown to be highly
dependent on the steric and electronic properties of the ligand, increase in steric bulk
of the arene ring resulted in a decrease in catalytic activity.31
In catalysis, the activity and selectivity of the complex is highly dependent on the
ligand of choice. N-heterocyclic carbenes (NHCs) are another class of ligands that
have been widely explored in transfer hydrogenation reactions. Ruthenium NHCs
complexes in variable oxidation states and coordination geometries have shown good
selectivity and catalytic activity in TH.33-36
Within the McGowan research group, a series of Ru-p-cymene complexes containing
diphosphine ligands37 and Ir-Cp* picolinamide complexes38 (Figure 6.2.4) were
synthesised for application in the ATH reaction of benzaldehyde. Picolinamide
ligands can bind (N,N) or (N,O) to the metal centre. For ATH of benzaldehyde with
tBuOK in isopropanol at 60°C, higher catalytic activity was observed for (N,O)
ligand coordination to the Ir metal centre with 97% conversion compared to 26% for
(N,N) ligand coordination, after 24 hours.
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Figure 6.2.4: Ir-Cp* picolinamide complexes for ATH by McGowan et al.
Catalytic Mechanisms
Hydrogen transfer reactions can occur in different pathways. Two mechanistic
pathways have been proposed by Brandt et al., direct hydrogen transfer, most
prevalent with main group metals and the hydridic route, most common with
transition metals.39
Hydridic Route
Direct hydrogen transfer and transfer hydrogenation are closely related
mechanistically. Both reactions have been shown to proceed through formation of a
metal hydride species, a key intermediate, acting as a catalyst or pre-catalyst in the
catalytic cycle.40 This mechanism is known as the hydridic route, which is further
classified into the monohydride and dihydride routes. In transfer hydrogenation
reactions, hydrogen transfer reagents such as isopropanol/base or formic acid/base
provide hydrides, through β-elimination reactions, for the formation of the highly 
active metal hydride species. As such, catalytic reactions in the presence of a base
are highly efficient compared to reactions in the absence of a base.22, 41, 42
The monohydride route can occur in the inner or outer coordination sphere of the
catalyst’s metal centre. In the inner sphere mechanism (Scheme 6.2.2) the substrate,
for example a ketone or imine, coordinates to a vacant site on the metal centre
allowing product formation through bonding to the metal centre. This allows the
electrophilic activation of the carbon of the ketone or imine group. Ancillary ligands
with acidic hydrogen bond donor groups on the metal centre are known to promote
hydride transfer to the substrate.42 Catalysts that favour inner sphere mechanism
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show poor selectivity for C=O over C=C bonds in the reduction of α, β unsaturated 
ketones and aldehydes.43, 44
Scheme 6.2.2: Inner sphere transfer hydrogenation mechanism
Contrary to inner sphere coordination, in the outer sphere coordination mechanism,
catalytic activity proceeds without coordination of the substrate to the metal centre.
The substrate is usually in the 2nd coordination sphere of the catalyst complex
(Scheme 6.2.3). In this mechanism C=O or C=N bonds are selected over C=C bonds.
The ancillary ligands are pivotal in activating the carbon of the substrate towards
nucleophilic hydride attack.42 This mechanism was further proposed by Noyori et al.
for the ruthenium complex, RuII-TsDPEN, as catalyst for ATH of ketones.26, 45
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Scheme 6.2.3: Outer sphere transfer hydrogenation mechanism
Catalytic viability of β-bis-Ketoiminate Ru(II) Dicarbonyl 
Complexes
Transfer hydrogenation studies on the β-bis-ketoiminate ruthenium(II) dicarbonyl 
complexes described in Chapter 2 with the general structure shown in Figure 6.2.5
were investigated. Complexes with various electronic and steric properties were
chosen in an attempt to investigate structure-activity relationships.
Complex Substituent (Rp/Ra)
C1 H(p)
C2 4’Br(p)
C3 4’Cl(p)
C4 4’F(p)
C5 3’F(p)
C7 3’,4’ diCl(p)
C8 4’Me(p)
C10 4’F(a)
C15 2’,4’ di F(a)
C16 2’,3’ diMe(a)
Figure 6.2.5: β-bis-ketoiminate Ru(II) dicarbonyl complexes under TH catalytic 
investigations
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The reduction of acetophenone with isopropanol to 1-phenylethanol shown in
Scheme 6.2.4 was chosen as the model reaction. The use of isopropanol as the
hydrogen donor is common in transfer hydrogenation reactions, isopropanol is easy
to handle, inexpensive, abundant, environmentally friendly and non-toxic. The by-
product of the reaction, acetone, is volatile and can be easily removed.
Scheme 6.2.4: Model reaction for TH catalytic investigations
Catalytic control experiments were carried out at 82 oC with acetophenone (1 mmol),
Ru(II) dicarbonyl complexes (0.01 mmol) as catalysts, potassium tert-butoxide (0.1
mmol) in isopropanol (30 mmol). Excess isopropanol was used to minimise the
occurrence of the reverse reaction. Conversions were calculated using 1H NMR
spectroscopy by comparing the integration of the methyl resonance of the product 1-
phenylethanol with the internal standard 1,3,5-trimethoxybenzene (0.33 mmol).46
Control reactions were carried out using no catalyst (entry 1), ruthenium(III) chloride
trihydrate (entry 2) and dichloro(p-cymene)ruthenium(II) dimer (entry 3).
Table 6.2.1: Investigation of a range of Ru(II) dicarbonyl catalysts in the transfer
hydrogenation of acetophenone to 1-phenylethanol
Entry Catalyst Conversion (%)
1 No catalyst 13
2 RuCl3.3H2O 19
3 [Ru(p-cymene)2Cl2]2 100
4 C1 50
5 C2 55
6 C3 63
7 C4 93
8 C5 92
9 C7 83
10 C8 28
11 C10 92
12 C15 32
13 C16 37
14a C4 0
a - no base added in reaction
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Table 6.2.1 shows the results obtained for a range of the Ru(II) dicarbonyl
complexes. The conversion values are an average of two separate runs. Comparison
of the results for the starting material (entry 2) to the complexes (entries 4–13) show
that coordination of bidentate ketoiminate ligands as well as carbonyl ligands greatly
improves the catalytic activity of the complexes.
The Ru(II) dicarbonyl complexes only differ through the functionalisation on the
ketoiminate ligands, specifically on the aniline (Ra) or phenolate (Rp) phenyl ring
(Figure 6.2.5). Functionalisation with electron withdrawing substituents on either of
the phenyl rings generally results in an increase in the catalytic efficacy of the
complexes, except for C15. This is seen when comparing entry 4 to entries 5-9, 11
and 12. The highest catalytic conversions (> 90%) are obtained when the substituent
on the complexes is fluorine, entries 7 (4’F(p): 93%), 8 (3’F(p): 92%) and 11
(4’F(a): 92%). As seen from these entries, the position of the fluoro substituent (meta
or para) and the ring substituted (aniline or phenolate) seemingly has no effect on
the overall catalytic activity of the complexes. However, the type of halogen present
as a substituent has an effect on the efficacy of the complex. The catalytic activity
increases with increase in electronegativity, entry 5 (4’Br: 55%), entry 6 (4’Cl: 63%)
and entry 7 (4’F: 93%).
Electron donating substituents on either of the phenyl rings results in an overall
decrease in the catalytic activity of the complexes. Comparison of catalytic
conversions for entry 4 with entries 10 and 13 clearly shows that addition of the
methyl substituents lowers the yield from 50% to 28% and 37% respectively. When
no base is added in the reaction, entry 14, no product is formed (0% conversion).
This suggests that the base plays a crucial role in the catalytic mechanism.
Further catalytic experiments to monitor the rate of catalytic activity where done
with the best performing Ru(II) dicarbonyl catalyst, complex C4. For comparison,
dichloro(p-cymene)ruthenium(II) dimer was chosen at it is the “gold standard” for
transfer hydrogenation and the ruthenium centre is in the same oxidation state as the
catalyst C4. The same reaction conditions as stated above were used, with samples
taken at 1, 2, 3, 6, 10 and 24 hour intervals. The results are displayed in Figure
6.2.6.
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Figure 6.2.6: Comparison of catalytic conversion rates of Ru(p-cymene) dimer and complex
C4; Key: Blue = Ru(p-cymene) and Orange = complex C4
Both catalysts are active within the 1st hour, reaching nearly the same conversion at
the end of the first hour, 29% for Ru(p-cymene) dimer and 25% for C4. However, in
the first 3 hours, the catalytic activity of the Ru(p-cymene) dimer exponentially
increases reaching 100% conversion, while that of C4 gradually increases to
reaching only 62% conversion. Maximum conversion for complex C4 (93%) is
reached after 10 hours. From these results, the catalytic activity of complex C4 is
comparable to that of the dimer although its catalytic rate is much slower.
6.3 Catalytic Ullmann reactions
Copper in catalysis
The application of late transition metals such as Ru and Pd in catalysis is well
understood and established. However with economic and environmental concerns to
go green and cut costs a quest in developing alternative catalysts is being pursued.
As such, first row transition metals such as copper are being exploited, being more
abundant, versatile and cheaper.47 Another advantage is that in catalysis copper can
easily access four of its five oxidation states (0 to +3).48
Copper is known to catalyse similar sets of reactions to that of palladium, one of the
most common modern day catalysts.49, 50 Examples of such reactions include the
Heck reaction, cyclo-addition with azide (click chemistry) and Sonogashira
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coupling.47 These reactions are common tools for synthetic organic chemists, with
applications in the pharmaceutical, fine chemicals, polymer and agricultural sectors.
However, one of the major drawbacks is the use of the expensive palladium catalyst;
as such copper is a better economic alternative.51-53
Introduction to Ullmann reaction
The pioneering works of Ullmann and Gordberg more than a century ago formed the
basis of cross coupling reactions and the subsequent use of copper in catalysis.54 In
1901 Fritz Ullmann reported the first copper catalysed cross coupling in which biaryl
moieties were formed through coupling of two molecules of aryl halides. This is now
referred to as the “classical Ullmann reaction”.55 The reaction has been used to
synthesise symmetric and asymmetric biaryls and to activate ring closure at an aryl-
aryl bond.56 Over the years “Ullmann reactions” have evolved to “Ullman
condensation reactions” as shown in Scheme 6.3.1. Examples of the latter include
copper catalysed formation of aryl amines from an aryl halide and an amine and/or
aryl ether from an aryl halide and a phenol.57-60 In 1906, Irma Goldberg reported the
copper mediated synthesis of aryl amides from an aryl halide and an amide.59
X X
+ [Cu]
Ullmann, 1901
NH2 Cl
+
[Cu]
Ullmann, 1903
R' R''
H
N
R' R''
210oC
OH Br
+
[Cu]
Ullmann, 1905
O
210oC
Br
+
[Cu]
Ullmann, 1905
O
210oC
O
NH2
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Scheme 6.3.1: Ullmann reaction progression from 1900s
Despite the impressive start, these reactions were characterised by high temperatures
(> 200oC), long reactions times, high catalyst loading, poor functional group
tolerance and use of strong bases. Gradually, in an effort to improve the efficiency of
the reaction palladium replaced copper as the catalyst of choice.47, 53 As highlighted
earlier, economic and environmental concerns have forced researchers to revisit the
application of copper in catalysis. Improved versions of the “classical Ullmann
reactions” have emerged. Termed “modified Ullmann reactions” these procedures
have addressed and improved on the efficiency of the initial Ullmann reactions. In
“modified Ullmann reaction”, the addition of ligands to the copper catalyst is highly
credited for the reactions proceeding under milder conditions.60
Ligand effect
Coordination of ligands to copper salts dramatically improves the efficiency of the
copper catalyst, making it chemo-, enantio- and regio-selective. Their role was
mostly linked to the increased solubility and reduced aggregation of Cu salts, rather
than to other effects. This subsequently led to reactions occurring under milder
conditions such as lower temperatures (usually 80-100oC) and catalytic loading (5-
20%). Figure 6.3.1 shows some of the first ligands to be used in copper mediated
catalytic reactions. The ligands can be classed as (O,O)-, (N,O)- or (N,N)- according
to their chemical structure.53, 60 Bidentate ligands have been shown to be more
efficient than monodentate ones.54, 61 A potential explanation is that the bidentate
ligands block the two adjacent coordination sites, forcing close proximity of the aryl
donor and the nucleophile and ensuring easier coupling.47
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Figure 6.3.1: Historic ligands in copper mediated catalytic reactions
In the McGowan Research group, Dr Carlo Sambiagio has extensively investigated a
range of N-phenylpicolinamide ligands as catalysts for Cu-catalysed aryl ether
formation. His work highlighted that electron withdrawing substituents on the phenyl
ring of the ligand increased the catalytic activity of the active species. The
picolinamide ligands showed high catalytic conversions, even for the sterically
hindered phenols, ortho- substituted phenols, tert-butyl and tert-amyl substituents,
some of which are known to be challenging coupling partners in Cu-catalysed
reaction.62 The geometrical and electronic similarities between N-
phenylpicolinamide copper(II) complexes [Figure 6.3.2(a)] and the authors’ β-bis-
ketoiminate copper(II) complexes [Figure 6.3.2(b)] prompted catalytic
investigations on the β-bis-ketoiminate copper(II) complexes
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(a) (b)
Figure 6.3.2: (a) Dr Sambiagio’s picolinamide copper (II) complexes,62 (b) the author,s
ketoiminate copper(II) complexes
The mechanism of the Ullmann reaction
Various copper sources ranging from Cu(I) to Cu(II) salts and metallic copper are
effective catalysts in Ullmann reactions, although Cu(I) salts result in higher
activities. It is generally accepted that a single catalytic active species, most likely
Cu(I) species, is produced from all these precursors and is the primary catalytic
species.58, 59, 63-65
X
R R R
Cu
R
X
R
CuX
R
R
Cu
Cu I
II
III
2
Scheme 6.3.2: General mechanism for Ullmann cross coupling reactions
Scheme 6.3.2 shows the mechanism generally accepted for Ullmann cross coupling
reactions. However, some of the catalytic steps have generated controversy over the
years and are still under debate.60 In step I an organo-cuprate intermediate is formed
from the reaction of a molecule of the aryl halide with the copper complex precursor.
Step II is oxidative addition of the second aryl halide molecule, followed by
reductive elimination to give the final product (step III).47
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Other proposed mechanisms within the literature differ on the activation of the aryl
halide, a rate determining step. The mechanisms can be classed into four main
categories:
i. Mechanistic pathways involving oxidative addition/reductive elimination
ii. Mechanistic pathways involving single electron transfer (SET) or Halogen
Atom Transfer (HAT).
iii. Mechanistic pathways involving π-complexation of the Cu(I) active species 
to the aromatic ring.
iv. Mechanistic pathways involving σ-bond metathesis 
In mechanisms i and ii the copper species changes its oxidation state during the
catalytic cycle, whilst in iii and iv the copper species maintain the same oxidation
state throughout.47, 60
Based on the literature it is clear that there is no single mechanism for all the copper
catalysed Ullmann reactions. However, for the modified Ullmann reaction most
researchers agree that the reaction between the copper complex and the nucleophile
precedes the activation of the aryl halide species. Overall the mechanism varies
depending on factors such as the substrates of choice, ligands, side reactions and
reaction conditions.47, 60
Catalytic viability of β-bis-Ketoiminate Copper(II) Complexes
The model reaction chosen to investigate the catalytic activity of the β-bis-
ketoiminate copper(II) complexes was the coupling between 3,5-dimethylphenol 1
and 4-iodoanisole 2, leading to the biaryl ether 3, Scheme 6.3.3.
OH
I
O
O
O
+
CuCl2 (1 eq.)
Ligand (2 eq.)
Cs2CO3 (2 eq.)
MeCN (3 mL)
90oC, 24 hrs1 2 3
Scheme 6.3.3: Ullmann reaction for the synthesis of aryl ethers
Electron donating substituents on the aryl halide, 2, make the substrate less reactive
through deactivation, hence the reaction shown in Scheme 6.3.3 would be relatively
challenging. More importantly the deactivated substrate can clearly highlight the
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differences in the versatility and efficacy of the ligand and metal complexes, an
observation that may be less obvious with a more reactive substrate. Caesium
carbonate and acetonitrile were chosen as the base and solvent of choice respectively
based on previous literature reports.62 All catalytic reactions were done under
nitrogen using un-purified reagents, reactions with anhydrous reagents did not
improve the catalytic efficiency.
H(p) C17 2’,3’ diMe(p) C28
2’Br(p) C18 2’,4’,6’triMe(p) C29
2’Cl(p) C19 3’,4’diCl(p) C30
4’Br(p) C20 3’,4’methylene(p) C31
4’Cl(p) C21 3’Br, 4’F(p) C32
4’F(p) C22 2’OMe(p) C33
4’I(p) C23 2’OEt, 4’F(p) C35
4’Me(p) C24 2’ Br (a) C36
4’OMe(p) C25 3’Cl(a) C39
4’OEt(p) C26 4’Cl(a) C40
4’CF3(p) C27
Figure 6.3.3: β-Bis-ketoiminate copper(II) complexes under study
Figure 6.3.4: Catalytic results for β-bis-ketoiminate copper(II) complexes (GC yields):
Key blue bars – complexes with EWG, red bars – complexes with EDG
0
20
40
60
80
100
C
17
C
18
C
19
C
20
C
21
C
22
C
23
C
27
C
30
C
31
C
32
C
36
C
39
C
40
C
uC
l2
C
24
C
25
C
26
C
28
C
29
C
33
C
35
60
79
69
60 59 57
61
90
96
74
60
89
83
71
19
10
42
21
42
20
42
26
C
on
ve
rs
io
n
(%
)
Complex
Catalytic Investigations Chapter 6
182
To investigate the effect of electronic and steric properties of the copper(II)
complexes, a range of complexes with different substituents on the ketoiminate
ligand were studied (Figure 6.3.3). Reactions with the alternative copper source,
copper(II) chloride, were also evaluated for comparison purposes. Figure 6.3.4
shows the results obtained for the various complexes. With the exception of C24, the
presence of the ketoiminate ligand with either EDG (electron donating groups) or
EWG (electron withdrawing groups) improved the catalytic activity of the copper
complexes when compared to the copper salt, CuCl2. Complex C17 with the parent
unsubstituted ligand was a competitive catalyst, with a conversion of 60%.
The presence of electron donating groups on the complexes [Figure 6.3.4 (red)]
resulted in poor conversions. Complexes C25 (4’Me), C28 (2’,3’ diMe) and C33
(2’OMe) gave the same conversion (42%) regardless of the differences in the extent
of the electron donating properties. Complexes with electron withdrawing groups on
the ligand phenyl rings gave high catalytic conversions (Figure 6.3.4 (blue),
particularly C27 (4’CF3) and C30 (3’,4’ diCl) with conversions of 90% and 96%
respectively. The effect of EDG and EWG were further displayed by the differences
in catalytic conversions of complexes C22 (4’F), C32 (3’ Br, 4’F) and C35 (2’OEt,
4’F). Complex C22 has the fluoro substituent in the para position, addition of a
bromo substituent in the meta position (C32) results in negligible increase in
catalytic conversion. However, addition of the electron donating ethoxy-substituent
in the ortho position (C35) results in a two-fold decrease in catalytic conversion.
The effect of halogenated substituents in catalysis is of particular interest; the
position and type of halogen can drastically change the catalytic activity of the
ligand or complex. Complexes, C22 (4’F: 57%), C21 (4’Cl: 59%), C20 (4’Br: 60%)
and C23 (4’I: 61%) show a slight decrease in catalytic efficacy going from the most
to the least electronegative halogen. Although not conclusive, these results imply
that the electronegative strength of the halogen has little effect on the overall
efficacy of the resultant complex. However, the position of the halogen substituent
on the ligand in the complex has a significant effect on the catalytic activity of the
complex. Complexes with ortho substituents resulted in higher conversions
compared to their para analogues, shown by C18 (2’Br: 79%) and C20 (4’Br: 60%)
as well as C19 (2’Cl: 69%) and C21 (4’Cl: 59%). In β-bis-ketoiminate copper(II)
complexes the substituent can either be on the aniline ring or the phenolate ring,
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shown as Ra and Rp respectively in Figure 6.3.3. Interestingly substitution on the
aniline ring resulted in an increase in the catalytic efficacy of the complexes when
compared to phenolate substituted analogues. These results are highlighted by
complexes C18 (2’Br(p): 79%) and its analogue C36 (2’Br(a): 89%) as well as C21
(4’Cl(p): 59%) and its analogue C40 (4’Cl(a): 71%).
For comparison purposes further investigations in catalytic efficacy when complexes
are formed in situ were carried out. The same model reaction as above was chosen,
Scheme 6.3.4. Copper(II) chloride was chosen as the copper source, similar to the
conditions in the actual copper complex synthesis.
Scheme 6.3.4: Model Ullmann reaction under investigation
The results for catalytic conversions when complexes are made in situ are shown in
Figure 6.3.5 and summarised in Table 6.3.1. These results show that for both EDG
and EWG the catalytic efficacy was higher when pre-synthesised complexes were
used compared to when the complexes were made in situ. This decrease in catalytic
activity can be explained by the high probability of the occurrence of side reactions
when the complexes are formed in situ. In the synthesis of the complexes side
reactions were avoided or minimised by carrying out the reaction under nitrogen and
further purification via recrystallization of the bulk product.
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Figure 6.3.5: Catalytic results for acnac ligands and Cu(acnac)2 complexes (GC yields)
Table 6.3.1: Catalytic results for acnac ligands and Cu(acnac)2 complexes (GC yields)
Entry Substituent Complex Catalytic conversion (%)
(Rp/Ra) Complex
made in situ
Pre-
synthesised
complex
1 H(p) C17 33 60
2 4’F(p) C22 6 57
3 4’Cl(p) C21 6 59
4 4’Br(p) C20 5 60
5 4’I(p) C23 17 61
6 2’Cl(p) C19 13 69
7 2’Br(p) C18 7 79
8 4’OMe(p) C25 16 42
9 3’,4’ diCl(p) C30 22 96
10 2’,3’ diMe(p) C28 21 42
11 3’Cl(a) C39 32 83
12 3’Br, 4’F(a) C32 7 60
(p) = substituent on phenolate ring; (a) = substituent on aniline ring
Having identified that pre-synthesised complexes result in higher catalytic efficacy,
with complex C30 giving the best conversion, solvents and bases were screened in
an effort to analyse their effect on the reaction.
Table 6.3.2: Screening results for solvents and bases for Ullmann reaction
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Entry Solvent Base Yield (%)
1 DMSO Cs2CO3 23
2 DMF Cs2CO3 29
3 Toluene Cs2CO3 32
4 MeCN Cs2CO3 90
5 MeCN K2CO3 17
6 MeCN Na2CO3 11
7 MeCN tBuOK 34
8 MeCN K3PO4 70
The results in Table 6.3.2 were compared to entry 4 as it gave the highest catalytic
conversion yield. The use of other polar solvents in the reaction resulted in poor
yield, entries 1-3, 23-32%. The substitution of caesium carbonate with other bases
resulted in relatively poor yields (entries 5-7). However K3PO4 (entry 8) gave a
competitive yield of 70%.
6.4 Conclusion
Several β–bis-ketoiminate ruthenium(II) dicarbonyl complexes have been studied as
catalysts in the reduction of acetophenone. The complexes tested were functionalised
in an effort to incorporate different steric and electronic properties in order to
investigate and deduce any structural-activity relationships. The coordination of the
ligands, mono- or bidentate, to the metal centre results in an increase in catalytic
efficiency. This can be seen when comparing the results of the starting material
(RuCl3.3H2O) and of the complexes. Electron donating substituents resulted in low
catalytic conversions, while an overall increase was observed when electron
withdrawing substituents were present on either of the phenyl rings. Catalytic
efficiency increased with increase in electronegativity with flouro substituents giving
the highest conversions irrespective of their position on the phenyl rings (i.e meta,
ortho or para). Complex C4, with a fluoro substituent in the para position of the
aniline phenyl ring gave the highest catalytic conversion of 94%. Interesting
complex C4 was also the most cytotoxic in anti-cancer studies against colon cancer
cell lines (see Chapter 4). Further catalytic experiments with complex C4 and
dichloro(p-cymene)ruthenium(II) dimer, the “gold standard”, showed that the rate of
catalytic activity of the dimer exponentially increases while that of C4 gradually
increases reaching maximum conversion after 6 hours. In conclusion, β–bis-
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ketoiminate ruthenium(II) dicarbonyl complexes have shown viable activity as
catalysts in the transfer hydrogenation of acetophenone using isopropanol.
This chapter also presents results for the catalytic activity of ketoiminate ligands and
β–bis-ketoiminate copper(II) complexes for the bi-aryl ether formation in Ullmann
type reactions. Comparison of catalytic activities with complexes made in situ and
pre-synthesised complexes showed higher conversions with pre-synthesised
complexes. The significant decrease in catalytic activity is likely due to the presence
of side reactions. The wide range of complexes tested with different electronic and
steric properties allowed for evaluation of structure-activity relationships. As seen
with copper(II) picolinamide complexes previously investigated in our group, the
presence of electron donating substituents on the phenyl rings resulted in poor
conversions, while electron withdrawing substituents gave high conversions.
Furthermore the effect of halogenated substituents was also considered; the extent of
electronegativity, electronegative strength, had no significant effect on the catalytic
activity of the complexes, while the position of the halogen substituent greatly
influenced the catalytic efficiency. The most active catalyst were complexes C27
(4’CF3) and C30 (3’,4’ diCl) with percentage conversions of 90 and 96 respectively.
Investigative reactions with different bases and solvent have shown that the best
combination for this type of Ullmann reaction is with acetonitrile as the solvent and
caesium carbonate as the base.
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7.1 General Experimental Procedure
All novel β-bis-ketoiminate copper(II) complexes were synthesised using standard
Schlenk line techniques, under an atmosphere of dry dinitrogen with a dual
vacuum/dinitrogen line to perform the synthesis. All β-bis-ketoiminate ruthenium(II)
dicarbonyl complexes were synthesised under aerobic conditions.
All chemicals were supplied by Sigma-Aldrich Chemical Co., Acros Organics, Alfa
Aesar and BOC gases. Deuterated NMR solvents were purchased from Sigma-
Aldrich Chemical Co. or Acros Organics. Functionalised β-diketonate and β-
ketoiminate ligands were prepared by adaptations of literature methods.1, 2
7.2 Instrumentation
All NMR spectra were recorded by the author on a Bruker DPX 300 or DRX 500
spectrometer. Chemical shifts (δ) are expressed in parts per million (ppm) and 
referenced to the solvent signal, used as an internal reference. Microanalyses were
acquired by Mr. Stephen Boyer at the London Metropolitan University Elemental
Analysis Service. Mass Spectra were recorded by the author or Dr Stuart Warriner
on a Bruker Daltonics MicroTOF instrument with electrospray ionisation (ESI) and a
photodiode array analyser at the University of Leeds Mass Spectrometry Service.
UV/vis absorption spectra were acquired on a Cary Series UV-Vis
spectrophotometer using 1 cm path length quartz cuvettes. Infrared spectra were
obtained using a Platinum ATR Spectrometer on a crystal plate with samples
analysed using OPUS software.
For catalytic studies reported in this thesis, the same commercial sources of
chemicals and solvents were used. Reactions were routinely performed in carousel
tubes of the same size and shape, using the same type of stirrer bars at a stirring rate
of 500 rpm. Reactions were analysed using a HP6890 series GC-MS with a
split/splitless injector system and FID was used. Chromatographic separation was
performed by using a 30 m X 0.32 m HP-5MS column (df = 0.25µm) and helium
used as a carrier gas at a flow rate of 97.4 mL·min-1. All 1µL injections were carried
out in a split flow mode with split ratio of 50:1. The injector was initially ramped to
60°C for 2 minutes, followed by an increase to 300°C at a rate of 20°C·min-1.
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7.3 X-ray crystallography
Single crystal X-ray diffraction data were collected either by the author or Dr.
Christopher Pask using an Agilent (Rigaku) SuperNova X-ray diffractometer fitted
with an Atlas area detector using mirror monochromated Mo-Kα (λ = 0.71073 Å) or 
Cu-Kα (λ = 1.54184 Å) radiation. The crystal was cooled to 120 K using an Oxford 
Cryosystem low temperature device.3 The full dataset was collected and the images
processed using CrysAlisPro program.4 Structure solution by direct methods was
achieved through the use of SHELXS86,5 SHELXL-20146 or SHELXT,7 and the
structural model refined by full matrix least squares on F2 using SHELX978
interfaced through the program Olex2.9 Molecular graphics were plotted, editing of
CIFs and construction of tables of bond lengths and angles were achieved using
Olex2. Unless otherwise stated, hydrogen atoms were placed using idealised
geometric positions (with free rotation for methyl groups), allowed to move in a
“riding model” along with the atoms to which they were attached, and refined
isotropically. The SQUEEZE routine of Platon was used to refine structures where
diffuse electron density could not be adequately modelled as solvent of
crystallisation.10
7.4 Synthesis of functionalised β-diketonate ligands 
β-Diketonate ligands, precursors to β-bis-ketoiminate ligands, have been previously 
synthesised and fully characterised within the McGowan research group by Dr. Felix
Janeway, Dr. Andrew Hebden and Dr Rianne Lord (University of Leeds), as such no
characterisation data is given herein.
General synthetic procedure for β-diketonate ligands 
Ligands were synthesised via modified literature methods.11, 12 Sodium ethoxide (1
equivalent) was added to a solution of the required acetophenone (1.2 equivalents) in
ethyl acetate and refluxed for 2 hours, followed by stirring at room temperature for a
further 16 hours. The solvent was removed under reduced pressure and washed with
petrol (60-80˚C) (3 x 10 mL). The suspension was then dissolved in water (40-100 
mL) and sulfuric acid (1 molar) was added until just acidic to litmus. The crude
product was extracted into diethyl ether (3 x 10 mL) and dried over MgSO4. After
cooling to room temperature, ice cold sulfuric acid was added dropwise until the
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mixture was just acidic. Solvent was removed under reduced pressure and the
residue recrystallised from hot ethanol.
7.5 Synthesis of functionalised β-bis-ketoiminate ligands
β-bis-ketoiminate ligands have been previously synthesised and fully characterised
by Dr Rianne Lord (University of Leeds).13 As such no characterisation data for
ligands L1-L32 are given herein.
General synthetic procedure for β-bis-ketoiminate ligands
Ligands L1-L32 were synthesised using a modified synthetic route based on work by Tang
et al.14 In this synthesis the functionalised diketonate was dissolved in toluene, and aniline
and dilute HCl added. This was allowed to stir at room temperature for 16 hours, after which
the precipitate was filtered off and the solvent removed under reduced pressure. The crude
products were recrystallised from hot ethanol. The synthesis of ligand L2 is given as an
example.
Ra = H, Rp = H L1 2’,4’,6’ triMe L16
4’F L2 3’,4’ methylene L17
4’Cl L3 3’Br, 4’F L18
4’Br L4 Rp = H, Ra = 4’Cl L21
3’F L5 4’F L22
3’Br L6 4’Me L23
4’I L7 3’Br L24
4’Me L8 3’Me L25
2’CI L9 2’F L26
2’Br L10 2’,4’ diCl L27
4’OMe L11 2’,4’ diF L28
4’CF3 L12 2’,3’ diMe L29
4’OEt L13 2’Br L30
2’OMe L14 3’Cl L31
3’,4’ diCl L15 2’,5’ diF L32
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Synthesis of L2
4’-Fluoro-β-diketonate (750 mg, 4.20 mmol) was dissolved in toluene (10 mL), 
aniline (1.5 mL) and HCl (0.75 mL) were then added. This was stirred for 16 hours,
after which the precipitate was filtered and the solvent removed under reduced
pressure. The crude product was recrystallised from hot ethanol (10 mL), yielding
yellow crystals of L2 (890 mg, 3.49 mmol, 83%).
1H NMR (CDCl3, 500.23 MHz, 299.9 K) δ 13.06 
(br. s, 1H, NH), 7.94 (br. dd, 2H, H12 and H16, 3J
(1H-1H) = 8.7, 4J (1H-19F) = 5.5)), 7.38 (br. t, 2H,
H3 and H5, 3J (1H-1H) = 8.0, 3J (1H-1H) = 7.8), 7.24
(br. t, 1H, H4, 3J (1H-1H) = 7.4 ), 7.19 (d, 2H, H2
and H6, 3J (1H-1H) = 7.5), 7.11 (br. t, 2H, H13 and
H15, 3J (1H-1H) = 8.7, 3J (1H-19F) = 8.7), 5.85 (s, 1H, H9), 2.16 (s, 3H, H7).
7.6 Synthesis of β-bis-ketoiminate Ru(II) dicarbonyl complexes
All β-bis-ketoiminate ruthenium(II) dicarbonyl complexes were synthesised as
follows. Ruthenium(III) chloride trihydrate (1 equivalent) was dissolved in 2-
ethoxyethanol (10 mL) and the solution warmed up to reflux temperature. In a
separate flask the ketoiminate ligand (2.2 equivalents) and triethylamine (4
equivalents) were dissolved in 2-ethoxyethanol (5-10 mL) and stirred for 20-30
minutes. The ligand and base solution was then added to the metal solution dropwise
and the dark coloured solution stirred under reflux for 6 hours. After cooling to room
temperature the product was filtered off and solvent removed under reduced
pressure. The product was purified by column chromatography using
dichloromethane/hexane as the eluant.
Synthesis of C1 (C34H28N2O4Ru)
Complex C1 was purified by column chromatography (DCM/hexane, 1:1) and
further recrystallised from hot acetonitrile to give a green solid (510 mg, 0.80 mmol,
35 %). Single crystals suitable for X-ray diffraction were obtained from vapour
diffusion of hexane into a saturated solution of the complex in DCM, at room
temperature.
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1H NMR (CDCl3, 500.23 MHz, 299.9 K) δ, 7.93-
7.87 (m, 2H, H12 and H16), 7.31-7.27 (br. t, 3H, H13,
H14 and H15, 3J (1H-1H) = 6.5 Hz), 7.26-7.21 (br. m,
3H, H3, H5 and H2 or H6), 7.05 (br. t, 1H, H4, 3J (1H-
1H) = 7.2 Hz), 6.77 (br. d, 1H, H2 or H6, 3J (1H-1H) =
8.3 Hz), 5.60 (s, 1H, H9), 1.83 (s, 3H, H7). 13C{1H}
NMR (CDCl3, 300 MHz, 299.9 K) δ 197.1 (CO), 173.3 (quartenary C, C10), 166.7
(quartenary C, C8), 157.9 (quartenary C, C1), 140.5 (quartenary C, C11), 129.3
(aniline CH, C3 or C5), 129.2 (aniline CH, C3 or C5), 128.8 (aromatic CH, C14), 128.0
(aromatic CH, C13 and C15), 127.0 (aromatic CH, C12 and C16), 125.1 (aniline CH,
C4), 124.6 (aniline CH, C2 or C6), 122.4 (aniline CH, C2 or C6), 95.2 (acnac CH, C9),
24.3 (acnac CH3, C7). IR (cm-1), 2039 (s, CO), 1964 (s, CO). Analysis calculated:
C, 64.85, H, 4.48, N, 4.45 % Analysis found: C, 64.89, H, 4.79, N, 4.50 %. ES MS
(+) m/z 631.12 [M+].
Synthesis of C2 (C34H26Br2N2O4Ru)
Complex C2 was purified using column chromatography (DCM/hexane, 3:2).
Further purification through vapour diffusion of hexane into a solution of the
complex in DCM gave C2 as yellow single crystals suitable for X-ray diffraction
(210 mg, 0.27 mmol, 34 %).
1H NMR (CDCl3, 500.23 MHz, 299.9 K) δ 7.71 
(br. d, 2H, H12 and H16, 3J (1H-1H) = 8.6 Hz), 7.50
(br. d, 2H, H13 and H15, 3J (1H-1H) = 8.4 Hz),
7.37-7.31 (m, 2H, H3 and H5), 7.24 (br. d, 1H, H2
or H6, 3J (1H-1H) = 7.3 Hz), 7.16 (br. t, 1H, H4, 3J
(1H-1H) = 7.5 Hz), 6.85 (d, 1H, H2 or H6, 3J (1H-
1H) = 7.6 Hz), 5.62 (s, 1H, H9), 1.91 (s, 3H, H7). 13C{1H} NMR (CDCl3, 300 MHz,
299.9 K) δ 196.9 (CO), 172.0 (quartenary C, C10), 167.0 (quartenary C, C8), 157.6
(quartenary C, C1), 139.3 (quartenary C, C11), 131.1 (quartenary C-Br, C14), 129.3
(aniline CH, C3 or C5), 129.0 (aniline CH, C3 or C5), 128.6 (aromatic CH, C13 and
C15), 125.3 (aromatic CH, C12 and C16), 124.3 (aniline CH, C2 or C6), 123.7 (aniline
CH, C4), 122.3 (aniline CH, C2 or C6), 95.2 (acnac CH, C9), 24.3 (acnac CH3, C7).
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IR (cm-1), 2037 (s, CO), 1963 (s, CO). Analysis calculated: C, 51.86, H, 3.33, N,
3.56 % Analysis found: C, 52.05, H, 3.70, N, 3.25 %. ES MS (+) m/z 788.94 [M+].
Synthesis of C3 (C34H26Cl2N2O4Ru)
The crude product was purified using column chromatography (DCM/hexane, 1:1),
to give complex C3 as a yellow-green solid (490 mg, 0.70 mmol, 36 %).
1H NMR (CDCl3, 500.23 MHz, 299.9 K) δ, 7.70 
(d, 2H, H12 and H16, 3J (1H-1H) = 8.55 Hz), 7.29-
7.22 (m, 4H, H3, H5, H13 and H15), 7.16 (d, 1H, H2
or H6, 3J (1H-1H) = 7.7 Hz), 7.07 (t, 1H, H4, 3J
(1H-1H) = 7.5 Hz), 6.76 (d, 1H, H2 or H6, 3J (1H-
1H) = 7.7 Hz), 5.56 (s, 1H, H9), 1.82 (s, 3H, H7).
13C{1H} NMR (CDCl3, 300 MHz, 299.9 K) δ 196.9 (CO), 172.0 (quartenary C, C10),
167.0 (quartenary C, C8), 157.7 (quartenary C, C1), 138.9 (quartenary C, C11), 135.3
(quartenary C-Cl, C14), 129.3 (aniline CH, C3 or C5), 129.0 (aniline CH, C3 or C5),
128.3 (aromatic CH, C13 and C15), 128.2 (aromatic CH, C12 and C16), 125.4 (aniline
CH, C4), 124.4 (aniline CH, C2 or C6), 122.3 (aniline CH, C2 or C6), 95.2 (acnac CH,
C9), 24.3 (acnac CH3, C7). IR (cm-1), 2039 (s, CO), 1969 (s, CO). Analysis
calculated: C, 58.46, H, 3.75, N, 4.01 % Analysis found: C, 58.57, H, 3.80, N, 4.15
%. ES MS (+) m/z 699.04 [M+].
Synthesis of C4 (C34H26F2N2O4Ru)
Complex C4 was purified using column chromatography (DCM/hexane, 1:1).
Further purification through vapour diffusion of hexane into a solution of the
complex in DCM gave C4 as single crystals suitable for X-ray diffraction (170 mg,
0.26 mmol, 39 %).
1H NMR (CDCl3, 500.23 MHz, 299.9 K) δ, 7.85 
(br. dd, 2H, H12 and H16, 3J (1H-1H) = 8.4 Hz, 4J
(1H-19F) = 5.7 Hz), 7.4 (br. dd, 2H, H13 and H15, 3J
(1H-1H) = 8.0 Hz, 3J (1H-19F) = 8.8 Hz), 7.26 (br. d,
1H, H2 or H6, 3J (1H-1H) = 8.3 Hz), 7.15 (t, 1H, H4,
3J (1H-1H) = 7.5 Hz), 7.05 (br. t, 2H, H3 and H5, 3J
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(1H-1H) = 8.5 Hz), 6.85 (d, 1H, H2 or H6, 3J (1H-1H) = 8.0 Hz), 5.62 (s, 1H, H9), 1.92
(s, 3H, H7). 13C{1H} NMR (CDCl3, 300 MHz, 299.9 K) δ 197.0 (CO), 172.2 
(quartenary C, C10), 166.8 (quartenary C, C8), 163.7 (quartenary C-F, C14, 1J (13C-
19F) = 248.8 Hz), 157.7 (quartenary C, C1), 136.4 (quartenary C, C11, 4J (13C-19F) =
3.1 Hz), 129.2 (aniline CH, C3 or C5), 128.9 (aniline CH, C3 or C5), 128.9 (aromatic
CH, C12 and C16, 3J (13C-19F) = 8.30 Hz), 125.3 (aniline CH, C4), 124.4 (aniline CH,
C2 or C6), 122.3 (aniline CH, C2 or C6), 114.8 (aromatic CH, C13 and C15, 2J (13C-
19F) = 21.8 Hz ), 94.9 (acnac CH, C9), 24.3 (acnac CH3, C7). IR (cm-1), 2033 (s,
CO), 1963 (s, CO). Analysis calculated: C, 61.35, H, 3.94, N, 4.21 % Analysis
found: C, 61.35, H, 4.14, N, 4.29 %. ES MS (+) m/z 667.10 [M+].
Synthesis of C5 (C34H26F2N2O4Ru)
The crude product was purified using column chromatography (DCM/hexane; 1:1) to
give complex, C5 as a yellow solid, which was further purified through
recystallisation with hot acetonitrile, (420 mg, 0.64 mmol, 30 %).
1H NMR (CDCl3, 500.23 MHz, 299.9 K) δ, 7.62 
(d, 1H, H16, 3J (1H-1H) = 7.8 Hz),7.57 (dt, 1H, 3J
(1H-19F) = 10.4 Hz), 7.39-7.31 (m, 3H, H3 H5 and
H15), 7.28 (d, 1H, H2 or H6, 3J (1H-1H) = 8.1 Hz),
7.17 (t, 1H, H4, 3J (1H-1H) = 7.4 Hz), 6.86 (d, 1H,
H2 or H6, 3J (1H-1H) = 7.9 Hz), 5.66 (s, 1H, H9),
1.93 (s, 3H, H7). 13C{1H} NMR (CDCl3, 300 MHz,
299.9 K) δ 196.9 (CO), 171.6 (d, quartenary C, C10, 4J (13C-19F) = 1.9 Hz), 167.1
(quartenary C, C8), 164.4 (quartenary C-F, C14, 1J (13C-19F) = 243.9 Hz), 157.6
(quartenary C, C1), 142.8 (d, quartenary C, C11, 3J (13C-19F) = 7.1 Hz), 129.3 (d,
aromatic CH, C15, 3J (13C-19F) = 7.4 Hz), 129.3 (aniline CH, C3 or C5), 129.0 (aniline
CH, C3 or C5), 125.4 (aniline CH, C4), 124.4 (aniline CH, C2 or C6), 122.4 (d,
aromatic CH, C16, 4J (13C-19F) = 2.6 Hz), 122.2 (aniline CH, C2 or C6), 116.1 (d,
aromatic CH, C14, 2J (13C-19F) = 22.5 Hz) 114.1 (d, aromatic CH, C12, 2J (13C-19F) =
22.9 Hz ), 95.5 (acnac CH, C9), 24.3 (acnac CH3, C7). IR (cm-1), 2039 (s, CO), 1963
(s, CO). Analysis calculated: C, 61.35, H, 3.94, N, 4.21 % Analysis found: C,
61.42, H, 3.84, N, 4.29 %. ES MS (+) m/z 667.10 [M+].
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Synthesis of C6 (C34H26Br2N2O4Ru)
The crude product was purified using column chromatography (DCM/hexane, 3:2) to
give complex C6 as a yellow solid (430 mg, 0.53 mmol, 33 %). Single crystals
suitable for X-ray diffraction were obtained from slow vapour diffusion of pentane
into a solution of the complex in DCM.
1H NMR (CDCl3, 500.23 MHz, 299.9 K) δ, 8.02 (t, 
1H, H12, 4J (1H-1H) = 1.8 Hz), 7.76 (d, 1H, H16, 3J
(1H-1H) = 7.8 Hz), 7.49 (dt, 1H, H14, 3J (1H-1H) =
7.9 Hz, 4J(1H-1H) = 0.9 Hz), 7.42-7.38 (m, 1H, H3 or
H5), 7.37-7.33 (m, 1H, H3 or H5), 7.28 (d, 1H, H2 or
H6, 3J (1H-1H) = 8.4 Hz), 7.24 (t, 1H, H15, 3J (1H-1H)
= 7.8 Hz), 7.17 (br. t, 1H, H4, 3J (1H-1H) = 7.5 Hz),
6.86 (d, 1H, H2 or H6, 3J (1H-1H) = 7.1 Hz), 5.63 (s, 1H, H9), 1.93 (s, 3H, H7).
13C{1H} NMR (CDCl3, 300 MHz, 299.9 K) δ 196.8 (CO), 171.6 (quartenary C, C10),
167.3 (quartenary C, C8), 157.4 (quartenary C, C1), 142.5 (quartenary C-Br, C13),
132.10 (quartenary C, C11), 130.3 (aromatic CH, C12 or C14), 129.6 (aromatic CH,
C12 or C14), 129.3 (aniline CH, C3 or C5), 129.0 (aniline CH, C3 or C5), 128.0
(aromatic CH, C15), 127.0 (aromatic CH, C16), 125.4 (aniline CH, C2 or C6), 124.4
(aniline CH, C4), 122.2 (aniline CH, C2 or C6), 95.8 (acnac CH, C9), 24.3 (acnac
CH3, C7). IR (cm-1), 2039 (s, CO), 1962 (s, CO). Analysis calculated (+ 0.5
pentane): C, 53.20, H, 3.57, N, 3.40 % Analysis found: C, 53.23, H, 3.92, N, 3.40
%. ES MS (+) m/z 788.94 [M+].
Synthesis of C7 (C34H24Cl4N2O4Ru)
The crude product was purified using column chromatography (DCM/hexane, 1:1) to
give complex C7 as a green solid (360 mg, 0.47 mmol, 31 %).
1H NMR (CDCl3, 500.23 MHz, 299.9 K) δ, 7.94 
(d, 1H, H12, 4J (1H-1H) = 1.9 Hz), 7.65 (dd, 1H,
H16, 3J (1H-1H) = 8.5 Hz, 4J (1H-1H) = 1.9 Hz),
7.43 (d, 1H, H15, 3J (1H-1H) = 8.3 Hz), 7.39 (t,
1H, H3 or H5, 3J (1H-1H) = 7.7 Hz), 7.35 (t, 1H,
H3 or H5, 3J (1H-1H) = 7.7 Hz), 7.23 (d, 1H, H2 or
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H6, 3J (1H-1H) = 7.7 Hz), 7.18 (t, 1H, H4, 3J (1H-1H) = 7.5 Hz), 6.85 (d, 1H, H2 or H6,
3J (1H-1H) = 7.5 Hz), 5.61 (s, 1H, H9), 1.92 (s, 3H, H7). 13C{1H} NMR (CDCl3, 300
MHz, 299.9 K) δ 196.7 (CO), 170.5 (quartenary C, C10), 167.4 (quartenary C, C8),
157.3 (quartenary C, C1), 140.3 (quartenary C-Cl, C13 and C14), 133.2 (quartenary C,
C11), 132.2 (aromatic CH, C15), 130.0 (aromatic CH, C12), 129.3 (aniline CH, C3 or
C5), 129.1 (aniline CH, C3 or C5), 126.0 (aromatic CH, C16), 125.5 (aniline CH, C2 or
C6), 124.2 (aniline CH, C4), 122.2 (aniline CH, C2 or C6), 95.7 (acnac CH, C9), 24.3
(acnac CH3, C7). IR (cm-1), 2043 (s, CO), 1975 (s, CO). Analysis calculated: C,
53.21, H, 3.51, N, 3.65 % Analysis found: C, 53.35, H, 3.39, N, 3.76 %.
Synthesis of C8 (C36H32N2O4Ru)
Complex C8 was purified by column chromatography (DCM/hexane, 7:3) and
further recrystallised from hot acetonitrile to give a yellow solid (220 mg, 0.33
mmol, 42 %).
1H NMR (CDCl3, 500.23 MHz, 299.9 K) δ, 7.78 
(d, 2H, H12 and H16, 3J (1H-1H) = 8.1 Hz), 7.36-
7.31 (m, 2H, H3, and H5), 7.28 (d, 1H, H2 or H6,
3J (1H-1H) = 7.1 Hz), 7.18 (d, 1H, H13 and H15, 3J
(1H-1H) = 8.1 Hz), 7.15–7.11 (m, 1H, H4,), 6.86
(d, 1H, H2 or H6, 3J (1H-1H) = 8.3 Hz), 5.66 (s,
1H, H9), 2.38 (s, 3H, H18), 1.83 (s, 3H, H7). 13C{1H} NMR (CDCl3, 300 MHz, 299.9
K) δ 197.2 (CO), 173.4 (quartenary C, C10), 166.4 (quartenary C, C8), 158.0
(quartenary C, C1), 139.3 (quartenary C, C11), 137.7 (quartenary C, C14), 129.1
(aniline CH, C3 or C5), 128.8 (aniline CH, C3 or C5), 128.6 (aromatic CH, C13 and
C15), 127.0 (aromatic CH, C12 and C16), 125.0 (aniline CH, C2 or C6), 124.7 (aniline
CH, C4), 122.5 (aniline CH, C2 or C6), 94.8 (acnac CH, C9), 24.2 (acnac CH3, C7),
21.3 (aromatic CH3, C18). IR (cm-1), 2033 (s, CO), 1964 (s, CO). Analysis
calculated: C, 65.74, H, 4.90, N, 4.26 % Analysis found: C, 65.85, H, 4.98, N, 4.31
%. ES MS (+) m/z 659.13 [M+].
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Synthesis of C9 (C36H32N2O4Ru)
The crude product was purified by column chromatography (DCM/hexane, 4:1) and
further recrystallised from hot acetonitrile to give a yellow solid of complex C9 (530
mg, 0.81 mmol, 37 %).
1H NMR (CDCl3, 500.23 MHz, 299.9 K) δ, 7.92-
7.86 (m, 2H, H12 and H16), 7.41-7.35 (m, 3H, H13,
H14 and H15), 7.26-7.16 (br. m, 1H, H5), 7.15–
7.11 (m, 1H, H2), 6.96 (d, 1H, H4, 3J (1H-1H) =
7.6 Hz), 6.67 (d, 1H, H6, 3J (1H-1H) = 7.4 Hz),
5.67 (s, 1H, H9), 2.33 (d, 3H, H18, 4J (1H-1H) =
4.9 Hz), 1.93 (d, 3H, H7, 4J (1H-1H) = 1.9 Hz).
13C{1H} NMR (CDCl3, 300 MHz, 299.9 K) δ 197.4 (CO), 173.7 (quartenary C, C10),
166.7 (quartenary C, C8), 157.5 (quartenary C, C1), 140.5 (quartenary C, C11), 138.8
(quartenary C, C3), 129.2 (aniline CH, C5), 128.8 (aromatic CH, C14), 127.9
(aromatic CH, C13 or C15), 127.9 (aromatic CH, C13 or C15), 127.0 (aromatic CH, C12
and C16), 125.8 (aniline CH, C4), 122.9 (aniline CH, C2 or C6), 121.6 (aniline CH, C2
or C6), 95.4 (acnac CH, C9), 24.2 (acnac CH3, C7), 21.4 (aromatic CH3, C18).
IR (cm-1), 2037 (s, CO), 1964 (s, CO). Analysis calculated: C, 65.74, H, 4.90, N,
4.26 % Analysis found: C, 65.85, H, 4.79, N, 4.31 %. ES MS (+) m/z 659.11 [M+].
Synthesis of C10 (C34H26F2N2O4Ru)
Complex C10 was purified by column chromatography (DCM/hexane, 7:3) and
further recrystallised from hot acetonitrile to give a yellow solid (560 mg, 0.85
mmol, 42 %).
1H NMR (CDCl3, 500.23 MHz, 299.9 K) δ, 7.86-
7.81 (m, 2H, H12 and H16), 7.41-7.35 (m, 3H, H13,
H14 and H15), 7.30 (br. d, 2H, H3 and H5, 3J (1H-
1H) = 8.6 Hz),7.25-7.21 (m, 1H, H2 or H6), 6.82-
6.78 (m, 1H, H2 or H6), 5.68 (s, 1H, H9), 1.91 (s,
3H, H7). 13C{1H} NMR (CDCl3, 300 MHz, 299.9
K) δ 197.0 (CO), 173.7 (quartenary C, C10), 167.3 (quartenary C, C8), 161.6
(quartenary C-F, C4, 1J (13C-19F) = 244.4 Hz), 154.0 (d, quartenary C, C1, 4J (13C-
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19F) = 3.1 Hz), 140.4 (quartenary C, C11), 129.4 (aromatic CH, C14), 128.0 (aromatic
CH, C13 and C15), 126.9 (aromatic CH, C12 and C16), 126.1 (d, aniline CH, C2 or C6,
3J (13C-19F) = 8.1 Hz) 123.7 (aniline CH, C2 or C6, 3J (13C-19F) = 8.1 Hz), 116.1
(aromatic CH, C3 or C5, 2J (13C-19F) = 22.4 Hz), 115.5 (aromatic CH, C3 or C5, 2J
(13C-19F) = 22.4 Hz), 94.9 (acnac CH, C9), 24.3 (acnac CH3, C7). IR (cm-1), 2036 (s,
CO), 1964 (s, CO). Analysis calculated: C, 61.35, H, 3.94, N, 4.21 % Analysis
found: C, 61.43, H, 3.81, N, 4.38 %. ES MS (+) m/z 6670.13 [M+].
Synthesis of C11 (C34H26Cl2N2O4Ru)
The crude product was purified using column chromatography (DCM/hexane, 1:1),
to give complex C11 as a green solid (600 mg, 0.86 mmol, 31 %). Single crystals
suitable for X-ray diffraction were obtained through vapour diffusion of hexane into
a saturated solution of the complex in dichloromethane.
1H NMR (CDCl3, 500.23 MHz, 299.9 K) δ, 7.86-
7.81 (m, 2H, H12 and H16), 7.41-7.35 (m, 3H, H13,
H14 and H15), 7.30 (br. d, 2H, H3 and H5, 3J (1H-
1H) = 8.6 Hz),7.25-7.21 (m, 1H, H2 or H6), 6.82-
6.78 (m, 1H, H2 or H6), 5.68 (s, 1H, H9), 1.91 (s,
3H, H7) 13C{1H} NMR (CDCl3, 300 MHz, 299.9
K) δ 196.9 (CO), 174.0 (quartenary C, C10), 167.1
(quartenary C, C8), 158.1 (quartenary C, C1), 140.3 (quartenary C, C11), 130.7
(quartenary C-Cl, C4), 129.5 (aniline CH, C3 or C5), 129.4 (aniline CH, C3 or C5),
129.0 (aromatic CH, C14 ), 128.0 (aromatic CH, C13 and C15), 127.0 (aromatic CH,
C12 and C16), 126.2 (aniline CH, C2 or C6), 123.8 (aniline CH, C2 or C6), 95.5 (acnac
CH, C9), 24.4 (acnac CH3, C7). IR (cm-1), 2041 (s, CO), 1971 (s, CO). Analysis
calculated: C, 58.46, H, 3.75, N, 4.01 % Analysis found: C, 58.56, H, 3.81, N, 4.10
%. ES MS (+) m/z 699.09 [M+].
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Synthesis of C12 (C34H26F2N2O4Ru)
Complex C12 was purified by column chromatography (DCM/hexane, 1:1) and
further recrystallised from hot acetonitrile to give an orange solid (380 mg, 0.57
mmol, 29 %).
1H NMR (CDCl3, 500.23 MHz, 299.9 K) δ, 7.99-7.86 
(m, 2H, H12 and H16), 7.49-7.34 (m, 4H, H3, H13, H14
and H15), 7.20-7.08 (m, 3H, H4 H5 and H6), 5.68 (t,
1H, H9), 1.91 (s, 3H, H7). 13C{1H} NMR (CDCl3, 300
MHz, 299.9 K) δ 196.2 (CO), 174.6 (quartenary C, 
C10), 168.1 (quartenary C, C8), 155.5 (quartenary C-F,
C2, 1J (13C-19F) = 245.7 Hz), 154.0 (quartenary C, C1, 2J (13C-19F) = 12.4 Hz), 140.3
(quartenary C, C11), 129.5 (aromatic CH, C14), 128.0 (aromatic CH, C13 and C15),
127.3 (d, aniline CH C4, 4J (13C-19F) = 6.8 Hz), 127.1 (aromatic CH, C12 and C16),
126.8 (d, aniline CH, C6, 3J (13C-19F) = 7.5 Hz) 124.5 (d, aniline CH, C5 4J (13C-19F)
= 3.7 Hz), 116.0 (aromatic CH, C3 2J (13C-19F) = 20.5 Hz), 94.9 (acnac CH, C9), 24.3
(acnac CH3, C7). IR (cm-1), 2047 (s, CO), 1972 (s, CO). Analysis calculated: C,
61.35, H, 3.94, N, 4.21 % Analysis found: C, 61.56, H, 4.05, N, 4.30 %. ES MS (+)
m/z 667.10 [M+].
Synthesis of C13 (C34H26Br2N2O4Ru)
The crude product was purified using column chromatography (DCM/hexane; 1:1) to
give complex, C13 as a yellow solid, which was further purified through
recystallisation with hot acetonitrile (680 mg, 0.86 mmol, 37 %).
1H NMR (CDCl3, 500.23 MHz, 299.9 K) δ, 7.90-
7.81 (m, 2H, H12 and H16), 7.41-7.35 (m, 3H, H13,
H14 and H15), 7.33-7.28 (m, 1H, H2), 7.27-7.20 (m,
2H, H4 and H5), 6.85 (br. d, 1H, H6, 3J (1H-1H) = 7.7
Hz), 5.72-5.67 (m, 1H, H9), 1.93 (d, 3H, H7).
13C{1H} NMR (CDCl3, 300 MHz, 299.9 K) δ 196.8 
(CO), 175.1 (quartenary C, C10), 167.1 (quartenary
C, C8), 158.6 (quartenary C, C1), 140.3 (quartenary
C, C11), 130.7 (quartenary C-Br, C3), 129.6 (aniline CH, C5), 129.4 (aniline CH, C3
Experimental Chapter 7
206
or C5), 128.5 (aromatic CH, C14 ), 128.1 (aromatic CH, C13 or C15), 128.0 (aromatic
CH, C13 or C15), 127.1 (aromatic CH, C12 and C16), 125.7 (aniline CH, C4 ),122.6
(aniline CH, C2 or C6), 121.4 (aniline CH, C2 or C6), 96.1 (acnac CH, C9), 24.4
(acnac CH3, C7). IR (cm-1), 2045 (s, CO), 1973 (s, CO). Analysis calculated: C,
51.86, H, 3.33, N, 3.56 % Analysis found: C, 52.05, H, 3.41, N, 3.68 %. ES MS (+)
m/z 788.94 [M+]
Synthesis of C14 (C34H24Cl4N2O4Ru)
Complex C14 was purified by column chromatography (DCM/hexane, 3:2) and
further recrystallised from hot acetonitrile to give a green solid (150 mg, 0.19 mmol,
21 %). Single crystals suitable for X-ray diffraction were obtained from vapour
diffusion of hexane into a saturated solution of the complex in DCM, at room
temperature.
1H NMR (CDCl3, 500.23 MHz, 299.9 K) δ, 7.45-
7.42 (m, 1H, H16), 7.40 (s, 1H, H13), 7.32 (d, 2H,
H2 or H6 and H15, 3J (1H-1H) = 7.6 Hz), 7.16 (d,
1H, H2 or H6, 3J (1H-1H) = 7.7 Hz), 7.20-7.20(br.
m. 2H, H3 and H5), 7.15 (br. t, 1H, H4, 3J (1H-1H) =
7.2 Hz), 6.82 (d, 1H, H2 or H6, 3J (1H-1H) = 7.9
Hz), 5.20 (s, 1H, H9), 1.78 (s, 3H, H7). 13C{1H}
NMR (CDCl3, 300 MHz, 299.9 K) δ 196.6 (CO), 172.9 (quartenary C, C10), 167.0
(quartenary C, C8), 157.6 (quartenary C, C1), 139.8 (quartenary C, C11), 134.2
(quartenary C-Cl, C12 or C14), 132.8 (quartenary C-Cl, C12 or C14), 130.5 (aromatic
CH, C15), 129.7 (aniline CH, C3 or C5), 129.2 (aromatic CH, C16), 128.7 (aniline CH,
C3 or C5), 124.2 (aromatic CH, C13), 125.4 (aniline CH, C2 or C6), 124.7 (aniline CH,
C4), 121.9 (aniline CH, C2 or C6), 99.2 (acnac CH, C9), 24.0 (acnac CH3, C7). IR
(cm-1), 2045 (s, CO), 1978 (s, CO). Analysis calculated: C, 53.21, H, 3.51, N, 3.65
% Analysis found: C, 53.33, H, 3.42, N, 3.74 %.
Synthesis of C15 (C34H24F4N2O4Ru)
The crude product was purified using column chromatography (DCM/hexane, 1:1),
to give complex C15 as a yellow solid (350 mg, 0.50 mmol, 30 %), which was
further purified from hot acetonitrile. Complex C15 crystallised as green plates from
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slow vapour diffusion of hexane into a concentrated solution of the complex in
dichloromethane
1H NMR (CDCl3, 500.23 MHz, 299.9 K) δ, 7.94-
7.83 (m, 2H, H12 and H16), 7.41-7.30 (m, 4H, H6,
H13, H14 and H15), 6.92-6.82 (m, 2H, H3 and H5),
5.68 (s, 1H, H9), 1.91 (s, 3H, H7). 13C{1H} NMR
(CDCl3, 300 MHz, 299.9 K) δ 196.0 (CO), 175.0 
(quartenary C, C10), 168.7 (quartenary C, C8),
161.7 (quartenary C-F, C2 or C4, 1J (13C-19F) = 237.0 Hz), 155.4 (quartenary C-F, C2
or C4, 1J (13C-19F) = 247.5 Hz) 140.9 (quartenary C, C1), 140.2 (quartenary C, C11),
129.7 (aromatic CH, C14), 128.1 (aromatic CH, C13 and C15), 127.0 (aromatic CH,
C12 and C16), 111.7 (d, aniline CH, C6, 3J (13C-19F) = 21.8 Hz), 104.6 (aromatic CH,
C3 and C5, 2J (13C-19F) = 50.4 Hz), 95.8 (acnac CH, C9), 24.0 (acnac CH3, C7). IR
(cm-1), 2047 (s, CO), 1971 (s, CO). Analysis calculated: C, 58.20, H, 3.45, N, 3.99
% Analysis found: C, 58.17, H, 3.47, N, 4.15 %.
Synthesis of C16 (C38H36N2O4Ru)
The crude product was purified using column chromatography (DCM/hexane, 3:2),
to give complex C16 as a yellow solid (530 mg, 0.77 mmol, 37 %). Single crystals
suitable for X-ray diffraction were obtained through vapour diffusion of hexane into
a saturated solution of the complex in dichloromethane.
1H NMR (CDCl3, 500.23 MHz, 299.9 K) δ, 7.92-7.86 
(m, 2H, H12 and H16), 7.41-7.35 (m, 3H, H13, H14 and
H15), 7.26-7.16 (br. m, 1H, H5), 7.15–7.11 (m, 1H,
H2), 6.96 (d, 1H, H4, 3J (1H-1H) = 7.6 Hz), 6.67 (d,
1H, H6, 3J (1H-1H) = 7.4 Hz), 5.67 (s, 1H, H9), 2.33
(d, 3H, H18, 4J (1H-1H) = 4.9 Hz), 1.93 (d, 3H, H7, 4J
(1H-1H) = 1.9 Hz). 13C{1H} NMR (CDCl3, 300 MHz,
299.9 K) δ 197.6 (CO), 173.3 (quartenary C, C10), 167.1 (quartenary C, C8), 155.9
(quartenary C, C1), 140.7 (quartenary C, C11), 138.1 (quartenary C, C2 or C3), 137.4
(quartenary C, C2 or C3), 129.4 (aniline CH, C5), 129.0 (aromatic CH, C14), 128.0
(aromatic CH, C13 or C15), 127.8 (aromatic CH, C13 or C15), 127.1 (aromatic CH, C12
and C16), 123.2 (aniline CH, C4), 121.1 (aniline CH, C6), 95.2 (acnac CH, C9), 23.9
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(acnac CH3, C7), 20.5 (aromatic CH3, C18 or C19), 14.4 (aromatic CH3, C18 or C19).
IR (cm-1), 2036 (s, CO), 1961 (s, CO). Analysis calculated: C, 66.55 H, 5.29, N,
4.08 % Analysis found: C, 66.44, H, 5.39, N, 4.16 %. ES MS (+) m/z 687.18 [M+]
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7.7 Synthesis of β-bis-ketoiminate copper(II) complexes
All copper complexes were synthesised at room temperature under nitrogen, using
standard Schlenk techniques, on 200 mg of a copper salt, CuCl2, unless otherwise
stated. The β-bis-ketoiminate ligand (2 eq.) and NaOMe (2 eq.) were dissolved in
dry solvent (MeOH or EtOH) (20-40 mL) and stirred for 30 minutes. In a separate
schlenk, the copper salt was dissolved in the same solvent as above (10-15 mL). The
ligand solution was then slowly added to the metal solution, and stirred at room
temperature for 20-24 hours. At the end of the reaction, the solid was filtered off and
washed with cold ethanol, dried under vacuum, and recrystallised through slow
vapour diffusion of hexane into a solution of the complex in dicholoromethane. All
the investigative reactions described in Chapter 3 were performed in the same way.
All yields reported below refer to recrystallised products. All complexes reported are
air stable.
Ra = H, Rp = H L1 Rp = H, Ra = .4’Cl L21
4’F L2 4’F L22
4’Cl L3 4’Me L23
4’Br L4 3’Br L24
3’F L5 3’Me L25
3’Br L6 2’F L26
4’I L7 2’,4’ diCl L27
4’Me L8 2’,4’ diF L28
2’CI L9 2’,3’ diMe L29
2’Br L10 2’Br L30
4’OMe L11 3’Cl L31
4’CF3 L12 2’,5’ diF L32
4’OEt L13
2’OMe L14
3’,4’ diCl L15
2’,4’,6’ triMe L16
3’,4’ methylene L17
3’Br, 4’F L18
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Synthesis of C17 (C32H28N2O2Cu)
Complex C17 was obtained from reaction with L1 as a red solid. Dark crystals were
obtained after recystallisation. Yield: 152.6 mg, 0.28 mmol, 20 %.
Analysis calculated: C, 71.69, H, 5.26, N, 5.23
%, Analysis found: C, 71.75, H, 5.36, N, 5.26 %.
ES MS (+) m/z 537.13 [MH+].
Synthesis of C18 (C32H26N2O2Br2Cu)
Obtained from reaction with L10 as a brown solid, upon recrystallization dark brown
crystals suitable for X ray crystallography were obtained. Yield: (319.6 mg, 0.46
mmol, 36 %).
Analysis calculated: C, 55.39, H, 3.78, N, 4.04 %
Analysis found: C, 54.60, H, 3.34, N, 4.52 %.
Synthesis of C19 (C32H26N2O2Cl2Cu)
Red solid obtained from reaction with ligand L9. Yield: 364.7 mg, 0.60 mmol, 41 %.
Analysis calculated: C 63.53, H 4.33, N, 4.63 %,
Analysis found: C, 63.64, H, 4.27, N, 4.75 %. ES
MS (+) m/z 606.12 [MH+].
Cu
NO
ON
Cl Cl
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Synthesis of C20 (C32H26N2O2Br2Cu)
Obtained from reaction with L4 as an olive green solid. Yield after recrystallization
(300.0 mg, 0.43 mmol, 51%).
Analysis calculated: C, 55.39, H, 3.78, N, 4.04
%, Analysis found: C, 55.34, H, 3.88, N, 4.11
%; ES MS (+) m/z 691.97 [MH+]
Synthesis of C21 (C32H26N2O2Cl2Cu)
Obtained from reaction with ligand L3 as a brick red solid. Recrystallisation yield:
428.0 mg, 0.71 mmol, 48 %.
Analysis calculated: C, 63.53, H, 4.58, N, 4.90
%, Analysis found: C, 63.42, H, 4.45, N, 4.66
%. ES MS (+) m/z 623.07 [MNa+].
Synthesis of C22 (C32H26N2O2F2Cu)
Obtained from reaction with L2 as an olive green solid. Dark green crystals obtained
after recrystallisation (250.0 mg, 0.44 mmol, 52 %).
Analysis calculated: C, 67.18 H, 4.58, N, 4.90 %,
Analysis Found: C, 67.14, H, 4.66, N, 4.91 %.
ES MS (+) m/z 572.13 [MH+].
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Synthesis of C23 (C32H26N2O2I2Cu)
Red solid obtained from reaction with ligand L7. Dark crystals obtained from
recrystallisation (637.0 mg, 0.81 mmol, 54 %).
Analysis calculated: C, 48.78, H, 3.38, N, 3.56
%, Analysis found: C, 48.83, H, 3.41, N, 3.65 %.
ES MS (+) m/z 810.93 [MNa+].
Synthesis of C24 (C34H32N2O2Cu)
Obtained from reaction with ligand L8 as a brown solid. Yield: 262.0 mg, 0.47
mmol, 63%.
Analysis calculated: C, 72.38, H, 5.72, N, 4.97 %,
Analysis found: C, 72.21, H, 5.81, N, 4.94 %. ES
MS (+) m/z (565.19) [MH+].
Synthesis of C25 (C34H32N2O4Cu)
Obtained from reaction with L11 as a dark brown solid. Dark crystals suitable for X
ray crystallography obtained at 40% yield (352.0 mg, 0.59 mmol).
Analysis calculated (+0.33 EtOH +0.33
pentane): C, 65.70, H, 5.46, N, 4.38 %,
Analysis found: C, 65.85, H, 5.46, N, 4.92 %.
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Synthesis of C26 (C36H36N2O4Cu)
After recrystallisation, dark crystals suitable for X-ray crystallography were obtained
as product from reaction with ligand L13. Yield: 634.2 mg, 1.02 mmol, 68 %.
Analysis calculated: C, 69.27, H, 5.81, N,
4.49 %, Analysis found: C, 69.58, H, 5.90,
N, 4.87 %.
Synthesis of C27 (C34H26N2O2F6Cu)
Gold crystalline solid obtained from reaction with ligand L12. Recrystallisation
yield, 550.0 mg, 0.82 mmol, 72%.
Analysis calculated: C, 60.76, H, 3.90,
N, 4.17 %, Analysis found: C, 60.85,
H, 3.96, N, 4.23 %.
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Synthesis of C28 (C36H36N2O2Cu)
Dark crystals obtained from reaction with ligand L29. Yield: 387.5 mg, 0.65 mmol,
44 %.
Analysis calculated: C, 73.01, H, 6.13, N,
4.73 %, Analysis found: C, 73.23, H, 6.12,
N 4.80 %.
Synthesis of C29 (C38H40N2O2Cu)
Obtained from reaction with L16, and gave dark crystals on recrystallization (263.3
mg, 0.43 mmol, 37%).
Analysis calculated: C, 73.58, H, 6.50, N, 4.52
%, Analysis found: C, 73.68, H, 6.60, N, 4.64
%. ES MS (+) m/z 620.25 [MH+].
Synthesis of C30 (C32H24N2O2Cl4Cu)
Obtained as a red solid from reaction with ligand L15. Yield: 244.1 mg, 0.36 mmol,
46 %.
Analysis calculated: C, 57.03, H, 3.59,
N, 4.16 %, Analysis found: C, 56.95, H,
3.66, N, 4.25 %. ES MS (+) m/z 674.90
[MH+].
Experimental Chapter 7
215
Synthesis of C31 (C34H32N2O6Cu)
Gold crystalline solid obtained from reaction with L17. Recrystallisation yield:
157.4 mg, 0.25 mmol, 28 %.
Analysis calculated (+ EtOH): C,
64.52, H, 5.11, N, 4.18 % Analysis
found: C, 64.81, H, 5.11, N, 4.18 %.
ES MS (+) m/z 624.12 [MH+].
Synthesis of C32 (C32H24N2O2F2Br2Cu)
Red solid obtained from reaction with ligand L18. Yield: 345.0 mg, 0.47 mmol, 63
%.
Analysis calculated: C, 52.66, H, 3.31,
N, 3.84 %, Analysis found: C, 52.77, H,
3.20, N, 3.91 %.
Synthesis of C33 (C34H32N2O4Cu)
Brown solid obtained from reaction with L14. Yield (420.0 mg, 0.70 mmol, 47 %).
Analysis calculated (+1.5 DCM): C,
63.78, H, 4.87, N, 5.05 %, Analysis
found: C, 63.00, H, 4.87, N, 5.05 %.
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Synthesis of C34 (C32H26CuF2N2O2)
Brown solid obtained from reaction with ligand L5. Yield after recrystallisation
(409.0 mg, 0.79 mmol, 53 %).
Analysis calculated (+0.5 EtOH): C,
66.79, H, 4.80, N, 4.77 %, Analysis found:
C, 67.00, H, 4.49, N, 4.97 %.
Synthesis of C35 (C36H34N2O4F2Cu)
Dark crystals obtained from reaction with ligand L33. Yield (387.2 mg, 0.59 mmol,
40 %). %).
Analysis calculated (+0.5 CH2Cl2): C, 62.39,
H, 5.02, N, 3.99 %, Analysis found: C, 62.16,
H, 4.90, N, 4.04 %.
Synthesis of C36 (C32H26N2O2Br2Cu)
Obtained from reaction with ligand L30 as a brown solid. Recrystallisation yield,
(243.7 mg, 0.35 mmol, 31 %).
Analysis calculated: C, 55.39, H, 3.78, N, 4.04 %,
Analysis found: C, 55.44, H, 3.86, N, 4.06 %. ES
MS (+) m/z 691.97 [MH+].
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Synthesis of C37 (C32H26N2O2F2Cu)
Obtained from reaction with ligand L26, and gave dark brown crystals suitable for X
ray crystallography. Yield: 441.9 mg, 0.77 mmol, 52 %.
Analysis calculated: C, 67.18, H, 4.58, N, 4.90 %,
Analysis found: C, 67.28, H, 4.67, N, 4.93 %.
Synthesis of C38 (C32H26N2O2 Br2Cu)
Obtained as a brick red solid from reaction with L24. Brown blocks obtained from
recrystallisation at 401.7 mg, 0.58 mmol, 39 % yield.
Analysis calculated: C, 55.39, H, 3.78, N, 4.04 %,
Analysis found: C, 55.33, H, 3.83, N, 4.05 %. ES
MS (+) m/z 694.93 [MH+].
Synthesis of C39 (C32H26N2O2Cl2Cu)
Obtained from reaction with ligand L31 as a red solid that gave dark brown
crystalline solid on recrystallisation. Yield: 235.5 mg, 0.39 mmol, 26 %.
Analysis calculated: C, 63.53, H, 4.33, N, 4.63 %,
Analysis found: C, 63.52, H, 4.39, N, 4.73 %. ES
MS (+) m/z 606.02 [MH+].
Cu
NO
ON
Br
Br
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Synthesis of C40 (C32H26N2O2Cl2Cu)
Dark crystals obtained from brick red product after reaction with ligand L21. Yield:
115.5 mg, 0.19 mmol, 33 %.
Analysis calculated: C, 63.53, H, 4.58, N, 4.90 %,
Analysis found: C, 63.53, H, 4.29, N, 4.75 %. ES
MS (+) m/z 604.07 [MH+].
Synthesis of C41 (C32H24N2O2F4Cu)
Olive green solid obtained from reaction with ligand L27. Yield: 395.5 mg, 0.65
mmol, 50 %.
Analysis calculated: C, 63.21, H, 3.98, N, 4.61
%, Analysis found: C, 63.25, H, 4.10, N, 4.71 %.
Synthesis of C42 (C32H24N2O2F4Cu)
From the reaction with ligand L32, complex C42 was obtained as a red solid that
gave dark crystals on purification. Yield: 233.6 mg, 0.38 mmol, 30 %.
Cu
NO
ON
Cl
Cl
Cu
NO
ON
F
F
F
F
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Analysis calculated: C, 63.21, H, 3.98, N, 4.61%, Analysis found: C, 63.16, H,
3.99, N, 4.75 %. ES MS (+) m/z 609.10 [MH+].
7.8 Cytotoxicity Evaluation
General
Sterile techniques were used throughout this work. Unless otherwise stated,
chemicals were purchased from Sigma Aldrich, consumables from Sarstedt and were
used as supplied MIA PaCa-2 (human pancreatic carcinoma), HCT116 ++ (human
colorectal carcinoma p53 upregulated) and ARPE-19 (human retinal epithelium –
none cancerous) were the cell lines used. These were purchased from ATCC.
The stock cultures were grown in T-75 flasks containing DMEM and DMEM:F12
complete cell medium (15 mL) for the cancerous and non-cancerous cell lines
respectively, and incubated at 37 ºC with 5.0% of CO2. The complete media was
prepared from DMEM high glucose without L-glutamine Incomplete Media (450
mL), L-Glutamine 2 mM (5 mL, 200 mM) and foetal bovine serum 10% (50 mL).
The complete media was prepared from DMEM:F12 (1:1) (450 mL), L-Glutamine 2
mM (5 mL, 200 mM) and foetal bovine serum 10% (50 mL). Phosphate Buffer
Saline (PBS) buffer sterile solution was used to wash the cells, Trypsin-EDTA (1x)
was used to detach the cells from the flask. DMEM (complete and incomplete),
DMEM:F12 (complete and incomplete), MTT (Alfa Aesar) and MTT stock solutions
(5 mg/mL), trypsin-EDTA (1x) were all stored at 4ºC. L-Glutamine, foetal bovine
serum and trypsin-EDTA stock solutions were stored at -20ºC. All chemicals except
the MTT solution were incubated in a water bath at 37ºC prior to use.
After removing the media from the T-75 flasks, cells were washed with PBS buffer
solution (1 x 5 mL) and carefully removed. Trypsin-EDTA (1 x 5 mL) was added
and the T-75 flask incubated for 3 min. When the cells were detached from the flask
wall, if needed for cell counting, 3 mL were taken and put in a falcon tube (50 mL)
and 12 mL of media (different depending on the cell line) added to the falcon tube
and 13 mL to the T-75 flask to allow cells to recover and be confluent.
Cells were detached using trypsin as above and centrifuged to 1000 r.p.m. for 3
minutes to form a cell pellet. Media was then carefully removed without disturbing
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the pellet, and depending on cell pellet size re-suspended in 1-10 mL of fresh media
added to make a homogenous cell suspension. From the suspension 10 μL were 
taken and carefully placed onto each side of the glass slide of a haemocytometer.
Cells were then counted under the microscope in four squares of the haemocytometer
and an average taken.
The MTT stock solution (5 mg/mL) was prepared by dissolving MTT (250 mg) in
PBS sterile (50 mL), followed by vortexing before passing through a 0.2 μm sterile 
filter.
The cell suspension was diluted with RPMI-1640 complete media to give a
concentration of 5 × 104 cells mL-1. 100 μL of cell media was added to the first lane 
of the 96-well plate to act as a blank. 100 μL of diluted cell suspension were added 
to the other wells and the plate incubated at 37 °C for 4 hours. After 4h, the solution
was carefully removed from each well and dissolved in 150 μL of DMSO. The plates 
were read by a Tecan plate reader set at 540 nm. Finally, the mean absorbance was
calculated (differing the mean of the blank) for each line and plotted against the cell
number, the R value was then calculated in order to quantify the accuracy of the user
pipetting technique.
Conducting the 5-Day MTT Assay (Normoxia)
After cell counting, a suspension with a concentration of 2 x 104 cell/mL was
prepared. A 96-well plate was used and 200 μL was added to lane 1 to serve as a 
blank. 200 μL of the diluted cell suspension was then added to lanes 2 to 12, and 
incubated for 24h at 37ºC in an atmosphere of 5.0% of CO2 prior to drug exposure.
The complexes were dissolved in DMSO and diluted further with media to obtain
drug solution concentrations ranging from 100 μM to 0.046 μM. The final DMSO 
concentration was 0.2% (v/v) which is non-toxic to cells. The second lane was left as
a blank. Drug solutions were then added to cells and incubated for 96 hours at 37ºC
in an atmosphere of 5% CO2. Cell survival was determined using the MTT assay and
MTT (20 μL of a 5 mg/mL stock) was added to each well and incubated for 4 hours 
at 37oC in an atmosphere of 5.0% of CO2. The solutions were then removed and 150
μL of DMSO added to each well plate to dissolve the formazan crystals. 
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A Tecan plate reader was used to measure the absorbance at 540 nm. Lanes
containing medium only and cell suspension (no drug) were used as blanks and
100% cell survival respectively. Cell survival was determined as the absorbance of
treated cells divided by the true absorbance of controls and expressed as percentage.
The IC50 values were determined from choosing where 50% of cells survive against
drug concentration. Each experiment was repeated a minimum of three times, to give
the average of IC50 and standard deviations.
Conducting the 5-Day MTT Assay (Hypoxia)
The hypoxic studies were carried out in a Hypoxic chamber (Whitley H35
hypoxystation) with 0.1% of O2, 5.0% of CO2, 94.9% of N2 and 81% of humidity,
on HCT116 ++ (human colon carcinoma p53 upregulated) cell lines. DMEM
complete media was conditioned for at least 24 hours in the hypoxic chamber prior
to start of the experiment in order to purge the oxygen from the media. The cells
were seeded as for the 4-day cytotoxic assay above and after 24 hours they were
moved to the hypoxic chamber where the cells were exposed to the lead compounds
from concentrations starting at 50 μM to 0.048 μM. In this assay, it was seeded one 
compound per plate in order to decrease the potential cell infection. Cell survival
was then determined using the MTT assay described for normoxic conditions.
7.9 Anti-bacterial Evaluation
All anti-bacterial studies were performed by The Community for Antimicrobial Drug
Discovery (CO-ADD) at The University of Queensland, funded by The Wellcome
Trust.
Anti-bacterial screening procedure
Complexes were prepared in DMSO and water to a give a final concentration of 32
μg mL-1 in 384-well non-binding surface (NBS) plate. The final DMSO
concentration was at a maximum of 1 % DMSO. All bacteria were cultured in
Cation-adjusted Mueller Hinton broth (CAMHB) at 37 °C overnight. A sample of
each culture was diluted 40-fold in fresh broth and incubated at 37 °C for 1.5 - 3
hours. The resultant mid-log phase cultures were diluted (CFU mL-1 measured by
OD600), then added to each well of the compound containing plates, giving a cell
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density of 5 × 105 CFU mL-1 and a total volume of 50 μL. Colistin and vancomycin 
were used as positive bacterial inhibitor standards for Gram-negative and Gram-
positive bacteria, respectively. The antibiotics were provided at four concentrations,
with two above and two below the MIC value. All the plates were covered and
incubated at 37 °C for 18 hours without shaking.
All experiments were carried out in duplicate. Inhibition of bacterial growth was
determined measuring absorbance at 600 nm (OD600), using a Tecan M1000 Pro
monochromator plate reader. The percentage of growth inhibition was calculated for
each well, using the negative control (media only) and positive control (bacteria
without inhibitors) on the same plate as references. The significance of the inhibition
values was determined by modified Z-scores, calculated using the median and MAD
of the samples (no controls) on the same plate. Samples with inhibition value above
80 % and Z-Score above 2.5 for either replicate were classed as actives. Samples
with inhibition values in the range 50 to 80 % and Z-Score above 2.5 for either
replicate were classed as partial actives.
7.10 Anti-fungal Evaluation
All anti-fungal studies were performed by The Community for Antimicrobial Drug
Discovery (CO-ADD) at The University of Queensland, funded by The Wellcome
Trust.
Anti-fungal screening procedure
Complexes were prepared in DMSO and water to a give a final concentration of 32
μg mL-1 in 384-well NBS plate. The final DMSO concentration was at a maximum
of 1 % DMSO. Fungal strains were cultured for three days on yeast extract-peptone
dextrose (YPD) agar at 30 °C. A yeast suspension of 1 x 106 to 5 x 106 CFU mL-1 (as
determined by OD530) was prepared from five colonies. The suspension was diluted
and added to each well of the compound-containing plates giving a final cell density
of fungi suspension of 2.5 × 103 CFU mL-1 and a total volume of 50 μL. Fluconazole 
was used as a positive fungal inhibitor standard. All the plates were covered and
incubated at 35 °C for 24 hours without shaking.
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All experiments were carried out in duplicate. Growth inhibition of C. albicans was
determined measuring absorbance at 530 nm (OD530) and the growth inhibition of C.
neoformans was determined measuring the difference in absorbance between 600
and 570 nm (OD600-570), after the addition of 0.001 % resazurin and incubation at 35
°C for an additional 2 hours. The absorbance was measured using a Biotek Synergy
HTX plate reader. The percentage of growth inhibition was calculated for each well,
using the negative control (media only) and positive control (fungi without
inhibitors) on the same plate. The significance of the inhibition values was
determined by modified Z-scores, calculated using the median and MAD of the
samples (no controls) on the same plate. Samples with inhibition value above 80 %
and Z-Score above 2.5 for either replicate were classed as actives. Samples with
inhibition values in the range 50 to 80 % and Z-Score above 2.5 for either replicate
were classed as partial actives.
7.11 Hydrolysis
Hydrolysis samples of complexes for investigation by NMR spectroscopy were
prepared from a 4:1 mixture of d3-acetonitrile/deuterium oxide to give a final
concentration of 8 mg mL-1. The NMR spectra of these samples were acquired every
24 hours over a five day period. Hydrolysis samples of complexes for investigation
by UV/vis spectroscopy were prepared from a 4:1 mixture of acetonitrile/water to
give a final concentration of 50 μM. The UV/vis spectra of these samples were 
acquired every 24 hours over a five day period. After the five day period
investigation period, the mass spectra of the hydrolysis samples were acquired.
7.12 Biomembrane studies
The biomembrane studies were performed by Miss. Danielle Marriott and Dr.
Shahrzad Mohamadi (University of Leeds).
The micro fabricated electrode coated with DOPC lipid was contained in a closed
flow cell. A constant flow of phosphate-buffered saline (PBS) (pH 7.4) was passed
over the electrode using a peristaltic pump at a flow rate of 5 - 10 mL min-1. A
constant flow of DOPC dispersion in PBS was deposited on the electrode with the
application of a potential excursion from -0.4 to -3.0 V at a scan rate of 100 Vs-1.
The electrode in the flow cell was connected to the PGSTATI2 potentiostat
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interfaced to a Powerlab signal generator and controlled by Scope software. A flow
of argon gas is maintained over the electrolytes and the DOPC layer throughout.
RCVs were obtained by applying a saw-tooth waveform from -0.4 to -1.2 V (vs
Ag/AgCl) with ramp rate 40 V s-1 applied to the electrode surface. In the absence of
faradaic reactions, the current on the RCV plot was directly proportional to the
capacitance of the surface and is displayed as a function of voltage. All assays were
carried out with 15.6 μM solutions of each complex in acetone with a constant flow 
of 0.1 M PBS. The complexes are sampled for 400 seconds followed by PBS for 400
seconds to allow in situ cleaning of the electrode.15, 16
7.13 Catalysis
Cleaning procedure for catalysis tubes: Carousel glass tubes used for catalytic
reactions were cleaned thoroughly after use. They were initially scrubbed with soapy
water, followed by a three-time rinse with acetone, and a soak in a base bath for 10-
15 hours (KOH approx. 1 M in water/isopropanol). Following the base bath, the
tubes were rinsed multiple times water and placed in an acid bath for 4-7 hours (HCl
37% approx. 1 L per 8-10 L of water). Finally, the tubes were rinsed thoroughly with
water and then with acetone, before being placed to dry in the oven. The same
process was followed for the stirrer bars.
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Identification code C1 C2
Empirical formula C34H28N2O4Ru C35H28Br2Cl2N2O4Ru
Formula weight 629.65 872.38
Temperature/K 120.02(11) 120.01(14)
Crystal system monoclinic triclinic
Space group C2/c P-1
a/Å 28.1978(15) 10.0294(4)
b/Å 12.4204(4) 11.7480(4)
c/Å 20.7143(11) 17.1687(6)
α/° 90 103.021(3)
β/° 126.304(8) 96.172(3)
γ/° 90 115.014(4)
Volume/Å3 5846.5(7) 1738.29(12)
Z 8 2
ρcalcg/cm3 1.431 1.667
μ/mm-1 0.577 2.944
F(000) 2576.0 864.0
Crystal size/mm3 0.16 × 0.12 × 0.09 0.14 × 0.09 × 0.06
Radiation MoKα (λ = 0.71073) MoKα (λ = 0.71073) 
2Θ range for data collection/° 6.3 to 62.598 4.012 to 62.6
Index ranges -39 ≤ h ≤ 39,  
-17 ≤ k ≤ 16,  
-30 ≤ l ≤ 29 
-14 ≤ h ≤ 13,  
-16 ≤ k ≤ 16,  
-18 ≤ l ≤ 23 
Reflections collected 26638 22298
Independent reflections 8527 [Rint = 0.0548,
Rsigma = 0.0673]
9827 [Rint = 0.0444,
Rsigma = 0.0815]
Data/restraints/parameters 8527/0/372 9827/18/426
Goodness-of-fit on F2 1.023 1.067
Final R indexes [I>=2σ (I)] R1 = 0.0454, wR2 =
0.0826
R1 = 0.0630, wR2 =
0.1377
Final R indexes [all data] R1 = 0.0658, wR2 =
0.0903
R1 = 0.0942, wR2 =
0.1519
Largest diff. peak/hole / e Å-3 0.49/-0.73 1.85/-1.36
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Identification code C3 C4
Empirical formula C37H34Cl2N2O4.5Ru C34H26F2N2O4Ru
Formula weight 750.63 665.64
Temperature/K 293(2) 120.01(13)
Crystal system triclinic triclinic
Space group P-1 P-1
a/Å 11.9078(3) 11.5868(3)
b/Å 16.1911(3) 15.8561(4)
c/Å 19.3368(4) 18.7876(4)
α/° 104.6926(19) 100.9224(19)
β/° 105.485(2) 104.341(2)
γ/° 94.5396(18) 96.7474(19)
Volume/Å3 3431.92(14) 3234.11(13)
Z 4 4
ρcalcg/cm3 1.453 1.367
μ/mm-1 0.656 0.534
F(000) 1536.0 1352.0
Crystal size/mm3 0.19 × 0.14 × 0.05 0.34 × 0.19 × 0.14
Radiation MoKα (λ = 0.71073) MoKα (λ = 0.71073) 
2Θ range for data collection/° 5.9 to 56.566 6.186 to 52.742
Index ranges -15 ≤ h ≤ 15,  
-21 ≤ k ≤ 21,  
-25 ≤ l ≤ 25 
-14 ≤ h ≤ 14,  
-19 ≤ k ≤ 19,  
-23 ≤ l ≤ 22 
Reflections collected 54792 39470
Independent reflections 17018 [Rint = 0.0509,
Rsigma = 0.0570]
13218 [Rint = 0.0654,
Rsigma = 0.0666]
Data/restraints/parameters 17018/0/775 13218/0/788
Goodness-of-fit on F2 1.054 1.053
Final R indexes [I>=2σ (I)] R1 = 0.0804, wR2 =
0.2395
R1 = 0.0782, wR2 =
0.2271
Final R indexes [all data] R1 = 0.1018, wR2 =
0.2585
R1 = 0.0890, wR2 =
0.2395
Largest diff. peak/hole / e Å-3 5.94/-0.63 6.03/-1.13
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Identification code C5 C6
Empirical formula C34H26F2N2O4Ru C34H26Br2N2O4Ru
Formula weight 665.64 787.46
Temperature/K 120.00(10) 120.00(10)
Crystal system triclinic triclinic
Space group P-1 P-1
a/Å 10.6629(6) 11.1240(4)
b/Å 11.4624(4) 11.6007(4)
c/Å 12.7982(7) 12.6400(5)
α/° 79.262(4) 79.330(3)
β/° 71.771(5) 74.574(3)
γ/° 82.312(4) 82.230(3)
Volume/Å3 1454.92(14) 1538.83(10)
Z 2 2
ρcalcg/cm3 1.519 1.699
μ/mm-1 0.594 3.147
F(000) 676.0 780.0
Crystal size/mm3 0.24 × 0.15 × 0.12 0.19 × 0.16 × 0.08
Radiation MoKα (λ = 0.71073) MoKα (λ = 0.71073) 
2Θ range for data collection/° 6.784 to 62.592 6.228 to 62.716
Index ranges -15 ≤ h ≤ 14,  
-16 ≤ k ≤ 16,  
-17 ≤ l ≤ 13 
-15 ≤ h ≤ 12,  
-16 ≤ k ≤ 15,  
-18 ≤ l ≤ 18 
Reflections collected 17327 19384
Independent reflections 8224 [Rint = 0.0567,
Rsigma = 0.0953]
8794 [Rint = 0.0384,
Rsigma = 0.0615]
Data/restraints/parameters 8224/0/390 8794/0/390
Goodness-of-fit on F2 1.046 1.054
Final R indexes [I>=2σ (I)] R1 = 0.0548, wR2 =
0.1041
R1 = 0.0533, wR2 =
0.1305
Final R indexes [all data] R1 = 0.0775, wR2 =
0.1207
R1 = 0.0699, wR2 =
0.1405
Largest diff. peak/hole / e Å-3 1.48/-1.34 1.26/-2.20
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Identification code C8 C9
Empirical formula C16H14NOFIRu0.11 C36H32N2O4Ru
Formula weight 292.73 657.70
Temperature/K 250.01(10) 120.01(16)
Crystal system monoclinic orthorhombic
Space group I2/a Pbcn
a/Å 11.9366(4) 23.6150(7)
b/Å 14.5646(4) 12.7987(4)
c/Å 19.2008(6) 20.7365(7)
α/° 90 90
β/° 104.682(3) 90
γ/° 90 90
Volume/Å3 3229.10(17) 6267.4(3)
Z 9 8
ρcalcg/cm3 1.3547 1.394
μ/mm-1 0.526 0.542
F(000) 1351.2 2704.0
Crystal size/mm3 0.13 × 0.15 × 0.06 0.21 × 0.14 × 0.11
Radiation Mo Kα (λ = 0.71073) MoKα (λ = 0.71073) 
2Θ range for data collection/° 3.56 to 62.62 6.076 to 59.14
Index ranges -15 ≤ h ≤ 17, 
 -21 ≤ k ≤ 19,  
-26 ≤ l ≤ 27 
-32 ≤ h ≤ 32,  
-17 ≤ k ≤ 17,  
-28 ≤ l ≤ 27 
Reflections collected 23143 41312
Independent reflections 4877 [Rint = 0.0440,
Rsigma = 0.0400]
7753 [Rint = 0.0482,
Rsigma = 0.0412]
Data/restraints/parameters 4877/12/250 7753/126/444
Goodness-of-fit on F2 1.050 1.088
Final R indexes [I>=2σ (I)] R1 = 0.0406, wR2 =
0.0796
R1 = 0.0404, wR2 =
0.0738
Final R indexes [all data] R1 = 0.0604, wR2 =
0.0906
R1 = 0.0735, wR2 =
0.0878
Largest diff. peak/hole / e Å-3 0.50/-0.76 1.04/-0.62
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Identification code C11 C12
Empirical formula C34.75H27.5Cl3.5N2O4Ru C34H26N2O4F2Ru
Formula weight 762.23 665.64
Temperature/K 120.00(10) 119.99(13)
Crystal system monoclinic monoclinic
Space group P21/c P21/c
a/Å 16.2848(5) 10.6592(9)
b/Å 11.5529(3) 23.780(2)
c/Å 19.2890(5) 11.8118(12)
α/° 90 90
β/° 109.019(3) 95.473(9)
γ/° 90 90
Volume/Å3 3430.86(18) 2980.4(5)
Z 4 4
ρcalcg/cm3 1.476 1.483
μ/mm-1 0.769 0.580
F(000) 1542.0 1352.0
Crystal size/mm3 0.33 × 0.21 × 0.11 0.26 × 0.18 × 0.12
Radiation MoKα (λ = 0.71073) MoKα (λ = 0.71073) 
2Θ range for data collection/° 4.174 to 62.588 3.864 to 59.232
Index ranges -21 ≤ h ≤ 19,  
-16 ≤ k ≤ 16,  
-26 ≤ l ≤ 25 
-11 ≤ h ≤ 14,  
-30 ≤ k ≤ 32, 
 -16 ≤ l ≤ 14 
Reflections collected 29853 22748
Independent reflections 9916 [Rint = 0.0416,
Rsigma = 0.0550]
7264 [Rint = 0.0540, Rsigma =
0.0720]
Data/restraints/parameters 9916/22/435 7264/132/462
Goodness-of-fit on F2 1.055 1.056
Final R indexes [I>=2σ (I)] R1 = 0.0484, wR2 =
0.1097
R1 = 0.0483, wR2 = 0.0716
Final R indexes [all data] R1 = 0.0651, wR2 =
0.1207
R1 = 0.0788, wR2 = 0.0836
Largest diff. peak/hole / e Å-3 1.19/-0.81 0.98/-0.53
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Identification code C14 C15
Empirical formula C34H24F4N2O4Ru C34H24F4N2O4Ru
Formula weight 701.62 701.62
Temperature/K 120.2(5) 120.2(5)
Crystal system monoclinic monoclinic
Space group I2/a I2/a
a/Å 20.2349(4) 20.2349(4)
b/Å 9.7851(2) 9.7851(2)
c/Å 31.1016(6) 31.1016(6)
α/° 90 90
β/° 96.5615(18) 96.5615(18)
γ/° 90 90
Volume/Å3 6117.8(2) 6117.8(2)
Z 8 8
ρcalcg/cm3 1.524 1.524
μ/mm-1 0.578 0.578
F(000) 2832.0 2832.0
Crystal size/mm3 0.27 × 0.21 × 0.19 0.27 × 0.21 × 0.19
Radiation MoKα (λ = 0.71073) MoKα (λ = 0.71073) 
2Θ range for data collection/° 6.274 to 59.214 6.274 to 59.214
Index ranges -28 ≤ h ≤ 27,  
-13 ≤ k ≤ 13,  
-42 ≤ l ≤ 39 
-28 ≤ h ≤ 27,  
-13 ≤ k ≤ 13,  
-42 ≤ l ≤ 39 
Reflections collected 53396 53396
Independent reflections 7948 [Rint = 0.0349,
Rsigma = 0.0238]
7948 [Rint = 0.0349,
Rsigma = 0.0238]
Data/restraints/parameters 7948/2/426 7948/2/426
Goodness-of-fit on F2 1.061 1.061
Final R indexes [I>=2σ (I)] R1 = 0.0292, wR2 =
0.0636
R1 = 0.0292, wR2 =
0.0636
Final R indexes [all data] R1 = 0.0365, wR2 =
0.0670
R1 = 0.0365, wR2 =
0.0670
Largest diff. peak/hole / e Å-3 0.42/-0.37 0.42/-0.37
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Complex C17 C18
Empirical formula C32H28N2O2Cu C32H26N2O2CuBr2
Formula weight 536.10 693.91
Temperature/K 120.00(11) 120.01(11)
Crystal system orthorhombic triclinic
Space group P212121 P-1
a / Å 9.3387(4) 7.9066(3)
b / Å 9.8103(5) 12.0483(6)
c / Å 27.8867(13) 15.8939(6)
α / ° 90 102.562(4)
β / ° 90 98.748(3)
γ / ° 90 105.207(4)
Volume / Å3 2554.8(2) 1390.48(11)
Z 4 2
ρcalc g / cm3 1.394 1.657
μ / mm-1 0.888 3.692
F(000) 1116.0 694.0
Crystal size / mm3 0.32 × 0.21 × 0.09 0.4 × 0.3 × 0.24
Radiation MoKα (λ = 0.71073) MoKα (λ = 0.71073) 
2θ range for data 
collection/°
5.844 to 59.448
5.476 to 59.666
Index ranges -12 ≤ h ≤ 10  
-13 ≤ k ≤ 10  
-38 ≤ l ≤ 28 
-10 ≤ h ≤ 10 
-16 ≤ k ≤ 16 
 -21 ≤ l ≤ 21 
Reflections collected 12227 15816
Independent reflections 5879 [Rint = 0.0650, Rsigma =
0.1173]
6714 [Rint = 0.0444, Rsigma =
0.0653]
Data/restraints/parameters 5879/0/336 6714/0/357
Goodness of fit on F2 1.057 0.670
Final R indexes [I>=2σ (I)] R1 = 0.0592, wR2 = 0.0900 R1 = 0.0401, wR2 = 0.0879
Final R indexes [all data] R1 = 0.1053, wR2 = 0.1074 R1 = 0.0574, wR2 = 0.1047
Largest diff. / e Å-3 0.40/-0.47 0.60/-0.66
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Complex C19 C20
Empirical formula C32H26N2O2Cl2Cu C32H26N2O2CuBr2
Formula weight 604.99 693.91
Temperature/K 120.00(10) 120.0(2)
Crystal system monoclinic orthorhombic
Space group I2/a P212121
a / Å 12.3890(4) 9.7122(6)
b / Å 13.7094(4) 9.8565(4)
c / Å 16.7856(5) 28.6096(17)
α / ° 90 90
β / ° 108.096(3) 90
γ / ° 90 90
Volume / Å3 2709.97(15) 2738.8(3)
Z 4 4
ρcalc g / cm3 1.483 1.683
μ / mm-1 1.037 3.749
F(000) 1244.0 1388.0
Crystal size / mm3 0.3 × 0.22 × 0.21 0.13 × 0.11 × 0.07
Radiation MoKα (λ = 0.71073) MoKα (λ = 0.71073) 
2θ range for data 
collection/°
5.944 to 59.356
6.542 to 59.414
Index ranges -15 ≤ h ≤ 16,  
-18 ≤ k ≤ 14,  
-23 ≤ l ≤ 19 
-7 ≤ h ≤ 12,  
-11 ≤ k ≤ 13,  
-39 ≤ l ≤ 32 
Reflections collected 7088 13396
Independent reflections 3239 [Rint = 0.0460, Rsigma =
0.0649]
6441 [Rint = 0.0397, Rsigma =
0.0687]
Data/restraints/parameters 3239/0/178 6441/0/354
Goodness of fit on F2 0.819 1.028
Final R indexes [I>=2σ (I)] R1 = 0.0804, wR2 = 0.2055 R1 = 0.0407, wR2 = 0.0642
Final R indexes [all data] R1 = 0.1016, wR2 = 0.2346 R1 = 0.0569, wR2 = 0.0686
Largest diff. / e Å-3 1.86/-1.16 0.48/-0.41
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Complex C21 C22
Empirical formula C32H26Cl2CuN2O2 C32H26CuF2N2O2
Formula weight 604.99 572.09
Temperature/K 120.01(18) 281(3)
Crystal system monoclinic monoclinic
Space group I2/a P21/n
a / Å 11.9816(8) 11.8091(4)
b / Å 13.1682(10) 7.4235(2)
c / Å 17.2486(13) 15.7723(5)
α / ° 90 90
β / ° 96.162(7) 101.660(3)
γ / ° 90 90
Volume / Å3 2705.7(3) 1354.16(8)
Z 4 2
ρcalc g / cm3 1.485 1.403
μ / mm-1 1.038 1.523
F(000) 1244.0 590.0
Crystal size / mm3 0.31 × 0.23 × 0.06 0.2 × 0.18 × 0.12
Radiation MoKα (λ = 0.71073) CuKα (λ = 1.54184) 
2θ range for data 
collection/°
6.352 to 59.688 11.458 to 133.118
Index ranges -13 ≤ h ≤ 16,  
-18 ≤ k ≤ 18,  
-23 ≤ l ≤ 22 
-14 ≤ h ≤ 13 
-7 ≤ k ≤ 8  
-18 ≤ l ≤ 18 
Reflections collected 14706 4610
Independent reflections 3472 [Rint = 0.0524, Rsigma =
0.0511]
2378 [Rint = 0.0135, Rsigma =
0.0164]
Data/restraints/parameters 3472/0/178 2378/0/179
Goodness of fit on F2 1.084 1.076
Final R indexes [I>=2σ (I)] R1 = 0.0370, wR2 = 0.0682 R1 = 0.0326, wR2 = 0.0906
Final R indexes [all data] R1 = 0.0521, wR2 = 0.0746 R1 = 0.0348, wR2 = 0.0926
Largest diff. / e Å-3 0.37/-0.38 0.24/-0.40
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Complex C23 C24
Empirical formula C32H26N2O2CuI2 C34H32N2O2Cu
Formula weight 787.89 564.19
Temperature/K 120.01(12) 120.2(3)
Crystal system orthorhombic monoclinic
Space group P212121 I2/a
a / Å 9.8152(4) 11.9805(4)
b / Å 10.0201(4) 13.1895(4)
c / Å 29.0295(11) 17.2664(5)
α / ° 90 90
β / ° 90 97.121(3)
γ / ° 90 90
Volume / Å3 2855.0(2) 2707.33(15)
Z 4 4
ρcalc g / cm3 1.833 1.3841
μ / mm-1 2.960 0.841
F(000) 1532.0 1181.8
Crystal size / mm3 0.78 × 0.33 × 0.21 0.4 × 0.2 × 0.11
Radiation MoKα (λ = 0.71073) Mo Kα (λ = 0.71073) 
2θ range for data 
collection/°
6.454 to 50.052
6.18 to 50.06
Index ranges -8 ≤ h ≤ 11,  
-11 ≤ k ≤ 10,  
-34 ≤ l ≤ 34 
-13 ≤ h ≤ 16,  
-14 ≤ k ≤ 18,  
-22 ≤ l ≤ 20 
Reflections collected 10274 8124
Independent reflections 4929 [Rint = 0.0325, Rsigma =
0.0473]
2390 [Rint = 0.0328, Rsigma =
0.0482]
Data/restraints/parameters 4929/0/354 2390/0/178
Goodness of fit on F2 1.039 1.057
Final R indexes [I>=2σ (I)] R1 = 0.0265, wR2 = 0.0514 R1 = 0.0312, wR2 = 0.0729
Final R indexes [all data] R1 = 0.0284, wR2 = 0.0523 R1 = 0.0374, wR2 = 0.0772
Largest diff. / e Å-3 0.38/-0.43 0.33/-0.45
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Complex C25 C26
Empirical formula C34H32N2O4Cu C36H36CuN2O4
Formula weight 596.19 624.21
Temperature/K 120.01(12) 120.0(2)
Crystal system orthorhombic triclinic
Space group Pbca P-1
a / Å 16.2295(8) 11.3623(6)
b / Å 5.7812(3) 12.1200(7)
c / Å 29.7673(12) 12.1712(7)
α / ° 90 77.677(5)
β / ° 90 66.949(5)
γ / ° 90 85.080(5)
Volume / Å3 2792.9(2) 1506.74(16)
Z 4 2
ρcalc g / cm3 1.4177 1.376
μ / mm-1 0.825 0.768
F(000) 1245.9 654.0
Crystal size / mm3 0.82 × 0.33 × 0.18 0.25 × 0.09 × 0.07
Radiation Mo Kα (λ = 0.71073) MoKα (λ = 0.71073) 
2θ range for data 
collection/°
5.72 to 50.04 5.896 to 59.422
Index ranges -17 ≤ h ≤ 22,  
-8 ≤ k ≤ 7,  
-41 ≤ l ≤ 32 
-14 ≤ h ≤ 14,  
-13 ≤ k ≤ 16,  
-16 ≤ l ≤ 16 
Reflections collected 11451 14703
Independent reflections 2461 [Rint = 0.0454, Rsigma =
0.0551]
7090 [Rint = 0.0410, Rsigma =
0.0721]
Data/restraints/parameters 2461/0/188 7090/121/450
Goodness of fit on F2 1.073 1.060
Final R indexes [I>=2σ (I)] R1 = 0.0405, wR2 = 0.0872 R1 = 0.0474, wR2 = 0.0881
Final R indexes [all data] R1 = 0.0590, wR2 = 0.0981 R1 = 0.0722, wR2 = 0.0993
Largest diff. / e Å-3 0.45/-0.45 0.40/-0.47
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Complex C27 C28
Empirical formula C34H26N2O2F6Cu C36H36N2O2Cu
Formula weight 672.11 592.21
Temperature/K 120.00(13) 120.01(14)
Crystal system monoclinic orthorhombic
Space group P21/c Pbca
a / Å 15.6718(14) 11.18443(18)
b / Å 16.3749(12) 19.8811(4)
c / Å 5.6359(5) 26.6673(5)
α / ° 90 90
β / ° 91.504(8) 90
γ / ° 90 90
Volume / Å3 1445.8(2) 5929.70(19)
Z 2 8
ρcalc g / cm3 1.544 1.327
μ / mm-1 0.830 0.772
F(000) 686.0 2488.0
Crystal size / mm3 0.36 × 0.27 × 0.16 0.3029 × 0.2097 × 0.1545
Radiation MoKα (λ = 0.71073) MoKα (λ = 0.71073) 
2θ range for data 
collection/°
5.614 to 50.05
5.692 to 50.05
Index ranges -18 ≤ h ≤ 18,  
-19 ≤ k ≤ 19,  
-6 ≤ l ≤ 6 
-13 ≤ h ≤ 12, 
-21 ≤ k ≤ 23, 
 -31 ≤ l ≤ 29 
Reflections collected 6727 32508
Independent reflections 2552 [Rint = 0.0686, Rsigma =
0.0746]
5232 [Rint = 0.0516, Rsigma =
0.0350]
Data/restraints/parameters 2552/36/234 5232/0/376
Goodness of fit on F2 1.044 1.055
Final R indexes [I>=2σ (I)] R1 = 0.0672, wR2 = 0.1707 R1 = 0.0361, wR2 = 0.0858
Final R indexes [all data] R1 = 0.0944, wR2 = 0.1943 R1 = 0.0515, wR2 = 0.0948
Largest diff. / e Å-3 1.36/-0.82 0.27/-0.46
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Complex C29 C30
Empirical formula C38H40N2O2Cu C32H24N2O2Cl4Cu
Formula weight 620.26 673.87
Temperature/K 120.02(13) 120.00(13)
Crystal system monoclinic monoclinic
Space group P21/n C2/c
a / Å 11.2401(5) 22.3235(8)
b / Å 22.1858(11) 7.2386(3)
c / Å 13.1955(5) 18.0461(6)
α / ° 90 90
β / ° 99.985(4) 100.669(3)
γ / ° 90 90
Volume / Å3 3240.7(3) 2865.7(2)
Z 4 4
ρcalc g / cm3 1.271 1.562
μ / mm-1 0.709 1.170
F(000) 1308.0 1372.0
Crystal size / mm3 0.41 × 0.2 × 0.14 0.4887 × 0.2088 × 0.0899
Radiation MoKα (λ = 0.71073) MoKα (λ = 0.71073) 
2θ range for data 
collection/°
6.27 to 50.054
6.232 to 50.05
Index ranges -12 ≤ h ≤ 13,  
-24 ≤ k ≤ 26, 
-15 ≤ l ≤ 15 
-26 ≤ h ≤ 22,  
-7 ≤ k ≤ 8,  
-21 ≤ l ≤ 21 
Reflections collected 22244 7665
Independent reflections 5727 [Rint = 0.0656, Rsigma =
0.0598]
2533 [Rint = 0.0363, Rsigma =
0.0406]
Data/restraints/parameters 5727/0/396 2533/0/187
Goodness of fit on F2 1.162 1.033
Final R indexes [I>=2σ (I)] R1 = 0.0794, wR2 = 0.1774 R1 = 0.0407, wR2 = 0.0960
Final R indexes [all data] R1 = 0.0999, wR2 = 0.1869 R1 = 0.0475, wR2 = 0.1008
Largest diff. / e Å-3 1.18/-1.09 1.40/-0.36
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Complex C31 C32
Empirical formula C34H32N2O6Cu C32H24N2O2F2CuBr2
Formula weight 628.15 729.89
Temperature/K 120.01(10) 120.0(2)
Crystal system monoclinic monoclinic
Space group P21/n C2/c
a / Å 8.8326(4) 22.8983(7)
b / Å 7.0294(3) 6.9815(2)
c / Å 22.0248(11) 17.6021(6)
α / ° 90 90
β / ° 100.425(5) 101.532(3)
γ / ° 90 90
Volume / Å3 1344.90(11) 2757.16(16)
Z 2 4
ρcalc g / cm3 1.551 1.758
μ / mm-1 0.866 3.739
F(000) 654.0 1452.0
Crystal size / mm3 0.35 × 0.32 × 0.18 0.28 × 0.16 × 0.11
Radiation MoKα (λ = 0.71073) MoKα (λ = 0.71073) 
2θ range for data 
collection/°
6.094 to 50.044
6.112 to 50.046
Index ranges
-10 ≤ h ≤ 10, -7 ≤ k ≤ 8, -23 
≤ l ≤ 26 
-21 ≤ h ≤ 27,  
-8 ≤ k ≤ 8,  
-20 ≤ l ≤ 17 
Reflections collected 6259 7648
Independent reflections 2383 [Rint = 0.0395, Rsigma =
0.0504]
2439 [Rint = 0.0326, Rsigma =
0.0334]
Data/restraints/parameters 2383/0/197 2439/0/187
Goodness of fit on F2 1.049 1.063
Final R indexes [I>=2σ (I)] R1 = 0.0380, wR2 = 0.0837 R1 = 0.0273, wR2 = 0.0582
Final R indexes [all data] R1 = 0.0471, wR2 = 0.0908 R1 = 0.0328, wR2 = 0.0604
Largest diff. / e Å-3 0.35/-0.41 0.89/-0.27
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Complex C36 C37
Empirical formula C32H26N2O2CuBr2 C32H26N2O2F2Cu
Formula weight 693.91 572.09
Temperature/K 120.00(10) 120.2(4)
Crystal system monoclinic monoclinic
Space group I2/a I2/a
a / Å 12.1403(8) 12.0159(4)
b / Å 14.0634(11) 13.3394(4)
c / Å 16.3054(14) 16.3350(5)
α / ° 90 90
β / ° 104.212(8) 100.244(3)
γ / ° 90 90
Volume / Å3 2698.7(4) 2576.53(14)
Z 4 4
ρcalc g / cm3 1.708 1.475
μ / mm-1 3.805 0.896
F(000) 1388.0 1180.0
Crystal size / mm3 0.17 × 0.15 × 0.123 0.35 × 0.19 × 0.16
Radiation MoKα (λ = 0.71073) MoKα (λ = 0.71073) 
2θ range for data 
collection/°
5.794 to 59.744 6.378 to 50.05
Index ranges -16 ≤ h ≤ 11,  
-19 ≤ k ≤ 15,  
-22 ≤ l ≤ 17 
-14 ≤ h ≤ 14, -14 ≤ k ≤ 15, -
19 ≤ l ≤ 17 
Reflections collected 6804 6238
Independent reflections 3231 [Rint = 0.0451, Rsigma =
0.0755]
2279 [Rint = 0.0265, Rsigma =
0.0314]
Data/restraints/parameters 3231/0/178 2279/0/178
Goodness of fit on F2 1.071 1.092
Final R indexes [I>=2σ (I)] R1 = 0.0495, wR2 = 0.1049 R1 = 0.0417, wR2 = 0.1057
Final R indexes [all data] R1 = 0.0892, wR2 = 0.1267 R1 = 0.0447, wR2 = 0.1079
Largest diff. / e Å-3 1.46/-1.00 1.89/-0.44
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Complex C40 C41
Empirical formula C32H26N2O2Cl2Cu C32H24N2O2F4Cu
Formula weight 604.99 608.07
Temperature/K 120.01(10) 120.00(10)
Crystal system monoclinic monoclinic
Space group P21/c P21/n
a / Å 9.8810(4) 11.9032(4)
b / Å 9.4847(3) 7.3795(3)
c / Å 14.5268(5) 15.8968(6)
α / ° 90 90
β / ° 102.242(3) 104.625(4)
γ / ° 90 90
Volume / Å3 1330.47(8) 1351.13(9)
Z 2 2
ρcalc g / cm3 1.510 1.495
μ / mm-1 1.056 0.869
F(000) 622.0 622.0
Crystal size / mm3 0.44 × 0.19 × 0.13 0.41 × 0.36 × 0.25
Radiation MoKα (λ = 0.71073) MoKα (λ = 0.71073) 
2θ range for data 
collection/°
6.274 to 50.054
6.558 to 50.05
Index ranges -11 ≤ h ≤ 10,  
-9 ≤ k ≤ 11,  
-17 ≤ l ≤ 15 
-14 ≤ h ≤ 13,  
-8 ≤ k ≤ 7,  
-18 ≤ l ≤ 17 
Reflections collected 6802 7459
Independent reflections 2347 [Rint = 0.0401, Rsigma =
0.0457]
2383 [Rint = 0.0376, Rsigma =
0.0411]
Data/restraints/parameters 2347/0/179 2383/0/188
Goodness of fit on F2 1.067 1.080
Final R indexes [I>=2σ (I)] R1 = 0.0339, wR2 = 0.0837 R1 = 0.0423, wR2 = 0.1102
Final R indexes [all data] R1 = 0.0413, wR2 = 0.0889 R1 = 0.0487, wR2 = 0.1161
Largest diff. / e Å-3 0.26/-0.43 1.57/-0.4
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Complex C42
Empirical formula C32H24N2O2F4Cu
Formula weight 608.07
Temperature/K 120.01(10)
Crystal system monoclinic
Space group P21/c
a / Å 18.5919(9)
b / Å 10.2406(6)
c / Å 14.2061(7)
α / ° 90
β / ° 95.537(5)
γ / ° 90
Volume / Å3 2692.1(2)
Z 4
ρcalc g / cm3 1.500
μ / mm-1 0.873
F(000) 1244.0
Crystal size / mm3 0.2266 × 0.1825 × 0.1373
Radiation MoKα (λ = 0.71073) 
2θ range for data 
collection/°
5.966 to 50.048
Index ranges -20 ≤ h ≤ 22,  
-11 ≤ k ≤ 12,  
-16 ≤ l ≤ 15 
Reflections collected 17355
Independent reflections 4746 [Rint = 0.0555, Rsigma =
0.0557]
Data/restraints/parameters 4746/0/372
Goodness of fit on F2 1.052
Final R indexes [I>=2σ (I)] R1 = 0.0426, wR2 = 0.0882
Final R indexes [all data] R1 = 0.0608, wR2 = 0.1000
Largest diff. / e Å-3 0.29/-0.39
